


Up-to-date with a click!

[View this email in your browser](#)

Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update November 2 - November 8, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 46 2020

874 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)
[COVID-19 Projections tracker](#)
[AAN - Neurology resources](#)
[COVID-19 resources \(Harvard\)](#)
[COVID-19 resources \(McMasters\)](#)
[COVID-19 resources \(NHLBI\)](#)
[COVID-19 resources \(MEDSCAPE\)](#)
[COVID-19 Diabetes \(JDRF\)](#)
[COVID-19 TELEMEDICINE \(BMJ\)](#)
[Global Causes of death \(Johns Hopkins\)](#)
[COVID-19 calculators \(Medscape\)](#)

[COVID reference \(Steinhauser Verlag\)](#)
[Retracted papers](#)
[COVID-19 risk tools - Apps](#)

Guidelines

[NICE Guidelines Covid-19](#)
[Korean CDC Covid-19 guidelines](#)
[Flattening the curve - Korea](#)
[IDSA COVID-19 Guidelines](#)
[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)
[ESICM Ventilation Guidelines](#)
[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)
[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)
[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)
[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)
[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)
[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)
[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)
[WHO launches global megatrial](#)
[FDA launches Convalescent plasma trial](#)
[Lets Beat Covid-19 Survey to help plan hospital services](#)
[COVID IBD registry](#)
[Google mobility reports per country COVID 19](#)
[World's largest trial of potential coronavirus treatments rolled out across the UK](#)
[Pregnancy Registry \(US\)](#)
[ICNARC report on COVID-19 in critical care - NHS April 24](#)
[COVID-19 Human Genetics - Biobanks](#)
[COVID19 settings of transmission database](#)
[COVID-19 prevention network](#)

Mainstream Media

New York Times - Corona update

[The Coronavirus Is Airborne Indoors. But We're Still Scrubbing Surfaces.](#)

[Confused About Masks? Here's What Scientists Know](#)

[States That Imposed Few Restrictions Now Have the Worst Outbreaks](#)

[New Pfizer Results: Coronavirus Vaccine Is Safe and 95% Effective](#)

[F.D.A. authorizes the first at-home coronavirus test.](#)

[Americans Are More Willing to Take a Coronavirus Vaccine, Poll Suggests](#)

[Immunity to the Coronavirus May Last Years, New Data Hint](#)

[Inside the Chaotic, Cutthroat Gray Market for N95 Masks](#)

[Coronavirus Vaccine Tracker](#)

[Coronavirus Drug and Treatment Tracker](#)

Washington Post - Corona update

[U.S. death toll nears 250,000 in wake of deadliest day since early May.](#)

[Even with a vaccine, this virus will take time to conquer](#)

[An Ohio wedding left dozens with the coronavirus, including the bride and groom](#)

[China's Sinovac reports mixed findings in early coronavirus vaccine trials](#)

[Has Sweden's coronavirus strategy failed?](#)

[Experts fear lessons from the 2009 H1N1 vaccine drive are being ignored](#)

[Coronavirus testing before flying could become the norm](#)

[South Dakota nurse says many patients deny the coronavirus right up until death](#)

Guardian - Corona update

[Coronavirus live news: Japan sees record daily infections; India close to 9m cases](#)

[Brutal Covid second wave exposes Italy's shortage of intensive care staff](#)

[Mayo Clinic: 900 employees at top US hospital catch Covid-19 in two weeks](#)

[Covid-19 mink variants discovered in humans in seven countries](#)

[Covid-19 antibodies reduce faster in men than women – study.](#)

Key Articles

1. **Update on Recommendations for SARS-CoV-2/COVID-19 during Pregnancy, Birth and Childbed.** [Z. Geburtshilfe Neonatol.](#) 2020; 224:217-222 Zöllkau J, Hagenbeck C, Hecher K *et al.*

The COVID-19 pandemic is responsible for unprecedented challenges across the spectrum of medical specialties. The German obstetric, peri-/neonatalogical, and pediatric professional societies published recommendations in March 2020. This update incorporates worldwide national recommendations (based on publications up to 30-05-20). A carefully formulated consensus that will be adapted when new findings become available.

2. **Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.** [J. Cardiol.](#) 2020; Ren L, Yu S, Xu W *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33168337>

This updated meta-analysis re-evaluated current data on anti-hypertensive medication use on the risk and severity of COVID-19. Publications before July 13 were included. The analysis contained 53 studies (39 cohort studies and 14 case-control studies). A total of 2,100,587 participants were included. No harm from using anti-hypertensive medication was observed; in patients that used blood pressure-lowering medication (including ACEi/ARB's), severity and mortality were significantly reduced.

3. Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients - a prospective observational study. *Infect Dis (Lond)* 2020;1-11 Auvinen R, Nohynek H, Syrjänen R *et al*.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33170050>

During the winter months, influenza infection rates increase rapidly, and distinguishing patients with flu from those infected with the SARS-CoV2 virus is of great importance. This Finnish cohort of hospitalized patients with respiratory infections was tested for influenza virus and SARS-CoV2 virus using RT-PCR. Imaging showed that COVID-19 patients were more likely to have ground-glass opacities and consolidation (68% vs. 21%; $P=0.01$). A more severe disease, ICU admission, and prolonged hospital stay were observed in COVID-19 patients to a greater extent than those diagnosed with an influenza viral infection.

4. Venous thrombosis, thromboembolism and biomarkers of inflammation and coagulation in COVID-19. *J Vasc Surg Venous Lymphat Disord* 2020;

Thondapu V, Montes D, Rosovsky R *et al*.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33188961>

5. Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. *Microorganisms* 2020;

8Thijssen M, Devos T, Ejtahed HS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167389>

6. Digging the Rabbit Hole, COVID-19 Edition: Anti-Vaccine Themes and the Discourse Around COVID-19. *Microbes Infect* 2020; Smith TC, Reiss DR.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33171267>

7. Thrombosis in Hospitalized Patients with Viral Respiratory Infections versus COVID-19. *Am. Heart J.* 2020; Smilowitz NR, Subashchandran V,

Yuriditsky E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181067>

8. Identifying patients with symptoms suspicious for COVID-19 at elevated risk of adverse events: The COVAS score. *Am J Emerg Med* 2020; Sharp

AL, Huang BZ, Broder B *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189516>

9. The coronavirus disease 2019: the prevalence, prognosis, and recovery from olfactory dysfunction (OD). *Acta Otolaryngol.* 2020;1-10 Samimi

Ardestani SH, Mohammadi Ardehali M, Rabbani Anari M *et al*.

10. **A review and content analysis of national apps for COVID-19 management using Mobile Application Rating Scale (MARS).** Inform Health Soc Care 2020;1-14Salehinejad S, Niakan Kalhori SR, Hajesmaeel Gohari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164594>
11. **Smoking Doubles the Mortality Risk in COVID-19: A Meta-Analysis of Recent Reports and Potential Mechanisms.** Cureus 2020; 12:e10837Salah HM, Sharma T, Mehta J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173643>
12. **Why will it never be known if convalescent plasma is effective for COVID-19.** J Transl Autoimmun 2020; 3:100069Rojas M, Anaya JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169114>
13. **Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium.** Anaesth Crit Care Pain Med 2020; Rello J, Belliato M, Dimopoulos MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172592>
14. **Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study.** Thromb Res 2020; 197:94-99Planquette B, Le Berre A, Khider L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190025>
15. **Pathophysiology of Cardiovascular Complications in COVID-19.** Front. Physiol. 2020; 11:575600Petrovic V, Radenkovic D, Radenkovic G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162899>

Basic Science (56 articles)

1. **Peptide and peptide-based inhibitors of SARS-CoV-2 entry.** Adv Drug Deliv Rev 2020; Schütz D, Ruiz-Blanco YB, Münch J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189768>
2. **Bioinspired DNase-I-Coated Melanin-Like Nanospheres for Modulation of Infection-Associated NETosis Dysregulation.** Adv Sci (Weinh) 2020;2001940Park HH, Park W, Lee YY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173718>
3. **Biomimetic Human Disease Model of SARS-CoV-2 Induced Lung Injury and Immune Responses on Organ Chip System.** Adv Sci (Weinh) 2020;2002928Zhang M, Wang P, Luo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173719>
4. **Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector.** Adv Ther (Weinh) 2020;2000172Dube T, Ghosh A, Mishra J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173808>

5. **In well-differentiated primary human bronchial epithelial cells, TGF- β 1 and TGF- β 2 induce expression of furin.** Am J Physiol Lung Cell Mol Physiol 2020; O'Sullivan MJ, Mitchel JA, Mwase C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174447>
6. **SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes.** Biochem Biophys Rep 2020; 24:100844Bhari VK, Kumar D, Kumar S, Mishra R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178900>
7. **Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein.** Biochimie 2020; Calcagnile M, Forgez P, Iannelli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181224>
8. **Fragment Library of Natural Products and Compound Databases for Drug Discovery.** Biomolecules 2020; 10Chávez-Hernández AL, Sánchez-Cruz N, Medina-Franco JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172012>
9. **How the zoonotic origins of SARS-CoV-2 ensure its survival as a human disease.** Br. J. Community Nurs. 2020; 25:562-566Phillis A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33161739>
10. **Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets.** Brief. Bioinform. 2020; Li R, Li Y, Liang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169132>
11. **Bioinformatic analysis of SMN1-ACE/ACE2 interactions hinted at a potential protective effect of spinal muscular atrophy against COVID-19-induced lung injury.** Brief. Bioinform. 2020; Li Z, Li X, Shen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190150>
12. **Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.** Cell 2020; Su Y, Chen D, Yuan D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171100>
13. **In silico analysis of selected alkaloids against main protease (M(pro)) of COVID-19.** Chem. Biol. Interact. 2020:109309Garg S, Roy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181114>
14. **In silico analysis of selected alkaloids against main protease (M(pro)) of SARS-CoV-2.** Chem. Biol. Interact. 2020:109309Garg S, Roy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181114>
15. **Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex.** Chembiochem 2020; McNaughton B, Rosario PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174669>
16. **Tinocordiside from *Tinospora cordifolia* (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain.** Comb. Chem. High Throughput Screen. 2020; Balkrishna A, Pokhrel S, Varshney A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172372>
17. **In-silico analysis of angiotensin converting enzyme 2 (ACE2) of livestock, pet and poultry animals to determine its susceptibility to SARS-CoV- 2 infection.** Comb. Chem. High Throughput Screen. 2020; Kumar A, Panwar A, Batra K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172369>
18. **CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.** Drug Dev Res 2020; Nagoor Meeran MF, Sharma C, Goyal SN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190277>

19. **Age-related mitochondrial dysfunction as a key factor in COVID-19 disease.** Exp. Gerontol. 2020; 142:111147Moreno Fernández-Ayala DJ, Navas P, López-Lluch G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171276>
20. **Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints.** Expert Rev. Anti Infect. Ther. 2020:1-10Rai M, Bonde S, Yadav A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164589>
21. **Prokaryote-Eukaryote Symbiosis to Produce RNA-Based Therapeutics.** Front Genet 2020; 11:583464Tahayori B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178254>
22. **Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?** Front. Immunol. 2020; 11:567710Beretta A, Cranage M, Zipeto D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178193>
23. **T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis.** Front. Immunol. 2020; 11:589380Kalfaoglu B, Almeida-Santos J, Tye CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178221>
24. **The Neat Dance of COVID-19: NEAT1, DANCER, and Co-Modulated Cholinergic RNAs Link to Inflammation.** Front. Immunol. 2020; 11:590870Meydan C, Madrer N, Soreq H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163005>
25. **Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case Severity.** Front. Microbiol. 2020; 11:603509Liu T, Jia P, Fang B, Zhao Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178176>
26. **Computational Study of the Ion and Water Permeation and Transport Mechanisms of the SARS-CoV-2 Pentameric E Protein Channel.** Front Mol Biosci 2020; 7:565797Cao Y, Yang R, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173781>
27. **Tempering Macrophage Plasticity for Controlling SARS-CoV-2 Infection for Managing COVID-19 Disease.** Front. Pharmacol. 2020; 11:570698Toor D, Jain A, Kalhan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178021>
28. **COVID-19 and the Curse of Piecemeal Perspectives.** Front Vet Sci 2020; 7:582983Walzer C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173796>
29. **A Hydrophobic-Interaction-Based Mechanism Triggers Docking between the SARS-CoV-2 Spike and Angiotensin-Converting Enzyme 2.** Glob Chall 2020:2000067Li J, Ma X, Guo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173592>
30. **New putative animal reservoirs of SARS-CoV-2 in Italian fauna: a bioinformatic approach.** Heliyon 2020; 6:e05430Buonocore M, Marino C, Grimaldi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173837>
31. **Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins.** Heliyon 2020; 6:e05421Weisshoff H, Krylova O, Nikolenko H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163683>
32. **The Progression of SARS Coronavirus 2 (SARS-CoV2): Mutation in the Receptor Binding Domain of Spike Gene.** Immune Netw. 2020; 20:e41Kim S, Lee JH, Lee S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163249>
33. **LPD-12, a Promising Lipopeptide to Control COVID-19.** Int J Antimicrob Agents 2020:106218Chowdhury T, Baidara P, Mandal SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166692>

34. **Analysis of the potential impact of genomic variants in global SARS-CoV-2 genomes on molecular diagnostic assays.** *Int J Infect Dis* 2020; Jain A, Rophina M, Mahajan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181329>
35. **Exposome and Immunity Training: How Pathogen Exposure Order Influences Innate Immune Cell Lineage Commitment and Function.** *Int J Mol Sci* 2020; 21Adams K, Weber KS, Johnson SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187101>
36. **Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection.** *Int J Mol Sci* 2020; 21Festa M, Sansone C, Brunet C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171852>
37. **NANDA-I, NOC, and NIC linkages to SARS-CoV-2 (COVID-19): Part 2. Individual response.** *Int J Nurs Knowl* 2020; Swanson E, Mantovani VM, Wagner C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169943>
38. **Identification of natural inhibitors against prime targets of SARS-CoV-2 using molecular docking, molecular dynamics simulation and MM-PBSA approaches.** *J Biomol Struct Dyn* 2020;1-16Sharma A, Vora J, Patel D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183178>
39. **In-silico drug repurposing for targeting SARS-CoV-2 main protease (M(pro)).** *J Biomol Struct Dyn* 2020;1-8Sharma S, Deep S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179568>
40. **A preparative chiral separation of hydroxychloroquine using supercritical fluid chromatography.** *J. Chromatogr. A* 2020; 1634:461661Wilson LJ, Mi C, Kraml CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166894>
41. **Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.** *J Infect Public Health* 2020; Indu P, Rameshkumar MR, Arunagirinathan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168456>
42. **Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.** *J. Mol. Model.* 2020; 26:338Alazmi M, Motwalli O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175236>
43. **A comprehensive overview of proteomics approach for COVID 19: new perspectives in target therapy strategies.** *J Proteins Proteom* 2020;1-10Rana R, Rath V, Ganguly NK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162722>
44. **ACE2: The Major Cell Entry Receptor for SARS-CoV-2.** *Lung* 2020;1-11Scialo F, Daniele A, Amato F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170317>
45. **Quantum mechanical, spectroscopic and docking studies of (2E)-1-(4-aminophenyl)-3-(4-benzyloxyphenyl)-prop-2-en-1-one Chalcone derivative by density functional theory - A prospective respiratory drug.** *Mater Today Proc* 2020; Hannah Clara T, Muthu S, Christian Prasana J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173755>
46. **Comparative analysis of nanomechanical features of coronavirus spike proteins and correlation with lethality and infection rate.** *Matter* 2020; Hu Y, Buehler MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163958>
47. **Effect of pre-existing diseases on COVID-19 infection and role of new sensors and biomaterials for its detection and treatment.** *Med Devices Sens*

- 2020:e10140Singh A, Kumar M, Dubey AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173852>
48. **SARS-CoV 2; Possible alternative virus receptors and pathophysiological determinants.** *Med. Hypotheses* 2020;110368Pruimboom L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189453>
 49. **Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M(pro) Protease.** *Molecules* 2020; 25Tejera E, Munteanu CR, López-Cortés A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172092>
 50. **A case report: Challenges in COVID-19 modeling at a public health department.** *Proc Assoc Inf Sci Technol* 2020; 57:e426Rogers M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173831>
 51. **Recent Patents and Advances on Nanotechnologies against Coronavirus.** *Recent Pat Nanotechnol* 2020; Abedini-Nassab R, Mahdaviyan N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172382>
 52. **[Sars-CoV-2 genomic and phylodynamic analyses].** *Rev Francoph Lab* 2020; 2020:57-62Elie B, Alizon S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163105>
 53. **Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy.** *Tumori* 2020;300891620974755Apolone G, Montomoli E, Manenti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176598>
 54. **Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein.** *Vaccine* 2020; 38:7697-7701Muraoka D, Situo D, Sawada SI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164796>
 55. **Deletion in the C-terminal region of the envelope glycoprotein in some of the Indian SARS-CoV-2 genome.** *Virus Res.* 2020; 291:198222Kumar BK, Rohit A, Prithvisagar KS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166565>
 56. **Spike Glycoprotein-Mediated Entry of SARS Coronaviruses.** *Viruses* 2020; 12Wang L, Xiang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187074>

Biomarkers - Genetics (89 articles)

1. **Rapid Fabrication of Sterile Medical Nasopharyngeal Swabs by Stereolithography for Widespread Testing in a Pandemic.** *Adv Eng Mater* 2020;2000759van der Elst LA, Gokce Kurtoglu M, Leffel T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173409>
2. **Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.** *Adv Respir Med* 2020; 88:468-469Mohebbi N, Abedini A, Lashgari R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169824>
3. **Gold Nanorod Assisted Enhanced Plasmonic Detection Scheme of COVID-19 SARS-CoV-2 Spike Protein.** *Adv Theory Simul* 2020; 3:2000185Das CM, Guo Y, Yang G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173847>
4. **A Descriptive and Quantitative Immunohistochemical Study Demonstrating a Spectrum of Platelet Recruitment Patterns Across Pulmonary Infections Including COVID-19.** *Am J Clin Pathol* 2020; McMullen PD, Cho JH, Miller JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174599>
5. **Linking lactate dehydrogenase to the severity of COVID-19 cannot ignore the employed methodology.** *Am J Emerg Med* 2020; Aloisio E, Pasqualetti S, Panteghini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168383>

6. **SARS-CoV-2: Influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP)-metabolism and on severity of COVID-19.** Am J Physiol Endocrinol Metab 2020; van Kempen TA, Deixler E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33174766>
7. **Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections.** Am J Physiol Lung Cell Mol Physiol 2020; Eapen MS, Lu W, Hackett TL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174446>
8. **Association between red blood cell distribution width and mortality of COVID-19 patients.** Anaesth Crit Care Pain Med 2020; Lorente L, Martín MM, Argueso M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171297>
9. **Trend analysis of lab tests requisitions of COVID-19 prognostic biomarkers at a clinical chemistry reference laboratory-an observational study.** Ann Med Surg (Lond) 2020; Ahmed S, Ghani F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173580>
10. **Prolonged shedding of SARS-CoV-2 in an elderly liver transplant patient infected by COVID-19: a case report.** Ann Palliat Med 2020; Wei L, Liu B, Zhao Y, Chen Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183020>
11. **Red cell distribution width (RDW): a prognostic indicator of severe COVID-19.** Ann Transl Med 2020; 8:1230Wang C, Zhang H, Cao X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178762>
12. **Lymphocyte percentage and hemoglobin as a joint parameter for the prediction of severe and nonsevere COVID-19: a preliminary study.** Ann Transl Med 2020; 8:1231Zhang W, Zhang Z, Ye Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178763>
13. **Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications.** Biochem. Soc. Trans. 2020; Jiang JC, Zhang Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33170924>
14. **Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein.** Biochimie 2020; Calcagnile M, Forgez P, Iannelli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181224>
15. **Biobanking in the COVID-19 Era and Beyond: Part 1. How Early Experiences Can Translate into Actionable Wisdom.** Biopreserv. Biobank. 2020; Allocca CM, Bledsoe MJ, Albert M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164554>
16. **Establishment of a Collection of Blood-Derived Products from COVID-19 Patients for Translational Research: Experience of the LPCE Biobank (Nice, France).** Biopreserv. Biobank. 2020; Tanga V, Leroy S, Fayada J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33175565>
17. **Developments in biosensors for CoV detection and future trends.** Biosens. Bioelectron. 2020; 173:112777Antiochia R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189015>
18. **Kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19: a descriptive study.** BMC Infect. Dis. 2020; 20:818Wang QJ, Yao YZ, Song JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167900>
19. **Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK Biobank.** BMC Med 2020;

- 18:355Petermann-Rocha F, Hanlon P, Gray SR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167965>
20. **Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.** Cell 2020; Chen Y, Zuiani A, Fischinger S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171099>
21. **Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.** Cell 2020; Su Y, Chen D, Yuan D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33171100>
22. **Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients.** Cell Rep Med 2020:100144Mueller AA, Tamura T, Crowley CP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163981>
23. **Electrochemical investigations for COVID-19 detection-A comparison with other viral detection methods.** Chem. Eng. J. 2020:127575Bukkitgar SD, Shetti NP, Aminabhavi TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162783>
24. **Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centers.** Clin Microbiol Infect 2020; Albert E, Torres I, Bueno F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189872>
25. **High neutrophil to lymphocyte ratio as a prognostic marker in COVID-19 patients.** Clin Nutr ESPEN 2020; 40:101-102Pimentel GD, Dela Vega MCM, Laviano A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183520>
26. **Stability Analysis in COVID-19 Within-Host Model with Immune Response.** Commun Nonlinear Sci Numer Simul 2020:105584Almocera AES, Quiroz G, Hernandez-Vargas EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162723>
27. **Nicotinamide: Oversight of Metabolic Dysfunction through SIRT1, mTOR, and Clock Genes.** Curr. Neurovasc. Res. 2020; Maiese K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33183203>
28. **COVID-19 and Comorbidities: is Inflammation the Underlying Condition in Children? A narrative Review.** Curr. Pediatr. Rev. 2020; Pinna G, Sanfilippo L, Bassareo PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183207>
29. **Shared Resource Laboratory Operations: Changes made during Initial Global COVID-19 Lockdown of 2020.** Cytometry A 2020; Back JB, Chadick CH, Garcia Vallejo JJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175466>
30. **Modifying regulatory practices to create a safe and effective working environment within a Shared Resource Laboratory (SRL) during a global pandemic.** Cytometry A 2020; Filby A, Haviland DL, Jones DD *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33190383>
31. **Pooling samples: a testing option for SARS-CoV-2 during a supply shortage.** Diagn. Microbiol. Infect. Dis. 2020; 99:115205Salimnia H, Mitchell R, Gundel A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33190092>
32. **Analysis of sputum/tracheal aspirate and nasopharyngeal samples for SARS-CoV-2 detection by laboratory-developed test and Panther Fusion system.** Diagn. Microbiol. Infect. Dis. 2020; 99:115228Thwe PM, Ren P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33190093>
33. **Development of Diagnostic Tests for Detection of SARS-CoV-2.** Diagnostics (Base) 2020; 10Nguyen NNT, McCarthy C, Lantigua D, Camci-Unal G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167445>
34. **A COVID-19 Multipurpose Platform.** Digit Biomark 2020; 4:89-98Petrellis N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173844>

35. **Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19.** EMBO Mol Med 2020:e13424Marfia G, Navone S, Guarnaccia L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190411>
36. **Performance of Nucleic Acid Amplification Tests for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Prospectively Pooled Specimens.** Emerg Infect Dis 2020; 27Wang H, Hogan CA, Miller JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183494>
37. **Excretion of SARS-CoV-2 through faecal specimens.** Emerg Microbes Infect 2020:1-28Zhang Y, Chen C, Song Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33161824>
38. **Recommendations for use of the diverse tests for detection of SARS-COV-2 infection.** Enferm. Clin. 2020; Gestoso-Pecellín L, García-Flores Y, González-Quintana P, Marrero-Arencia JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168452>
39. **Sero-epidemiological study of SARS-CoV-2 infection among healthcare personnel in a healthcare department.** Enferm. Infecc. Microbiol. Clin. 2020; Gras-Valentí P, Chico-Sánchez P, Algado-Sellés N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162223>
40. **Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.** Front. Immunol. 2020; 11:584241Borghi MO, Beltagy A, Garrafa E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178218>
41. **A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.** Front. Immunol. 2020; 11:573526Schöler L, Le-Trilling VTK, Eilbrecht M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162987>
42. **Frequencies of CD33+CD11b+HLA-DR-CD14-CD66b+ and CD33+CD11b+HLA-DR-CD14+CD66b- Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19.** Front Med (Lausanne) 2020; 7:580677Alberca RW, Andrade MMS, Branco A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178720>
43. **Analytical and Clinical Validation for RT-qPCR Detection of SARS-CoV-2 Without RNA Extraction.** Front Med (Lausanne) 2020; 7:567572Miranda JP, Osorio J, Videla M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178714>
44. **Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case Severity.** Front. Microbiol. 2020; 11:603509Liu T, Jia P, Fang B, Zhao Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178176>
45. **Clinical Features and Temporal Changes of RT-PCR and Chest CT in COVID-19 Pediatric Patients.** Front Pediatr 2020; 8:579512Xia W, Guo Y, Tian Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163466>
46. **Effective optimization of SARS-CoV-2 laboratory testing variables in an era of supply chain constraints.** Future Microbiol. 2020:1483-1487N SS, Mondal AK, Njau A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179525>
47. **Genomics in the era of COVID-19: ethical implications for clinical practice and public health.** Genome Med. 2020; 12:95Geller G, Duggal P, Thio CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168072>
48. **Composition of the immunoglobulin G glycome associates with the severity of COVID-19.** Glycobiology 2020; Petrović T, Alves I, Bugada D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174592>

49. **Association of HLA-B22 serotype with SARS-CoV-2 susceptibility in Hong Kong Chinese patients.** Hla 2020; Yung YL, Cheng CK, Chan HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179437>
50. **Lower levels of vitamin D are associated with SARS-CoV-2 infection and mortality in the Indian population: An observational study.** Int Immunopharmacol 2020; 88:107001 Padhi S, Suvankar S, Panda VK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182040>
51. **Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D.** Int Immunopharmacol 2020; 88:106995 Silberstein M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182059>
52. **Analysis of the potential impact of genomic variants in global SARS-CoV-2 genomes on molecular diagnostic assays.** Int J Infect Dis 2020; Jain A, Rophina M, Mahajan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181329>
53. **High prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-Sahara Africa.** Int J Infect Dis 2020; Tso FY, Lidenge SJ, Peña PB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176202>
54. **The hematology laboratory's response to the COVID-19 pandemic: A scoping review.** Int. J. Lab. Hematol. 2020; Bell R, Zini G, d'Onofrio G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180380>
55. **Admission cardiac diagnostic testing with electrocardiography and troponin measurement prognosticates increased 30-day mortality in COVID-19.** J Am Heart Assoc 2020:e018476 Poterucha TJ, Elias P, Jain SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169643>
56. **Thyroid function before, during and after COVID-19.** J. Clin. Endocrinol. Metab. 2020; Khoo B, Tan T, Clarke SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180932>
57. **Extensive Testing and Public Health Interventions for the Control of COVID-19 in the Republic of Cyprus between March and May 2020.** J Clin Med 2020; 9:Quattrocchi A, Mamais I, Tsioutis C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171651>
58. **Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus.** J Clin Virol 2020; 133:104684 Mak GC, Lau SS, Wong KK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176236>
59. **Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples.** J. Immunol. Methods 2020:112909 Black MA, Shen G, Feng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166549>
60. **Analysis of a persistent viral shedding patient infected with SARS-CoV-2 by RT-qPCR, FilmArray Respiratory Panel v2.1, and antigen detection.** J Infect Chemother 2020; Hirotsu Y, Maejima M, Shibusawa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183963>
61. **Detection of SARS-CoV-2 in Nasal Swabs: comparison with Nasopharyngeal Swabs.** J Infect Dev Ctries 2020; 14:1081-1083 Kim HA, Hyun M, Lee JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175699>
62. **SARS-CoV-2 seroprevalence and antibody kinetics among health care workers in a Spanish hospital after three months of follow-up.** J Infect Dis 2020; Moncunill G, Mayor A, Santano R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175145>

63. **Desaturation and heme elevation during COVID-19 infection: A potential prognostic factor of heme oxygenase-1.** J Microbiol Immunol Infect 2020; Su WL, Lin CP, Hang HC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176981>
64. **Determining the relationship between SARS-CoV-2 infection, dopamine, and COVID-19 complications.** J Taibah Univ Med Sci 2020; Khalefah MM, Khalifah AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173452>
65. **Venous thrombosis, thromboembolism and biomarkers of inflammation and coagulation in COVID-19.** J Vasc Surg Venous Lymphat Disord 2020; Thondapu V, Montes D, Rosovsky R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188961>
66. **Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of IL-23.** JAAD Case Rep 2020; Ward M, Gooderham M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173806>
67. **Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19.** Kidney Blood Press. Res. 2020;1-15Chaudhri I, Moffitt R, Taub E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171466>
68. **Effect of pre-existing diseases on COVID-19 infection and role of new sensors and biomaterials for its detection and treatment.** Med Devices Sens 2020:e10140Singh A, Kumar M, Dubey AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173852>
69. **Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus.** medRxiv 2020; Gupta S, Nakabo S, Chu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184616>
70. **A Genome Epidemiological Study of SARS-CoV-2 Introduction into Japan.** mSphere 2020; 5Sekizuka T, Itokawa K, Hashino M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177213>
71. **Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.** mSphere 2020; 5Vetter P, Eberhardt CS, Meyer B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177214>
72. **High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households.** One Health 2020; 11:100192Fritz M, Rosolen B, Krafft E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169106>
73. **Analysis of genomic distributions of SARS-CoV-2 reveals a dominant strain type with strong allelic associations.** Proc Natl Acad Sci U S A 2020; Yang HC, Chen CH, Wang JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184173>
74. **Severe, Symptomatic Reinfection in a Patient with COVID-19.** R I Med J (2013). 2020; 103:24-26Selvaraj V, Herman K, Dapaah-Afryie K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172223>
75. **COVID-19 susceptibility in pregnancy: Immune/inflammatory considerations, the role of placental ACE-2 and research considerations.** Reprod. Biol. 2020; Malinowski AK, Noureldin A, Othman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183974>
76. **High-density lipoprotein cholesterol as a factor affecting virus clearance in covid-19 patients.** Respir. Med. 2020; 175:106218Ding X, Zhang J, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181413>
77. **[Sars-CoV-2 genomic and phylodynamic analyses].** Rev Francoph Lab 2020; 2020:57-62Elie B, Alizon S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163105>
78. **Detection of SARS-CoV-2 RNA in hospital wastewater from a low COVID-19 disease prevalence area.** Sci Total Environ 2020:143226Gonçalves J, Koritnik T,

- Mioč V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176933>
79. **Review on the contamination of wastewater by COVID-19 virus: Impact and treatment.** *Sci Total Environ* 2021; 751:142325Lahrich S, Laghrib F, Farahi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182015>
 80. **How should diagnostic kits development adapt quickly in COVID 19-like pandemic models? Pros and cons of sensory platforms used in COVID-19 sensing.** *Talanta* 2021; 222:121534Moulahoum H, Ghorbanizamani F, Zihnioglu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167242>
 81. **Unexpected detection of SARS-CoV-2 antibodies in the pre-pandemic period in Italy.** *Tumori* 2020;300891620974755Apolone G, Montomoli E, Manenti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176598>
 82. **Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein.** *Vaccine* 2020; 38:7697-7701Muraoka D, Situo D, Sawada SI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164796>
 83. **Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN- γ as a Novel Antiviral Approach Against COVID-19.** *Viral Immunol* 2020; Anjum FR, Anam S, Abbas G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181057>
 84. **COVID-19: Way Forward With Serosurveillance Without Overemphasizing Neutralizing Antibodies.** *Viral Immunol* 2020; Krsak M, Henao-Martínez AF, Franco-Paredes C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181055>
 85. **Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand.** *Virology* 2020; 17:177Chaimayo C, Kaewnaphan B, Tanlieng N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187528>
 86. **A Prognostic Model to Predict Recovery of COVID-19 Patients Based on Longitudinal Laboratory Findings.** *Virology* 2020;1-9Tian S, Zhu X, Sun X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170450>
 87. **Novel biomarkers for the prediction of COVID-19 progression a retrospective, multi-center cohort study.** *Virology* 2020; 11:1569-1581Yu Y, Liu T, Shao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172355>
 88. **CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study.** *Viruses* 2020; 12Calvet J, Gratacós J, Amengual MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182268>
 89. **A Cell-Based ELISA to Improve the Serological Analysis of Anti-SARS-CoV-2 IgG.** *Viruses* 2020; 12Zarletti G, Tiberi M, De Molfetta V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171590>

Children (26 articles)

1. **Multisystem inflammatory syndrome in children rose and fell with the first wave of the COVID-19 pandemic in France.** *Acta Paediatr* 2020; Carbajal R, Lorrot M, Levy Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190340>
2. **Clinical characteristics of 10 children with a pediatric inflammatory multisystem syndrome associated with COVID-19 in Iran.** *BMC Pediatr.* 2020; 20:513Shahbaznejad L, Navaeifar MR, Abbaskhanian A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167916>

3. **Reporting of child maltreatment during the SARS-CoV-2 pandemic in New York City from March to May 2020.** Child Abuse Negl. 2020:104719Rapoport E, Reiser H, Schoeman E, Adelman A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162107>
4. **Endomyocardial Biopsy in a Pediatric Patient With Cardiac Manifestations of COVID-19.** Circ Heart Fail 2020:Circheartfailure120007384Laurence C, Haini M, Thiruchelvam T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176458>
5. **Changes in pediatric emergency department visits for mental health during the COVID-19 pandemic: A cross-sectional study.** Clin. Child Psychol. Psychiatry 2020:1359104520972453Leff RA, Setzer E, Cicero MX, Auerbach M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183097>
6. **Susceptibility to Sars-COV-2 Infection Among Children And Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain.** Clin Infect Dis 2020; Brotons P, Launes C, Buetas E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180914>
7. **COVID-19 and Comorbidities: is Inflammation the Underlying Condition in Children? A narrative Review.** Curr. Pediatr. Rev. 2020; Pinna G, Sanfilippo L, Bassareo PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183207>
8. **Rehabilitation services lockdown during the COVID-19 emergency: the mental health response of caregivers of children with neurodevelopmental disabilities.** Disabil. Rehabil. 2020:1-6Grumi S, Provenzi L, Gardani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167738>
9. **A Pediatric Strategy for the Next Phase of the SARS-CoV-2 Pandemic.** Front Pediatr 2020; 8:582798Buonsenso D, Valentini P, Moscato U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163467>
10. **A Fatal Course of Multiple Inflammatory Syndrome in Children Coinfection with Dengue. A Case Report from Indonesia.** IDCases 2020:e01002Somasetia DH, Malahayati TT, Andriyani FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163360>
11. **Stress, Resilience, and Well-Being in Italian Children and Their Parents during the COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17Cusinato M, Iannattone S, Spoto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182661>
12. **Psychological response of children to home confinement during COVID-19: A qualitative arts-based research.** Int J Soc Psychiatry 2020:20764020972439Abdulah DM, Abdulla BMO, Liamputtong P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183155>
13. **Telling the Truth to Child Cancer Patients in COVID-19 Times.** J. Bioeth. Inq. 2020:1-5Gillam L, Spriggs M, Delany C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169257>
14. **Caregiver Satisfaction and Effectiveness of Teleconsultation in Children and Adolescents With Migraine During the Ongoing COVID-19 Pandemic.** J. Child Neurol. 2020:883073820968653Sharawat IK, Panda PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170754>
15. **Awareness, Perception, Attitude Regarding CoViD -19 and Infection Control among Indian Pediatric Dentists: A Cross Sectional Study.** J. Clin. Pediatr. Dent. 2020; 44:211-220Maru V, Padawe D, Singh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167013>
16. **Multisystem Inflammatory Syndrome in Children.** J. Emerg. Med. 2020; Tabaac S, Kothari P, Cassidy-Smith T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162259>

17. **The Impact of COVID-19 on the Delivery of an Evidence-Based Child Maltreatment Prevention Program: Understanding the Perspectives of SafeCare® Providers.** *J Fam Violence* 2020;1-11 Self-Brown S, Reuben K, Perry EW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173254>
18. **Multisystem Inflammatory Syndrome in Children Related to COVID-19: the First Case in Korea.** *J Korean Med Sci* 2020; 35:e391 Kim H, Shim JY, Ko JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169560>
19. **New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19.** *J. Pediatr. Endocrinol. Metab.* 2020; Naguib MN, Raymond JK, Vidmar AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180050>
20. **Relationship between parenting practices and children's screen time during the COVID-19 Pandemic in Turkey.** *J. Pediatr. Nurs.* 2020; 56:24-29 Ozturk Eyimaya A, Yalçın Irmak A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181369>
21. **COVID-19 pandemic: Early effects on pediatric rehabilitation medicine training.** *J. Pediatr. Rehabil. Med.* 2020; Kivlehan E, Chaviano K, Fetsko L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164964>
22. **Pediatric intrathecal baclofen management during the COVID-19 pandemic in the US and Canad.** *J. Pediatr. Rehabil. Med.* 2020; Thomas SP, Hardesty CK, Buxton KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164962>
23. **Protein losing enteropathy and pneumatosis intestinalis in a child with COVID 19 infection.** *J Pediatr Surg Case Rep* 2021; 64:101667 Rohani P, Karimi A, Tabatabaie SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173753>
24. **[Corona in Children: the Co-Ki Study].** *Monatsschr Kinderheilkd* 2020;1-6 Schwarz S, Jenetzky E, Krafft H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162611>
25. **Strategies to exiting the COVID-19 lockdown for workplace and school: A scoping review.** *Saf Sci* 2021; 134:105067 D'Angelo D, Sinopoli A, Napoletano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162676>
26. **CAFE: An Instructional Design Model to Assist K-12 Teachers to Teach Remotely during and beyond the Covid-19 Pandemic.** *TechTrends* 2020;1-9 Wang CX. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169121>

Clinical Features (39 articles)

1. **The coronavirus disease 2019: the prevalence, prognosis, and recovery from olfactory dysfunction (OD).** *Acta Otolaryngol.* 2020;1-10 Samimi Ardestani SH, Mohammadi Ardehali M, Rabbani Anari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176530>
2. **Multisystem inflammatory syndrome in children rose and fell with the first wave of the COVID-19 pandemic in France.** *Acta Paediatr* 2020; Carbajal R, Lorrot M, Levy Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190340>
3. **Identifying patients with symptoms suspicious for COVID-19 at elevated risk of adverse events: The COVAS score.** *Am J Emerg Med* 2020; Sharp AL, Huang BZ, Broder B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189516>
4. **Sleep Disordered Breathing Among Hospitalized Patients due to COVID-19.** *Am J Respir Crit Care Med* 2020; Perger E, Soranna D, Pengo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180549>
5. **Clinical and radiographic characteristics, management and short-term outcomes of patients with COVID-19 in Wenzhou, China.** *BMC Infect. Dis.* 2020;

- 20:841Hong L, Ye E, Sun G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187475>
6. **First patient management of COVID-19 in Changsha, China: a case report.** BMC Infect. Dis. 2020; 20:824Zhou J, Cao Z, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176693>
 7. **Clinical characteristics of 10 children with a pediatric inflammatory multisystem syndrome associated with COVID-19 in Iran.** BMC Pediatr. 2020; 20:513Shahbaznejad L, Navaeifar MR, Abbaskhanian A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167916>
 8. **Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study.** BMJ Open 2020; 10:e042398Jiménez E, Fontán-Vela M, Valencia J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172949>
 9. **Clinical characteristics of inpatients with Coronavirus disease 2019 and acute ischemic stroke: from epidemiology to outcomes.** Curr. Neurovasc. Res. 2020; Chen S, Pan C, Zhang P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176647>
 10. **Clinical characteristics and outcomes of severe or critical COVID-19 patients presenting no respiratory symptoms or fever at onset.** Engineering.(Beijing) 2020; Xu J, Yin Z, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163252>
 11. **The Clinical Features and Prognostic Assessment of SARS-CoV-2 Infection-Induced Sepsis Among COVID-19 Patients in Shenzhen, China.** Front Med (Lausanne) 2020; 7:570853Ren C, Yao RQ, Ren D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178716>
 12. **A suspected case of COVID-19 turned into a confirmed case: a case report.** Future Virol. 2020; 15:335-339Yang D, Wei K, Gao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169084>
 13. **Epidemiological and clinical characteristics of patients with COVID-19 from a designated hospital in Hangzhou City: a retrospective observational study.** Hong Kong Med. J. 2020; Gao J, Zhang S, Zhou K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177240>
 14. **Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients - a prospective observational study.** Infect Dis (Lond) 2020:1-11Auvinen R, Nohynek H, Syrjänen R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170050>
 15. **Systematically comparing COVID-19 with 2009 influenza pandemic for hospitalized patients.** Int J Infect Dis 2020; Li P, Wang Y, Peppelenbosch MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189938>
 16. **Clinical characteristics and longitudinal chest CT features of healthcare workers hospitalized with coronavirus disease 2019 (COVID-19).** Int. J. Med. Sci. 2020; 17:2644-2652Liu H, Luo S, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162792>
 17. **May 2020: Is It Always COVID-19 No Matter What?** Int Med Case Rep J 2020; 13:563-567Livrieri F, Ghidoni G, Piro R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173352>
 18. **Clinical characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room: a single-center retrospective study.** Intern Emerg Med 2020:1-10Di Domenico SL, Coen D, Bergamaschi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175297>

19. **Clinical presentations of pain in patients with COVID-19 infection.** Ir. J. Med. Sci. 2020; Murat S, Dogruoz Karatekin B, Icgasioglu A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33188626>
20. **Clinical characteristics of COVID-19 patients with asthma in Wuhan, China: a retrospective cohort study.** J. Asthma 2020;1-14 Jin M, Chen C, Huang J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33183117>
21. **Clinical significance of the serum IgM and IgG to SARS-CoV-2 in coronavirus disease-2019.** J. Clin. Lab. Anal. 2020:e23649 Wu LX, Wang H, Gou D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33184940>
22. **Clinical Features and Pathogenic Mechanisms of Gastrointestinal Injury in COVID-19.** J Clin Med 2020; 9 Mitsuyama K, Tsuruta K, Takedatsu H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33187280>
23. **Lessons From the First Wave of the Pandemic: Skin Features of COVID-19 can be Divided Into Inflammatory and Vascular Patterns.** J. Cutan. Med. Surg. 2020:1203475420972343 Naderi-Azad S, Vender R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33179534>
24. **Cutaneous eruption in COVID-19-infected patients in Thailand: An observational descriptive study.** J. Dermatol. 2020; Punyaratabandhu P, Chirachanakul P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180327>
25. **An itchy erythematous papular skin rash as a possible early sign of COVID-19: a case report.** J Med Case Rep 2020; 14:216 Serafini A, Kurotschka PK, Bertolani M, Riccomi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168054>
26. **Evaluating Clinical Course and Risk Factors of Infection and Demographic Characteristics of Pregnant Women with COVID-19 in Hamadan Province, West of Iran.** J Res Health Sci 2020; 20:e00488 Sattari M, Bashirian S, Masoumi SZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169720>
27. **Unilateral livedo reticularis in COVID-19 patient: Case with fatal outcome.** JAAD Case Rep 2020; Tusheva I, Damevska K, Dimitrovska I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169105>
28. **Suspected appendicitis and COVID-19, a change in investigation and management-a multicentre cohort study.** Langenbecks Arch. Surg. 2020:1-9 English W, Habib Bedwani N, Smith C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169297>
29. **Subjective evaluation of smell and taste dysfunction in patients with mild COVID-19 in Spain.** Med Clin (Barc) 2020; Ninchritz-Becerra E, Soriano-Reixach MM, Mayo-Yáñez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168151>
30. **Chikungunya fever and COVID-19: oral ulcers are a common feature.** Oral Dis 2020; Gueiros LA, Neves MCS, Marques CDL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33179342>
31. **Attributes of Dysgeusia and Anosmia of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients.** Oral Dis 2020; Samaranayake LP, Fakhruddin KS, Mohammad OE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176049>
32. **Potential Influence of Olfactory, Gustatory, and Pharyngolaryngeal Sensory Dysfunctions on Swallowing Physiology in COVID-19.** Otolaryngol Head Neck Surg 2020:194599820972680 Vergara J, Lirani-Silva C, Brodsky MB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167752>
33. **[Covid-19: clinical aspects and management].** Rev Francoph Lab 2020; 2020:40-47 Desvaux É, Faucher JF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163103>

34. **[Ocular manifestations of viral diseases].** Rev. Med. Interne 2020; Devilliers MJ, Ben Hadj Salah W, Barreau E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168354>
35. **[Analysis of anti-SARS-CoV-2 IgG antibodies in hematologic patients with asymptomatic or mildly symptomatic COVID-19 infections].** Rinsho Ketsueki 2020; 61:1459-1463 Hagihara M, Ohara S, Ide S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162440>
36. **COVID-19 in HIV: a Review of Published Case Reports.** SN Compr Clin Med 2020:1-11 Morani Z, Patel S, Ghosh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163861>
37. **Using Anti-SARS-CoV-2 IgG and IgM Antibodies to Detect Outpatient Cases with Olfactory and Taste Disorders Suspected as Mild Form of COVID-19: a Retrospective Survey.** SN Compr Clin Med 2020:1-7 Taziki Balajelini MH, Vakili MA, Saeidi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169109>
38. **Clinical course of COVID-19 disease in immunosuppressed renal transplant patients.** Turk J Med Sci 2020; Dheir H, Sipahi S, Yaylaci S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185367>
39. **Characteristics and Outcomes of Critically Ill Patients with Covid-19 in Sakarya, Turkey: A Single Center Cohort Study.** Turk J Med Sci 2020; Kocayigit H, Özmen SÜner K, Tomak Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185365>

CNS (16 articles)

1. **Is Guillain Barre syndrome truly caused by SARS-CoV-2?** Am J Emerg Med 2020; Finsterer J, Scorza CA, Scorza FA, Fiorini AC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172743>
2. **COVID-19-associated encephalitis successfully treated with combination therapy.** Clin Infect Pract 2020:100053 Freire-Álvarez E, Guillén L, Lambert K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163956>
3. **Neurological manifestations associated with COVID-19: a multicentric registry.** Clin Microbiol Infect 2020; Meppiel E, Peiffer-Smadja N, Maury A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189873>
4. **Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review.** Clin. Neurol. Neurosurg. 2020:106349 Kubota T, Kuroda N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172719>
5. **A COVID-19 Multipurpose Platform.** Digit Biomark 2020; 4:89-98 Petrellis N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173844>
6. **A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies.** eNeurologicalSci 2020; 21:100287 Kataria S, Tandon M, Melnic V, Sriwastava S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163634>
7. **Locked-in Syndrome in a Young Patient Due to SARS-CoV-2: A Case Report.** Front Med (Lausanne) 2020; 7:574690 Sattar SBA, Iqbal QZ, Haider MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178718>
8. **An Italian Neurorehabilitation Hospital Facing the SARS-CoV-2 Pandemic: Data From 1207 Patients and Workers.** Front. Neurol. 2020; 11:584317 Salvia A, Morone G, Iosa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162930>

9. **Potential Role of Autonomic Dysfunction in Covid-19 Morbidity and Mortality.** Front. Physiol. 2020; 11:561749 Del Rio R, Marcus NJ, Inestrosa NC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178034>
10. **Neurological manifestations of Coronavirus Infections: Role of Angiotensin-Converting Enzyme 2 in COVID-19.** Int. J. Neurosci. 2020:1-11 Parsamanesh N, Pezeshgi A, Hemmati M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175635>
11. **Nurses' perceptions and demands regarding COVID-19 care delivery in critical care units and hospital emergency services.** Intensive Crit Care Nurs 2020:102966 González-Gil MT, González-Blázquez C, Parro-Moreno AI *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33172732>
12. **Encephalopathy as the Presenting Symptom of COVID-19.** Kans J Med 2020; 13:272-274 Hayat U, Ahmed S, Hussain MA, Hameed N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173565>
13. **Subjective evaluation of smell and taste dysfunction in patients with mild COVID-19 in Spain.** Med Clin (Barc) 2020; Ninchritz-Becerra E, Soriano-Reixach MM, Mayo-Yáñez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168151>
14. **Reversible Myoclonus-Ataxia as a Postinfectious Manifestation of COVID-19.** Mov Disord Clin Pract 2020; 7:977-979 Schellekens MMI, Bleeker-Rovers CP, Keurlings PAJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163570>
15. **The Need for Digital Health Solutions in Deep Brain Stimulation for Parkinson's Disease in the Time of COVID-19 and Beyond.** Neuromodulation 2020; Rammo R, Gostkowski M, Rasmussen PA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33174292>
16. **Attributes of Dysgeusia and Anosmia of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients.** Oral Dis 2020; Samaranayake LP, Fakhruddin KS, Mohammad OE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176049>

Coagulation (16 articles)

1. **Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.** Adv Respir Med 2020; 88:468-469 Mohebbi N, Abedini A, Lashgari R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169824>
2. **Thrombosis in Hospitalized Patients with Viral Respiratory Infections versus COVID-19.** Am. Heart J. 2020; Smilowitz NR, Subashchandran V, Yuriditsky E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181067>
3. **Pulmonary Endothelial Dysfunction and Thrombotic Complications in COVID-19 Patients.** Am. J. Respir. Cell Mol. Biol. 2020; Rodríguez C, Luque N, Blanco I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180562>
4. **COVID-19, thromboembolic risk, and Virchow's triad: Lesson from the past.** Clin. Cardiol. 2020; Mehta JL, Calcaterra G, Bassareo PP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33176009>
5. **COVID-19 pneumonia and pulmonary microembolism in a patient with B-thalassemia major.** Clin Case Rep 2020; Marziali M, Ribersani M, Losardo AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173583>
6. **Spontaneous Brainstem Hemorrhagic Stroke in the Setting of Novel Coronavirus Disease 2019 - A Case Report.** Cureus 2020; 12:e10809 Flores G, Kumar JI, Pressman E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163313>

7. **Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.** Eur J Intern Med 2020; Di Nisio M, Potere N, Candeloro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162299>
8. **Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.** Front. Immunol. 2020; 11:584241Borghi MO, Beltagy A, Garrafa E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178218>
9. **Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: autopsy results from 'Spanish flu' 1918/1919 in Switzerland to Coronavirus disease 2019.** J Pathol Clin Res 2020; Burkhard-Koren NM, Haberecker M, Maccio U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185036>
10. **Cerebral Venous Sinus Thrombosis in COVID-19 Infection: A Case Series and Review of The Literature.** J. Stroke Cerebrovasc. Dis. 2020; 30:105434Dakay K, Cooper J, Bloomfield J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190109>
11. **Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness.** J Thromb Haemost 2020; 18:3099-3105Goldenberg NA, Sochet A, Albisetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174388>
12. **Venous thrombosis, thromboembolism and biomarkers of inflammation and coagulation in COVID-19.** J Vasc Surg Venous Lymphat Disord 2020; Thondapu V, Montes D, Rosovsky R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188961>
13. **Coagulopathies in novel coronavirus (SARS-CoV-2) pandemic: emerging evidence for hematologists.** Saudi J. Biol. Sci. 2020; AlSubaie AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169062>
14. **Lower limb deep vein thrombosis in COVID-19 patients admitted to intermediate care respiratory units.** Thromb Res 2020; 197:44-47Pancani R, Villari L, Foci V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181470>
15. **Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study.** Thromb Res 2020; 197:94-99Planquette B, Le Berre A, Khider L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190025>
16. **Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:920Lins PRG, de Albuquerque CCC, Assis CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176886>

Complications (73 articles)

1. **Prone positioning in mechanically ventilated patients with severe acute respiratory distress syndrome and coronavirus disease 2019.** Acta Anaesthesiol. Scand. 2020; Gleissman H, Forsgren A, Andersson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165936>
2. **COVID-19 patients in intensive care develop predominantly oliguric acute kidney injury.** Acta Anaesthesiol. Scand. 2020; Luther T, Bülow-Anderberg S, Larsson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190222>

3. **An inaugural diabetic ketoacidosis with acute pancreatitis during COVID-19.** Acta Diabetol 2020; Tollard C, Champenois V, Delemer B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33184733>
4. **The coronavirus disease 2019: the prevalence, prognosis, and recovery from olfactory dysfunction (OD).** Acta Otolaryngol. 2020:1-10 Samimi Ardestani SH, Mohammadi Ardehali M, Rabbani Anari M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33176530>
5. **Risk factors for intensive care unit admission and mortality in hospitalized COVID-19 patients.** Acute Crit Care 2020; Ayaz A, Arshad A, Malik H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33172229>
6. **Experience of percutaneous tracheostomy in critically ill COVID-19 patients.** Acute Crit Care 2020; Kim EJ, Yoo EH, Jung CY, Kim KC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33176402>
7. **Pneumomediastinum and subcutaneous emphysema after noninvasive ventilation in a COVID-19 patient.** Adv Respir Med 2020; 88:466-467 Vazzana N, Ognibene S, Dipaola F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169823>
8. **Biomimetic Human Disease Model of SARS-CoV-2 Induced Lung Injury and Immune Responses on Organ Chip System.** Adv Sci (Weinh). 2020:2002928 Zhang M, Wang P, Luo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173719>
9. **A predictive model for the severity of COVID-19 in elderly patients.** Aging (Albany NY) 2020; 12 Zeng F, Deng G, Cui Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33170150>
10. **Thrombosis in Hospitalized Patients with Viral Respiratory Infections versus COVID-19.** Am. Heart J. 2020; Smilowitz NR, Subashchandran V, Yuriditsky E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181067>
11. **Adapted Diving Mask (ADM) device as respiratory support with oxygen output during COVID-19 pandemic.** Am J Emerg Med 2020; Bibiano-Guillen C, Arias-Arcos B, Collado-Escudero C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172745>
12. **Identifying patients with symptoms suspicious for COVID-19 at elevated risk of adverse events: The COVAS score.** Am J Emerg Med 2020; Sharp AL, Huang BZ, Broder B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189516>
13. **SARS-CoV-2: Influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP)-metabolism and on severity of COVID-19.** Am J Physiol Endocrinol Metab 2020; van Kempen TA, Deixler E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33174766>
14. **In well-differentiated primary human bronchial epithelial cells, TGF- β 1 and TGF- β 2 induce expression of furin.** Am J Physiol Lung Cell Mol Physiol 2020; O'Sullivan MJ, Mitchel JA, Mwase C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174447>
15. **Pulmonary Endothelial Dysfunction and Thrombotic Complications in COVID-19 Patients.** Am. J. Respir. Cell Mol. Biol. 2020; Rodríguez C, Luque N, Blanco I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180562>
16. **Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium.** Anaesth Crit Care Pain Med 2020; Rello J, Belliato M, Dimopoulos MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172592>
17. **Caution against precaution: A case report on silent hypoxia in COVID-19.** Ann Med Surg (Lond) 2020; 60:301-303 Lari A, Alherz M, Nouri A *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169089>
18. **Short-term outcomes after Ivor Lewis oesophagectomy for cancer during the COVID-19 pandemic.** *Ann. R. Coll. Surg. Engl.* 2020; Chan D, MacCormick A, Rashid B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179514>
 19. **PRactice of VENTilation in Patients with Novel Coronavirus Disease (PProVENT-COVID): rationale and protocol for a national multicenter observational study in The Netherlands.** *Ann Transl Med* 2020; 8:1251Boers NS, Botta M, Tsonas AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178783>
 20. **Red cell distribution width (RDW): a prognostic indicator of severe COVID-19.** *Ann Transl Med* 2020; 8:1230Wang C, Zhang H, Cao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178762>
 21. **Lymphocyte percentage and hemoglobin as a joint parameter for the prediction of severe and nonsevere COVID-19: a preliminary study.** *Ann Transl Med* 2020; 8:1231Zhang W, Zhang Z, Ye Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178763>
 22. **Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza - a single-center registry study.** *Artif. Organs* 2020; Jäckel M, Rilinger J, Lang CN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188714>
 23. **Differences in terms of presentation and outcomes between patients with lung cancer as opposed to other solid organ cancer after infection with SARS-CoV-2: protocol for a systematic review.** *BMJ Open* 2020; 10:e041790Chen H, Shi J, Shi W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172947>
 24. **Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study.** *BMJ Open* 2020; 10:e042398Jiménez E, Fontán-Vela M, Valencia J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172949>
 25. **Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.** *BMJ Open* 2020; 10:e041520Tavernier E, McNicholas B, Pavlov I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177145>
 26. **SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients.** *Cancers (Basel)* 2020; 12Quagliariello V, Bonelli A, Caronna A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182653>
 27. **SARS-CoV-2 Infection in Cancer Patients: Effects on Disease Outcomes and Patient Prognosis.** *Cancers (Basel)* 2020; 12Seth G, Sethi S, Bhattarai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167313>
 28. **COVID-19 pneumonia and pulmonary microembolism in a patient with B-thalassemia major.** *Clin Case Rep* 2020; Marziali M, Ribersani M, Losardo AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173583>
 29. **COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort.** *Clin Rheumatol* 2020; Pellegrino G, Mohammad Reza Beigi D, Angelelli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188620>
 30. **Spontaneous Brainstem Hemorrhagic Stroke in the Setting of Novel Coronavirus Disease 2019 - A Case Report.** *Cureus* 2020; 12:e10809Flores G, Kumar JI, Pressman E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163313>
 31. **Providing Culturally Competent Care for COVID-19 Intensive Care Unit Delirium: A Case Report and Review.** *Cureus* 2020; 12:e10867Lomiguen CM,

- Rosete I, Chin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178520>
32. **Outcomes of COVID-19 in Solid Organ Transplants.** Cureus 2020; 12:e11344Ranabothu S, Kanduri SR, Nalleballe K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173653>
 33. **Decreased Mortality in Patients With Severe Bronchospasm Associated With SARS-CoV-2: An Alternative to Invasive Mechanical Ventilation.** Cureus 2020; 12:e10822Salazar R, Sr., Hallo A, Vasquez S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173630>
 34. **Is Timing of Tracheotomy a Factor Influencing the Clinical Course in COVID-19 Patients?** Ear Nose Throat J 2020:145561320974140Mesolella M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172287>
 35. **A case of postpartum thyroiditis following SARS-CoV-2 infection.** Endocr. J. 2020; Mizuno S, Inaba H, Kobayashi KI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177251>
 36. **Clinical characteristics and outcomes of severe or critical COVID-19 patients presenting no respiratory symptoms or fever at onset.** Engineering.(Beijing) 2020; Xu J, Yin Z, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163252>
 37. **Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.** Eur J Heart Fail 2020; Tomasoni D, Inciardi RM, Lombardi CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179839>
 38. **Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.** Eur J Intern Med 2020; Di Nisio M, Potere N, Candeloro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162299>
 39. **Predictors of COVID-19 severity: a systematic review and meta-analysis.** F1000Res 2020; 9:1107Mudatsir M, Fajar JK, Wulandari L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163160>
 40. **Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.** Front. Immunol. 2020; 11:584241Borghini MO, Beltagy A, Garrafa E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178218>
 41. **The Clinical Features and Prognostic Assessment of SARS-CoV-2 Infection-Induced Sepsis Among COVID-19 Patients in Shenzhen, China.** Front Med (Lausanne) 2020; 7:570853Ren C, Yao RQ, Ren D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178716>
 42. **Locked-in Syndrome in a Young Patient Due to SARS-CoV-2: A Case Report.** Front Med (Lausanne) 2020; 7:574690Sattar SBA, Iqbal QZ, Haider MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178718>
 43. **Pathophysiology of Cardiovascular Complications in COVID-19.** Front. Physiol. 2020; 11:575600Petrovic V, Radenkovic D, Radenkovic G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162899>
 44. **A Fatal Course of Multiple Inflammatory Syndrome in Children Coinfection with Dengue. A Case Report from Indonesia.** IDCases 2020:e01002Somasetia DH, Malahayati TT, Andriyani FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163360>
 45. **Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients - a prospective observational study.** Infect Dis

- (Lond) 2020:1-11 Auvinen R, Nohynek H, Syrjänen R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33170050>
46. **Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.** *J. Cardiol.* 2020; Ren L, Yu S, Xu W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33168337>
 47. **COVID-19 Hospitalization in Adults with Type 1 Diabetes: Results from the T1D Exchange Multi-Center Surveillance Study.** *J. Clin. Endocrinol. Metab.* 2020; O'Malley G, Ebekozen O, Desimone M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165563>
 48. **Multisystem Inflammatory Syndrome in Children.** *J. Emerg. Med.* 2020; Tabaac S, Kothari P, Cassidy-Smith T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162259>
 49. **Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV-A Case Report from Argentina and Literature Review.** *J Fungi (Basel)* 2020; 6 Messina FA, Marin E, Caceres DH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33182836>
 50. **Immune responses and residual SARS-CoV-2 in two critically ill COVID-19 patients before and after lung transplantation.** *J Infect* 2020; Yan Y, Jiang X, Fu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188798>
 51. **An Acute Pulmonary Coccidioidomycosis Coinfection in a Patient Presenting With Multifocal Pneumonia With COVID-19.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620972244 Chang CC, Senining R, Kim J, Goyal R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167717>
 52. **Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: autopsy results from 'Spanish flu' 1918/1919 in Switzerland to Coronavirus disease 2019.** *J Pathol Clin Res* 2020; Burkhard-Koren NM, Haberecker M, Maccio U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185036>
 53. **Determining the relationship between SARS-CoV-2 infection, dopamine, and COVID-19 complications.** *J Taibah Univ Med Sci* 2020; Khalefah MM, Khalifah AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173452>
 54. **Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness.** *J Thromb Haemost* 2020; 18:3099-3105 Goldenberg NA, Sochet A, Albisetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174388>
 55. **The Use of POCUS to Manage ICU Patients With COVID-19.** *J Ultrasound Med* 2020; Schriff D, Barron K, Arya R, Choe C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174650>
 56. **Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19.** *Kidney Blood Press. Res.* 2020:1-15 Chaudhri I, Moffitt R, Taub E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171466>
 57. **Myoclonus and COVID-19: A Challenge for the Present, a Lesson for the Future.** *Mov Disord Clin Pract* 2020; 7:888-890 Latorre A, Rothwell JC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163558>
 58. **Reversible Myoclonus-Ataxia as a Postinfectious Manifestation of COVID-19.** *Mov Disord Clin Pract* 2020; 7:977-979 Schellekens MMI, Bleeker-Rovers CP, Keurlings PAJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163570>
 59. **Acute kidney failure in patients admitted due to COVID-19.** *Nefrologia* 2020; Tarragón B, Valdenebro M, Serrano ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163570>

term=33162225

60. **[Air ambulance intensive care transport in prone position for COVID-19 ARDS].** Notf Rett Med 2020;1-5Schellhaaß A, Pösel S, Schwietring J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173408>
61. **ECMO implantation training: Needle penetration in 3D printable materials and porcine aorta.** Perfusion 2020;267659120967194Salewski C, Spintzyk S, von Steuben T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174474>
62. **Tuberculosis and COVID-19.** Pneumologie 2020; 74:639Manych M.
63. **Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients.** Public Health 2020; 189:66-72Prado-Galbarro FJ, Sanchez-Piedra C, Gamiño-Arroyo AE, Cruz-Cruz C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166857>
64. **Type A Aortic Dissection during COVID-19 Pandemic: Report from Tertiary Aortic Centers in the United States and China.** Semin. Thorac. Cardiovasc. Surg. 2020; Fukuhara S, Tang H, Kim KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171243>
65. **COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatlenT Outcomes in North London) cohort study.** Ther. Adv. Med. Oncol. 2020; 12:1758835920971147Crolley VE, Hanna D, Joharatnam-Hogan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178336>
66. **ICU outcomes in Covid-19 patients with obesity.** Ther. Adv. Respir. Dis. 2020; 14:1753466620971146Parikh R, Garcia MA, Rajendran I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176612>
67. **Lower limb deep vein thrombosis in COVID-19 patients admitted to intermediate care respiratory units.** Thromb Res 2020; 197:44-47Pancani R, Villari L, Foci V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181470>
68. **Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study.** Thromb Res 2020; 197:94-99Planquette B, Le Berre A, Khider L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190025>
69. **Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection.** Transpl Infect Dis 2020:e13500Chowdary P, Shetty S, Booth J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174284>
70. **Cardiovascular Manifestations and Mechanisms in Patients with COVID-19.** Trends Endocrinol. Metab. 2020; Dou Q, Wei X, Zhou K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172748>
71. **Characteristics and Outcomes of Critically Ill Patients with Covid-19 in Sakarya, Turkey: A Single Center Cohort Study.** Turk J Med Sci 2020; Kocayİğİt H, Özmen SÜner K, Tomak Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185365>
72. **A Prognostic Model to Predict Recovery of COVID-19 Patients Based on Longitudinal Laboratory Findings.** Virologica Sinica 2020;1-9Tian S, Zhu X, Sun X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170450>
73. **Specific Management of Patients with Acute Abdomen during the COVID-19 Pandemic: A Surgical Perspective from Germany.** Visc Med 2020; 36:417-420Kühn F, Klein M, Laven H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173797>

Cured – Recovered (3 articles)

1. **Residual Lung Injury in Patients Recovering From COVID-19 Critical Illness: A Prospective Longitudinal Point-of-Care Lung Ultrasound Study.** J Ultrasound Med 2020; Alharthy A, Abuhamdah M, Balhamar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185316>
2. **Postdischarge Intervention for Stroke Caregivers: Protocol for a Randomized Controlled Trial.** JMIR Res Protoc 2020; 9:e21799 LeLaurin JH, Lamba AH, Eliazar-Macke ND *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174856>
3. **Severe, Symptomatic Reinfection in a Patient with COVID-19.** R I Med J (2013). 2020; 103:24-26 Selvaraj V, Herman K, Dapaah-Afryie K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172223>

Cardiovascular disease (53 articles)

1. **Patient experiences and willingness-to-pay for cardiac telerehabilitation during the first surge of the COVID-19 pandemic: single-centre experience.** Acta Cardiol. 2020;1-7 Scherrenberg M, Falter M, Dendale P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183162>
2. **Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.** Adv Respir Med 2020; 88:468-469 Mohebbi N, Abedini A, Lashgari R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169824>
3. **Thrombosis in Hospitalized Patients with Viral Respiratory Infections versus COVID-19.** Am. Heart J. 2020; Smilowitz NR, Subashchandran V, Yuriditsky E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181067>
4. **Increased prevalence of myocardial injury in patients with SARS-CoV-2 viremia.** Am. J. Med. 2020; Siddiqi HK, Weber B, Zhou G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181107>
5. **Pulmonary Endothelial Dysfunction and Thrombotic Complications in COVID-19 Patients.** Am. J. Respir. Cell Mol. Biol. 2020; Rodríguez C, Luque N, Blanco I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180562>
6. **Response to: 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey' by Comarmond et al.** Ann. Rheum. Dis. 2020; Tomelleri A, Sartorelli S, Baldissera EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184047>
7. **COVID-19 and stroke, a case series and review of literature.** Brain Behav Immun Health 2020; 9:100172 Elkhider H, Ibrahim F, Sharma R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173859>
8. **SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients.** Cancers (Basel) 2020; 12 Quagliariello V, Bonelli A, Caronna A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182653>
9. **Cardiovascular view of intermediate and high-risk COVID-19 patients: single-centre experience with low mortality and intensive care hospitalisation rates.** Cardiovasc. J. Afr. 2020; 31:1-9 Medetalibeyoglu A, Emet S, Senkal N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165497>
10. **The endothelium as Achilles' heel in COVID-19 patients.** Cardiovasc Res 2020; Gladka MM, Maack C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167001>

11. **Impact of a Stay-at-Home Order on Stroke Admission, Subtype, and Metrics during the COVID-19 Pandemic.** Cerebrovasc Dis Extra 2020; 10:159-165 Rameez F, McCarthy P, Cheng Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166950>
12. **Patient and Provider Risk in Managing ST-Elevation Myocardial Infarction During the COVID-19 Pandemic: A Decision Analysis.** Circ. Cardiovasc. Interv. 2020:Circinterventions120010027 Butala NM, Patel NK, Chhatwal J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167699>
13. **Standards of Care in Crisis: ST-Segment-Elevation Myocardial Infarction Management in COVID-19.** Circ. Cardiovasc. Interv. 2020:Circinterventions120010143 Mihatov N, Kirtane AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167704>
14. **Endomyocardial Biopsy in a Pediatric Patient With Cardiac Manifestations of COVID-19.** Circ Heart Fail 2020:Circheartfailure120007384 Laurence C, Haini M, Thiruchelvam T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176458>
15. **Impact of the COVID-19 Pandemic on Door-to-Balloon Time for Primary Percutaneous Coronary Intervention - Results From the Singapore Western STEMI Network.** Circ. J. 2020; Chew NW, Sia CH, Wee HL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162491>
16. **COVID-19, thromboembolic risk, and Virchow's triad: Lesson from the past.** Clin. Cardiol. 2020; Mehta JL, Calcaterra G, Bassareo PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176009>
17. **COVID-19 pneumonia and pulmonary microembolism in a patient with B-thalassemia major.** Clin Case Rep 2020; Marziali M, Ribersani M, Losardo AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173583>
18. **Spontaneous Brainstem Hemorrhagic Stroke in the Setting of Novel Coronavirus Disease 2019 - A Case Report.** Cureus 2020; 12:e10809 Flores G, Kumar JI, Pressman E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163313>
19. **Clinical characteristics of inpatients with Coronavirus disease 2019 and acute ischemic stroke: from epidemiology to outcomes.** Curr. Neurovasc. Res. 2020; Chen S, Pan C, Zhang P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176647>
20. **Cardiotoxicity of Contemporary Anticancer Immunotherapy.** Curr. Treat. Options Cardiovasc. Med. 2020; 22:62 Dal'bo N, Patel R, Parikh R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162729>
21. **Management and Treatment of Myocarditis in Athletes.** Curr. Treat. Options Cardiovasc. Med. 2020; 22:65 Hurwitz B, Issa O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169059>
22. **ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities.** Elife 2020; 9 Zamorano Cuervo N, Grandvaux N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164751>
23. **Relative Bradycardia in Patients with Mild-to-Moderate Coronavirus Disease, Japan.** Emerg Infect Dis 2020; 27 Yan G, Ang A, Tham SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183492>
24. **Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.** Eur J Heart Fail 2020; Tomasoni D, Inciardi RM, Lombardi CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179839>
25. **An Example of a Stroke Unit Reshaping in the Context of a Regional Hub and Spoke System in the COVID-19 Era.** Front. Neurol. 2020; 11:1029 Candeloro E,

- Carimati F, Tabaei Damavandi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178094>
26. **Impact of Covid-19 on the Behavior of Community Residents With Suspected Transient Ischemic Attack.** *Front. Neurol.* 2020; 11:590406 Yao S, Lin B, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178128>
 27. **Pathophysiology of Cardiovascular Complications in COVID-19.** *Front. Physiol.* 2020; 11:575600 Petrovic V, Radenkovic D, Radenkovic G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162899>
 28. **Reduction of acute myocardial infarction (AMI) hospital admissions in the region of Messinia in Greece during the Covid-19 lockdown period.** *Hellenic J. Cardiol.* 2020; Makaris E, Kourek C, Karatzanos E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166653>
 29. **COVID-19 and sudden cardiac death: A new potential risk.** *Indian Heart J.* 2020; 72:333-336 Yadav R, Bansal R, Budakoty S, Barwad P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189190>
 30. **Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.** *Int J Antimicrob Agents* 2020:106212 Oscanova TJ, Vidal X, Kanters JK, Romero-Ortuno R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164789>
 31. **Management of acute coronary syndromes during the COVID-19 outbreak in Lombardy: The "macro-hub" experience.** *Int J Cardiol Heart Vasc* 2020; 31:100662 Carugo S, Ferlini M, Castini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173807>
 32. **Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection.** *Int J Mol Sci* 2020; 21 Festa M, Sansone C, Brunet C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171852>
 33. **Neurological manifestations of Coronavirus Infections: Role of Angiotensin-Converting Enzyme 2 in COVID-19.** *Int. J. Neurosci.* 2020:1-11 Parsamanesh N, Pezeshgi A, Hemmati M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175635>
 34. **Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI.** *J Am Coll Cardiol* 2020; 76:2321-2330 De Luca G, Verdoia M, Cercek M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183506>
 35. **COVID-19 and Heart Failure: Harsh Reality of Pre-Existing Conditions.** *J Am Coll Cardiol* 2020; 76:2349-2351 Panjrath GS, Krepp J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183508>
 36. **Delay, Death, and Heterogeneity of Primary PCI During the COVID-19 Pandemic: An International Perspective.** *J Am Coll Cardiol* 2020; 76:2331-2333 Park DW, Yang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183507>
 37. **Admission cardiac diagnostic testing with electrocardiography and troponin measurement prognosticates increased 30-day mortality in COVID-19.** *J Am Heart Assoc* 2020:e018476 Poterucha TJ, Elias P, Jain SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169643>
 38. **Turn down of acute aortic syndrome cases during COVID-19: Results from UK multicentre studies.** *J. Card. Surg.* 2020; Roman M, Harky A, Brazier A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169430>
 39. **Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.** *J. Cardiol.* 2020; Ren L, Yu S, Xu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168337>

40. **Lessons From the First Wave of the Pandemic: Skin Features of COVID-19 can be Divided Into Inflammatory and Vascular Patterns.** J. Cutan. Med. Surg. 2020;1203475420972343Naderi-Azad S, Vender R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33179534>
41. **Characteristics and Comparison of 32 COVID-19 and Non-COVID-19 Ischemic Strokes and Historical Stroke Patients.** J. Stroke Cerebrovasc. Dis. 2020; 30:105435Akhtar N, Abid FB, Kamran S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171425>
42. **The Impact of Covid-19 Lockdown on Stroke Admissions and Treatments in Campania.** J. Stroke Cerebrovasc. Dis. 2020; 30:105448Candelaresi P, Manzo V, Servillo G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166767>
43. **Cerebral Venous Sinus Thrombosis in COVID-19 Infection: A Case Series and Review of The Literature.** J. Stroke Cerebrovasc. Dis. 2020; 30:105434Dakay K, Cooper J, Bloomfield J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190109>
44. **Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness.** J Thromb Haemost 2020; 18:3099-3105Goldenberg NA, Sochet A, Albisetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174388>
45. **Venous thrombosis, thromboembolism and biomarkers of inflammation and coagulation in COVID-19.** J Vasc Surg Venous Lymphat Disord 2020; Thondapu V, Montes D, Rosovsky R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188961>
46. **Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.** JACC Case Rep 2020; Gubitosa JC, Kakar P, Gerula C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163977>
47. **High-density lipoprotein cholesterol as a factor affecting virus clearance in covid-19 patients.** Respir. Med. 2020; 175:106218Ding X, Zhang J, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181413>
48. **Coagulopathies in novel coronavirus (SARS-CoV-2) pandemic: emerging evidence for hematologists.** Saudi J. Biol. Sci. 2020; AlSubaie AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169062>
49. **Type A Aortic Dissection during COVID-19 Pandemic: Report from Tertiary Aortic Centers in the United States and China.** Semin. Thorac. Cardiovasc. Surg. 2020; Fukuhara S, Tang H, Kim KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171243>
50. **Lower limb deep vein thrombosis in COVID-19 patients admitted to intermediate care respiratory units.** Thromb Res 2020; 197:44-47Pancani R, Villari L, Foci V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181470>
51. **Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study.** Thromb Res 2020; 197:94-99Planquette B, Le Berre A, Khider L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33190025>
52. **Cardiovascular Manifestations and Mechanisms in Patients with COVID-19.** Trends Endocrinol. Metab. 2020; Dou Q, Wei X, Zhou K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33172748>
53. **Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:920Lins PRG, de Albuquerque CCC, Assis CF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33176886>

Diagnosis (6 articles)

1. **Avoiding Anchoring Bias in the Times of the Pandemic!** Case Rep. Neurol. 2020; 12:359-364 Yousaf Z, Siddiqui MYA, Mushtaq K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173496>
2. **Post-Mortem Diagnostics in COVID-19 AKI, More Often but Timely.** J Am Soc Nephrol 2020; Zijlstra JG, van Meurs M, Moser J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170136>
3. **[Biological diagnosis of Sars-CoV-2 infection: strategies and interpretation of results].** Rev Francoph Lab 2020; 2020:48-56 Hantz S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163104>
4. **Coronavirus Disease 2019 (COVID-19): An Overview of the Immunopathology, Serological Diagnosis and Management.** Scand. J. Immunol. 2020:e12998 Anka AU, Tahir MI, Abubakar SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190302>
5. **How should diagnostic kits development adapt quickly in COVID 19-like pandemic models? Pros and cons of sensory platforms used in COVID-19 sensing.** Talanta 2021; 222:121534 Moulahoum H, Ghorbanizamani F, Zihnioglu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167242>
6. **Insufficient etiological workup of COVID-19-associated acute pancreatitis: A systematic review.** World J. Gastroenterol. 2020; 26:6270-6278 Juhász MF, Ocskay K, Kiss S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177799>

DM-MS-Obesity (13 articles)

1. **An inaugural diabetic ketoacidosis with acute pancreatitis during COVID-19.** Acta Diabetol 2020; Tollard C, Champenois V, Delemer B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184733>
2. **Telemonitoring type 1 diabetes patients during the COVID-19 pandemic in Brazil: was it useful?** Arch Endocrinol Metab 2020; de Mattos Matheus AS, Cabizuca CA, Tannus LRM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166438>
3. **SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients.** Cancers (Basel) 2020; 12 Quagliariello V, Bonelli A, Caronna A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182653>
4. **Prevalence of obesity and hypovitaminosis D in elderly with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** Clin Nutr ESPEN 2020; 40:110-114 Gonçalves TJM, Gonçalves S, Guarnieri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183522>
5. **COVID-19 in People with Diabetes: Perspectives from Saudi Arabia.** Curr. Diabetes Rev. 2020; Robert AA, Al Dawish MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176657>
6. **Prevalence of Diabetes, Management and Outcomes among Covid-19 Adult Patients Admitted in a Specialized Tertiary Hospital in Riyadh, Saudi Arabia.** Diabetes Res Clin Pract 2020:108538 Sheshah E, Sabico S, Albakr RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189790>
7. **Treatment of diabetic patients with COVID-19.** Diabetologie und Stoffwechsel 2020; 15:360-361 Lichert F.

8. **Obesity in the COVID era: A global health challenge.** Endocrinol Diabetes Nutr 2020; Rubio Herrera MA, Bretón Lesmes I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162383>
9. **COVID-19 Hospitalization in Adults with Type 1 Diabetes: Results from the T1D Exchange Multi-Center Surveillance Study.** J. Clin. Endocrinol. Metab. 2020; O'Malley G, Ebekozien O, Desimone M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165563>
10. **Impact of COVID-19 Lockdown on Glycemic Control in Adults with Type 1 Diabetes Mellitus.** J Endocr Soc 2020; 4:bvaa149Pla B, Arranz A, Knott C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173841>
11. **New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19.** J. Pediatr. Endocrinol. Metab. 2020; Naguib MN, Raymond JK, Vidmar AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180050>
12. **COVID-19 and the Impact on Surgical Fellows: Uniquely Vulnerable Learners.** J Surg Educ 2020; Nicholas C, Hatchell A, Webb C, Temple-Oberle C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184017>
13. **ICU outcomes in Covid-19 patients with obesity.** Ther. Adv. Respir. Dis. 2020; 14:1753466620971146Parikh R, Garcia MA, Rajendran I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176612>

Education and training and science (34 articles)

1. **Exploring the Residents' Perspective on Smart learning Modalities and Contents for Virtual Urology Education: Lesson Learned During the COVID-19 Pandemic.** Actas Urol. Esp. 2020; Campi R, Amparore D, Checcucci E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168176>
2. **Family medicine internship support during the COVID-19 pandemic in Cape Town, South Africa - A narrative report.** Afr J Prim Health Care Fam Med 2020; 12:e1-e3Solomon G, Allie A, Fakier R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181875>
3. **Integrating Medical Students in Tele-Palliative Care.** Am. J. Hosp. Palliat. Care 2020:1049909120973199Chow B, Rallis KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167668>
4. **Differences between fellows and fellowship program directors in their perception of the impact of the COVID-19 pandemic on gastroenterology training: results from a nationwide survey in Greece.** Ann Gastroenterol 2020; 33:680-686Karampekios G, Gkolfakis P, Tziatzios G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162746>
5. **Stress and behavioral changes with remote E-exams during the Covid-19 pandemic: A cross-sectional study among undergraduates of medical sciences.** Ann Med Surg (Lond) 2020; 60:271-279Elsalem L, Al-Azzam N, Jum'ah AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163179>
6. **Impact of an e-learning module on personal protective equipment knowledge in student paramedics: a randomized controlled trial.** Antimicrob Resist Infect Control 2020; 9:185Suppan L, Stuby L, Gartner B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168097>
7. **Biobanking in the COVID-19 Era and Beyond: Part 1. How Early Experiences Can Translate into Actionable Wisdom.** Biopreserv. Biobank. 2020; Allocca CM,

- Bledsoe MJ, Albert M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164554>
8. **Establishment of a Collection of Blood-Derived Products from COVID-19 Patients for Translational Research: Experience of the LPCE Biobank (Nice, France).** *Biopreserv. Biobank.* 2020; Tanga V, Leroy S, Fayada J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175565>
 9. **Attitudes and concerns of undergraduate university health sciences students in Croatia regarding complete switch to e-learning during COVID-19 pandemic: a survey.** *BMC Med. Educ.* 2020; 20:416Puljak L, Čivljak M, Haramina A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167960>
 10. **[Moral distress in medical students and young professionals: research desiderata in the context of the COVID-19 pandemic].** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2020; Köhlmeier K, Kuhn E, Knochel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180160>
 11. **Residents' Perceived Impact of COVID-19 on Saudi Ophthalmology Training Programs-A Survey.** *Clin. Ophthalmol.* 2020; 14:3755-3761Alahmadi AS, Alhatlan HM, Bin Helayel H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173273>
 12. **Mental health problems and correlates among 746 217 college students during the coronavirus disease 2019 outbreak in China.** *Epidemiol Psychiatr Sci* 2020; 29:e181Ma Z, Zhao J, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185174>
 13. **Medical Simulation: The Least Advertised and Most Versatile Weapon in Pandemic.** *Front Med (Lausanne)* 2020; 7:582150Favier V, Daniel SJ, Braun M, Gallet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163502>
 14. **Systematic Review of the Literature About the Effects of the COVID-19 Pandemic on the Lives of School Children.** *Front. Psychol.* 2020; 11:569348Cachón-Zagalaz J, Sánchez-Zafra M, Sanabrias-Moreno D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162910>
 15. **Cameroonian responses to COVID-19 in the education sector: Exposing an inadequate education system.** *Int Rev Educ* 2020:1-21Béché E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162608>
 16. **"The lockdown of physical co-operation touches the heart of adult education": A Delphi study on immediate and expected effects of COVID-19.** *Int Rev Educ* 2020:1-19Käpplinger B, Lichte N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173243>
 17. **Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel.** *J Am Coll Cardiol* 2020; 76:2368-2378Psotka MA, Abraham WT, Fiuzat M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183511>
 18. **Ethical Challenges in Clinical Research During the COVID-19 Pandemic.** *J. Bioeth. Inq.* 2020:1-6Bierer BE, White SA, Barnes JM, Gelinas L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169251>
 19. **COVID-19 and the Impact on Surgical Fellows: Uniquely Vulnerable Learners.** *J Surg Educ* 2020; Nicholas C, Hatchell A, Webb C, Temple-Oberle C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184017>
 20. **Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness.** *J Thromb Haemost* 2020; 18:3099-3105Goldenberg NA, Sochet A, Albisetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174388>
 21. **Is written informed consent 'cast in iron' even during a pandemic?** *Med J Armed Forces India* 2020; 76:367-369Gupta P, Naeem SS, Mohan P, Banerjee A.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162647>
22. **Optimizing clinical research procedures in public health emergencies.** Med. Res. Rev. 2020; Madariaga A, Kasherman L, Karakasis K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33174617>
 23. **Medical Student Participation in Otolaryngology Telemedicine Clinic During COVID-19: A Hidden Opportunity.** Otolaryngol Head Neck Surg 2020:194599820970964Pellegrini WR, Danis DO, 3rd, Levi JR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167750>
 24. **ECMO implantation training: Needle penetration in 3D printable materials and porcine aorta.** Perfusion 2020:267659120967194Salewski C, Spintzyk S, von Steuben T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174474>
 25. **What we can learn from information flows about COVID-19: Implications for research and practice.** Proc Assoc Inf Sci Technol 2020; 57:e245Afzal W.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173811>
 26. **Social media and COVID-19: Can social distancing be quantified without measuring human movements?** Proc Assoc Inf Sci Technol 2020; 57:e378Anderson M, Karami A, Bozorgi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173828>
 27. **Through the magnifying glass: Exploring aggregations of COVID-19 datasets by county, state, and taxonomies of U.S. regions.** Proc Assoc Inf Sci Technol 2020; 57:e355Cheng YY, Ludäscher B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173824>
 28. **Psychological impact of the COVID-19 outbreak on students in a French region severely affected by the disease: results of the PIMS-CoV 19 study.** Psychiatry Res 2020:113559Bourion-Bédès S, Tarquinio C, Batt M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33189368>
 29. **Gaps in Knowledge About COVID-19 Among US Residents Early in the Outbreak.** Public Health Rep. 2020:33354920970182McCormack LA, Squiers L, Frasier AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176108>
 30. **Increased Levels of Anxiety Among Medical and Non-Medical University Students During the COVID-19 Pandemic in the United Arab Emirates.** Risk Manag. Healthc. Policy 2020; 13:2395-2406Saddik B, Hussein A, Sharif-Askari FS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177898>
 31. **Strategies to exiting the COVID-19 lockdown for workplace and school: A scoping review.** Saf Sci 2021; 134:105067D'Angelo D, Sinopoli A, Napoletano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162676>
 32. **COVID-19: Opportunities for interdisciplinary research to improve care for older people in Sweden.** Scand J Public Health 2020:1403494820969544Baxter R, Jemberie WB, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33161880>
 33. **CAFE: An Instructional Design Model to Assist K-12 Teachers to Teach Remotely during and beyond the Covid-19 Pandemic.** TechTrends 2020:1-9Wang CX. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169121>
 34. **Perception of Neurosurgery Residents and Attendings on Online Webinars During COVID-19 Pandemic and Implications on Future Education.** World Neurosurg 2020; Al-Ahmari AN, Ajlan AM, Bajunaid K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181378>

Elderly (13 articles)

1. **Life in lockdown: A telephone survey to investigate the impact of COVID-19 lockdown measures on the lives of older people (≥ 75 years).** Age Ageing 2020; Brown L, Mossabir R, Harrison N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173949>
2. **A predictive model for the severity of COVID-19 in elderly patients.** Aging (Albany NY) 2020; 12Zeng F, Deng G, Cui Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170150>
3. **Prolonged shedding of SARS-CoV-2 in an elderly liver transplant patient infected by COVID-19: a case report.** Ann Palliat Med 2020; Wei L, Liu B, Zhao Y, Chen Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183020>
4. **Prevalence of obesity and hypovitaminosis D in elderly with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** Clin Nutr ESPEN 2020; 40:110-114Gonçalves TJM, Gonçalves S, Guarnieri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183522>
5. **Older People Living in Long-Term Care Facilities and Mortality Rates During the COVID-19 Pandemic in Italy: Preliminary Epidemiological Data and Lessons to Learn.** Front Psychiatry 2020; 11:586524de Girolamo G, Bellelli G, Bianchetti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173526>
6. **The Effects of COVID-19 and Quarantine Measures on the Lifestyles and Mental Health of People Over 60 at Increased Risk of Dementia.** Front Psychiatry 2020; 11:578628Di Santo SG, Franchini F, Filiputti B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173523>
7. **The AGE Effect on Protective Behaviors During the COVID-19 Outbreak: Sociodemographic, Perceptions and Psychological Accounts.** Front. Psychol. 2020; 11:561785Pasion R, Paiva TO, Fernandes C, Barbosa F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178069>
8. **Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020.** Int J Antimicrob Agents 2020:106219Ly TDA, Zanini D, Laforge V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189890>
9. **How does a (Smart) Age-Friendly Ecosystem Look in a Post-Pandemic Society?** Int J Environ Res Public Health 2020; 17Marston HR, Shore L, White PJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182413>
10. **COVID-19 and the Impact on Surgical Fellows: Uniquely Vulnerable Learners.** J Surg Educ 2020; Nicholas C, Hatchell A, Webb C, Temple-Oberle C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184017>
11. **Age separation dramatically reduces COVID-19 mortality rate in a computational model of a large population.** Open Biol 2020; 10:200213Mizrahi L, Shekhidem HA, Stern S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171068>
12. **SARS-CoV-2 associated COVID-19 in Geriatric Population: A Brief Narrative Review.** Saudi J. Biol. Sci. 2020; Mohamad Al-Zahrani J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169063>
13. **COVID-19: Opportunities for interdisciplinary research to improve care for older people in Sweden.** Scand J Public Health 2020:1403494820969544Baxter R, Jemberie WB, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33161880>

1. **COVID-19 in China: Risk Factors and R(0) Revisited.** Acta Trop. 2020; 213:105731Khan IM, Haque U, Zhang W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33164890>
2. **Using a simple open-source automated machine learning algorithm to forecast COVID-19 spread: A modelling study.** Adv Respir Med 2020; 88:400-405Asfahan S, Gopalakrishnan M, Dutt N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169811>
3. **Suppression of Groups Intermingling as an Appealing Option for Flattening and Delaying the Epidemiological Curve While Allowing Economic and Social Life at a Bearable Level during the COVID-19 Pandemic.** Adv Theory Simul 2020:2000132Bâldea I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173845>
4. **Life in lockdown: A telephone survey to investigate the impact of COVID-19 lockdown measures on the lives of older people (≥ 75 years).** Age Ageing 2020; Brown L, Mossabir R, Harrison N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173949>
5. **COVID-19 mortality and neighborhood characteristics in Chicago.** Ann. Epidemiol. 2020; Bryan MS, Sun J, Jagai J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181262>
6. **A country comparison of place-based activity response to COVID-19 policies.** Appl Geogr 2020; 125:102363McKenzie G, Adams B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162624>
7. **SARS-CoV-2: Remarks on the COVID-19 Pandemic.** Arch. Immunol. Ther. Exp. (Warsz.) 2020; 68:35Piasecki E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185755>
8. **Ethical Responses to the COVID-19 Pandemic-Lessons from Sri Lanka.** Asian Bioeth Rev 2020:1-9Hettiarachchi D, Noordeen N, Gamakaranage C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169085>
9. **Separating the impact of gradual lockdown measures on air pollutants from seasonal variability.** Atmos Pollut Res 2020; Hörmann S, Jammoul F, Kuenzer T, Stadlober E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162774>
10. **Mathematical Modeling and Robustness Analysis to Unravel COVID-19 Transmission Dynamics: The Italy Case.** Biology (Basel) 2020; 9Antonini C, Calandrini S, Stracci F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187109>
11. **Control of COVID-19 system using a novel nonlinear robust control algorithm.** Biomed. Signal Process. Control 2021; 64:102317Hadi MA, Ali HI.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173541>
12. **Quarantine at home may not enough!-from the epidemiological data in Shaanxi Province of China.** BMC Res. Notes 2020; 13:506Shi L, Li Q, Li K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33187555>
13. **Factors associated with COVID-19 infections and mortality in Africa: a cross-sectional study using publicly available data.** BMJ Open 2020; 10:e042750Okeahalam C, Williams V, Ot wombe K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33177146>
14. **SEAIR Epidemic spreading model of COVID-19.** Chaos Solitons Fractals 2020:110394Basnarkov L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162690>
15. **SIRSi compartmental model for COVID-19 pandemic with immunity loss.** Chaos Solitons Fractals 2020:110388Batistela CM, Correa DPF, Bueno Á M, Piqueira JRC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162689>

16. **Spread of COVID-19 in China: analysis from a city-based epidemic and mobility model.** Cities 2020;103010Wei Y, Wang J, Song W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162634>
17. **Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries.** Clin Epidemiol Glob Health 2020; Joy M, Malavika B, Asirvatham ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163696>
18. **Susceptibility to Sars-CoV-2 Infection Among Children And Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain.** Clin Infect Dis 2020; Brotons P, Launes C, Buetas E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33180914>
19. **Household Transmission of SARS-CoV-2 in the United States.** Clin Infect Dis 2020; Lewis NM, Chu VT, Ye D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185244>
20. **Hajj and Umrah Mass Gatherings and COVID-19 Infection.** Curr Trop Med Rep 2020;1-8Hoang VT, Gautret P, Memish ZA, Al-Tawfiq JA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169095>
21. **A survey dataset to evaluate the changes in mobility and transportation due to COVID-19 travel restrictions in Australia, Brazil, China, Ghana, India, Iran, Italy, Norway, South Africa, United States.** Data Brief 2020; 33:106459Barbieri DM, Lou B, Passavanti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163599>
22. **So far, how effective were distancing measures during the COVID-19 pandemic?** Deutsche Medizinische Wochenschrift 2020; 145:1530-1531Klein F.
23. **Universal Social Protection and Health Care as a Social Common.** Development (Rome) 2020;1-6Mestrum F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173263>
24. **Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA.** Emerg Infect Dis 2020; 27Feehan AK, Velasco C, Fort D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171096>
25. **Large-Scale Isolation Facilities and Potential for Secondary Infectious Disease Outbreak.** Emerg Infect Dis 2020; 27Lim SYD, Tey HL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33183491>
26. **Sero-epidemiological study of SARS-CoV-2 infection among healthcare personnel in a healthcare department.** Enferm. Infecc. Microbiol. Clin. 2020; Gras-Valentí P, Chico-Sánchez P, Algado-Sellés N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162223>
27. **Exposome-based public health interventions for infectious diseases in urban settings.** Environ Int 2020; 146:106246Andrianou XD, Pronk A, Galea KS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181410>
28. **The Gendered Poverty Effects of the COVID-19 Pandemic in Colombia.** Eur J Dev Res 2020;1-34Cuesta J, Pico J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162688>
29. **Impact of lockdown on COVID-19 prevalence and mortality during 2020 pandemic: observational analysis of 27 countries.** Eur. J. Med. Res. 2020; 25:56Meo SA, Abukhalaf AA, Alomar AA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33168104>
30. **The Effects of COVID-19 and Quarantine Measures on the Lifestyles and Mental Health of People Over 60 at Increased Risk of Dementia.** Front Psychiatry 2020; 11:578628Di Santo SG, Franchini F, Filiputti B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173523>

31. **The AGE Effect on Protective Behaviors During the COVID-19 Outbreak: Sociodemographic, Perceptions and Psychological Accounts.** Front. Psychol. 2020; 11:561785Pasion R, Paiva TO, Fernandes C, Barbosa F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178069>
32. **A Preventive and Control Strategy for COVID-19 Infection: An Experience From a Third-Tier Chinese City.** Front Public Health 2020; 8:562024Fan S, Wu M, Ma S, Zhao S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178660>
33. **Perceptions and Attitudes Toward COVID-19-Related National Response Measures of Vietnamese: Implications for Pandemic Prevention and Control.** Front Public Health 2020; 8:589053Nguyen TTP, Nguyen LH, Le HT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163473>
34. **Framework for a Community Health Observing System for the Gulf of Mexico Region: Preparing for Future Disasters.** Front Public Health 2020; 8:578463Sandifer P, Knapp L, Lichtveld M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178663>
35. **All times are special—but some are more special than others.** Gefasschirurgie 2020; 25:383-384Larena-Avellaneda A.
36. **Genomic exploration light on multiple origin with potential parsimony-informative sites of the severe acute respiratory syndrome coronavirus 2 in Bangladesh.** Gene Rep 2020; 21:100951Saha O, Hossain MS, Rahaman MM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163695>
37. **Containing the impact of COVID-19: Review of Ghana's response approach.** Health Policy Technol 2020; Sibiri H, Prah D, Zankawah SM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169101>
38. **Predictors of Staying at Home during the COVID-19 Pandemic and Social Lockdown based on Protection Motivation Theory: A Cross-Sectional Study in Japan.** Healthcare (Basel) 2020; 8Okuhara T, Okada H, Kiuchi T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33187368>
39. **Software engineering standards for epidemiological models.** Hist Philos Life Sci 2020; 42:54Horner JK, Symons JF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170375>
40. **Epidemiological and clinical characteristics of patients with COVID-19 from a designated hospital in Hangzhou City: a retrospective observational study.** Hong Kong Med. J. 2020; Gao J, Zhang S, Zhou K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33177240>
41. **Identifying the measurements required to estimate rates of COVID-19 transmission, infection, and detection, using variational data assimilation.** Infect Dis Model 2020; Armstrong E, Runge M, Gerardin J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163738>
42. **Estimating effective reproduction number using generation time versus serial interval, with application to covid-19 in the Greater Toronto Area, Canada.** Infect Dis Model 2020; 5:889-896Knight J, Mishra S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163739>
43. **An overview on COVID-19 pandemic: from discovery to treatment.** Infect Disord Drug Targets 2020; Panati K, Tatireddygar VRA, Narala VR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167846>
44. **A review and content analysis of national apps for COVID-19 management using Mobile Application Rating Scale (MARS).** Inform Health Soc Care 2020;1-

- 14Salehinejad S, Niakan Kalhori SR, Hajesmaeel Gohari S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33164594>
45. **Early transmission of SARS-CoV-2 in South Africa: An epidemiological and phylogenetic report.** *Int J Infect Dis* 2020; Giandhari J, Pillay S, Wilkinson E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33189939>
46. **Systematically comparing COVID-19 with 2009 influenza pandemic for hospitalized patients.** *Int J Infect Dis* 2020; Li P, Wang Y, Peppelenbosch MP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33189938>
47. **The time-varying transmission dynamics of COVID-19 and synchronous actions in China.** *Int J Infect Dis* 2020; Xiao J, Hu J, He G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181330>
48. **The experience of contact tracing in Singapore in the control of COVID-19: highlighting the use of digital technology.** *Int. Orthop.* 2020; Lai SHS, Tang CQY, Kurup A, Thevendran G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188602>
49. **COVID-19 from Wellington New Zealand.** *J. Bioeth. Inq.* 2020:1-6Gray B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169244>
50. **COVID-19 and Australian Prisons: Human Rights, Risks, and Responses.** *J. Bioeth. Inq.* 2020:1-5Stewart C, Tomossy GF, Lamont S, Brunero S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169262>
51. **Ethical Considerations for Restrictive and Physical Distancing Measures in Brazil During COVID-19: Facilitators and Barriers.** *J. Bioeth. Inq.* 2020:1-5Thomé BC, Matta GC, Rego STA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169249>
52. **Relationship of Forced Social Distancing and Home Confinement Derived from the COVID-19 Pandemic with the Occupational Balance of the Spanish Population.** *J Clin Med* 2020; 9González-Bernal JJ, Santamaría-Peláez M, González-Santos J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182379>
53. **Impact of COVID-19 Lockdown Measures on Spanish People with Chronic Pain: An Online Study Survey.** *J Clin Med* 2020; 9Nieto R, Pardo R, Sora B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167322>
54. **Extensive Testing and Public Health Interventions for the Control of COVID-19 in the Republic of Cyprus between March and May 2020.** *J Clin Med* 2020; 9Quattrocchi A, Mamais I, Tsioutis C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171651>
55. **Demystifying the varying case fatality rates (CFR) of COVID-19 in India: Lessons learned and future directions.** *J Infect Dev Ctries* 2020; 14:1128-1135Asirvatham ES, Lakshmanan J, Sarman CJ, Joy M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33175707>
56. **COVID-19 Pandemic: How is Bangladesh coping with the rapid spread of coronavirus infection?** *J Infect Dev Ctries* 2020; 14:1098-1105Islam S, Mannan F, Islam T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175702>
57. **Quantitative analysis and mathematic modeling of the global outbreak of COVID-19.** *J Infect Dev Ctries* 2020; 14:1106-1110Jiang Y, Jiang X, Tong W, Zhou J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33175703>
58. **No new community COVID-19 infection in four consecutive weeks: what lesson can be learned from Vietnam.** *J Infect Dev Ctries* 2020; 14:1125-1127Nam NH, Quy PN, Pham TM, Branch J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175706>
59. **Sars-Cov-2 in Argentina: Lockdown, Mobility, and Contagion.** *J Med Virol* 2020; Larrosa JMC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165959>

60. **How Can the Epidemic Curve of COVID-19 in Iran Be Interpreted?** J Res Health Sci 2020; 20:e00491 Doosti-Irani A, Haghdoost AA, Najafi F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169723>
61. **The forgotten numbers: A closer look at COVID-19 non-fatal valuations.** J Risk Uncertain 2020; 1-22 Kniesner TJ, Sullivan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169048>
62. **The Hajj pilgrimage during the COVID-19 pandemic in 2020: event hosting without the mass gathering.** J Travel Med 2020; Ebrahim SH, Ahmed Y, Alqahtani SA, Memish ZA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184626>
63. **A Genome Epidemiological Study of SARS-CoV-2 Introduction into Japan.** mSphere 2020; 5 Sekizuka T, Itokawa K, Hashino M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33177213>
64. **Predicting the number of total COVID-19 cases and deaths in Brazil by the Gompertz model.** Nonlinear Dyn 2020; 1-7 Valle JAM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162673>
65. **A comparative analysis of the COVID-19 pandemic response: The case of Turkey.** North Clin Istanbul 2020; 7:443-451 Simsek EE, Guner AE, Kul S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163879>
66. **COVID-19 Pandemic in the Midst of Civil War: Planetary Health and Plant Omics Field Notes from Aden, Yemen.** OMICS 2020; Abdullah AT, Hassen J, Abdullah AA, Ağırbaşı M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180003>
67. **COVID-19 and Africa: Surviving between a rock and a hard place.** An Pediatr (Engl Ed) 2020; de Aranzabal M, Fumadó V, Alegria I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169103>
68. **Spatial modeling could not differentiate early SARS-CoV-2 cases from the distribution of humans on the basis of climate in the United States.** PeerJ 2020; 8:e10140 Harbert R, Cunningham SW, Tessler M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173618>
69. **A systematic approach for COVID-19 predictions and parameter estimation.** Pers Ubiquitous Comput 2020; 1-13 Srivastava V, Srivastava S, Chaudhary G, Al-Turjman F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173450>
70. **Scaling effect in COVID-19 spreading: The role of heterogeneity in a hybrid ODE-network model with restrictions on the inter-cities flow.** Physica D 2020; 415:132792 Miranda JGV, Silva MS, Bertolino JG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169041>
71. **Scaling effect in COVID-19 spreading: The role of heterogeneity in a hybrid ODE-network model with restrictions on the inter-cities flow.** Physica D 2021; 415:132792 Miranda JGV, Silva MS, Bertolino JG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169041>
72. **Social media and COVID-19: Can social distancing be quantified without measuring human movements?** Proc Assoc Inf Sci Technol 2020; 57:e378 Anderson M, Karami A, Bozorgi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173828>
73. **Through the magnifying glass: Exploring aggregations of COVID-19 datasets by county, state, and taxonomies of U.S. regions.** Proc Assoc Inf Sci Technol 2020; 57:e355 Cheng YY, Ludäscher B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173824>
74. **Network typology, information sources, and messages of the infodemic twitter network under COVID-19.** Proc Assoc Inf Sci Technol 2020; 57:e363 Chong M.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173826>
75. **COVID-19 pandemic and information diffusion analysis on Twitter.** Proc Assoc Inf Sci Technol 2020; 57:e252Dinh L, Parulian N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173813>
76. **Social media and COVID-19: Characterizing anti-quarantine comments on Twitter.** Proc Assoc Inf Sci Technol 2020; 57:e349Karami A, Anderson M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173823>
77. **A preliminary investigation of COVID-19 transmission in the United States by incorporating social media sentiments.** Proc Assoc Inf Sci Technol 2020; 57:e370Tan T, Huang T, Wang X, Zuo Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173827>
78. **The state of practice of COVID-19 tracking systems: An inventory study.** Proc Assoc Inf Sci Technol 2020; 57:e397Tang R, Erdelez S, May E, Zhang Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173829>
79. **The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections.** Proc Natl Acad Sci U S A 2020; Baker RE, Park SW, Yang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168723>
80. **The interplay of movement and spatiotemporal variation in transmission degrades pandemic control.** Proc Natl Acad Sci U S A 2020; Kortessis N, Simon MW, Barfield M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172993>
81. **Deep learning-based forecasting model for COVID-19 outbreak in Saudi Arabia.** Process Saf Environ Prot 2021; 149:223-233Elsheikh AH, Saba AI, Elaziz MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162687>
82. **Containing COVID-19 Through Contact Tracing : A Local Health Agency Approach.** Public Health Rep. 2020:33354920967910Kalyanaraman N, Fraser MR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33170094>
83. **[Mathematical epidemiology and modeling of the Covid-19 pandemic: issues and diversity].** Rev Francoph Lab 2020; 2020:63-69Djidjou-Demasse R, Selinger C, Sofonea MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163106>
84. **Strategies to exiting the COVID-19 lockdown for workplace and school: A scoping review.** Saf Sci 2021; 134:105067D'Angelo D, Sinopoli A, Napoletano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162676>
85. **Changes in source contributions to particle number concentrations after the COVID-19 outbreak: Insights from a dispersion normalized PMF.** Sci Total Environ 2020:143548Dai Q, Ding J, Song C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33189385>
86. **Impact of weather on COVID-19 transmission in south Asian countries: An application of the ARIMAX model.** Sci Total Environ 2020:143315Hossain MS, Ahmed S, Uddin MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162141>
87. **Evidences of SARS-CoV-2 virus air transmission indoors using several untouched surfaces: A pilot study.** Sci Total Environ 2021; 751:142317Orenes-Piñero E, Baño F, Navas-Carrillo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182011>
88. **COVID-19 effective reproduction number dropped during Spain's nationwide dropdown, then spiked at lower-incidence regions.** Sci Total Environ 2021; 751:142257Santamaría L, Hortal J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181975>
89. **Deep Learning Applications to Combat Novel Coronavirus (COVID-19) Pandemic.** SN Comput Sci 2020; 1:363Asraf A, Islam MZ, Haque MR, Islam MM.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163975>
90. **Motivating social distancing during the COVID-19 pandemic: An online experiment.** *Soc. Sci. Med.* 2020:113478Lunn PD, Timmons S, Belton CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162198>
 91. **A deep learning-based social distance monitoring framework for COVID-19.** *Sustain Cities Soc* 2020:102571Ahmed I, Ahmad M, Rodrigues J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163330>
 92. **A city cluster risk-based approach for Sars-CoV-2 and isolation barriers based on anonymized mobile phone users' location data.** *Sustain Cities Soc* 2020:102574Silva JCS, de Lima Silva DF, Delgado Neto AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178556>
 93. **Poorly known aspects of flattening the curve of COVID-19.** *Technol Forecast Soc Change* 2020:120432Debecker A, Modis T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162618>
 94. **Impact of COVID-19 in Minas Gerais, Brazil: Excess Deaths, Sub-Notified Cases, Geographic and Ethnic Distribution.** *Transbound Emerg Dis* 2020; Amaral PHR, Andrade LM, da Fonseca FG, González JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188656>
 95. **The health effects of quarantine during the COVID-19 pandemic.** *Work* 2020; Feiz Arefi M, Babaei-Pouya A, Poursadeqiyan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164969>
 96. **Putting the world back to work: an expert system using big data and artificial intelligence in combating the spread of COVID-19 and similar contagious diseases.** *Work* 2020; Tkatek S, Belmzoukia A, Nafai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164971>

Gastro-enterology (19 articles)

1. **Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis.** *Ann Gastroenterol* 2020; 33:615-630Aziz M, Haghbin H, Lee-Smith W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162738>
2. **Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned.** *Ann Gastroenterol* 2020; 33:591-602Gajendran M, Perisetti A, Aziz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162736>
3. **Prolonged shedding of SARS-CoV-2 in an elderly liver transplant patient infected by COVID-19: a case report.** *Ann Palliat Med* 2020; Wei L, Liu B, Zhao Y, Chen Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183020>
4. **Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic.** *Curr. Oncol.* 2020; 27:e501-e511Bennett S, Søreide K, Gholami S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173390>
5. **Gastrointestinal Symptoms Onset in COVID-19 Patients in Wuhan, China.** *Dig. Dis. Sci.* 2020:1-10An P, Chen H, Ren H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180244>
6. **Newly Reported Studies on the Increase in Gastrointestinal Symptom Prevalence with COVID-19 Infection: A Comprehensive Systematic Review and Meta-Analysis.** *Diseases* 2020; 8Akin H, Kurt R, Tufan F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182651>

7. **APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19.** Hepatol Int 2020;1-10 Shiina S, Gani RA, Yokosuka O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174159>
8. **Application value of artificial liver support system in the treatment of cytokine storm in patients with COVID-19.** Int Immunopharmacol 2020;107:120 Xia Q, Xu K, Yu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162345>
9. **Clinical Features and Pathogenic Mechanisms of Gastrointestinal Injury in COVID-19.** J Clin Med 2020; 9 Mitsuyama K, Tsuruta K, Takedatsu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187280>
10. **Protein losing enteropathy and pneumatosis intestinalis in a child with COVID 19 infection.** J Pediatr Surg Case Rep 2021; 64:101667 Rohani P, Karimi A, Tabatabaie SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173753>
11. **Expressive writing to combat distress associated with the COVID-19 pandemic in people with inflammatory bowel disease (WriteForIBD): A trial protocol.** J Psychosom. Res. 2020; 139:110286 Mikocka-Walus A, Olive L, Skvarc D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171431>
12. **SARS-CoV-2 infection in patients with a normal or abnormal liver.** J. Viral Hepat. 2020; Cabibbo G, Rizzo GEM, Stornello C, Craxì A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190321>
13. **Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area.** JHEP Rep 2020;100:199 Amaddeo G, Brustia R, Allaire M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163949>
14. **COVID-19 in the Early Postoperative Period of Liver Transplantation: Is the Outcome Really So Positive?** Liver Transpl. 2020; Waisberg DR, Abdala E, Nacif LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166024>
15. **Intestinal Barrier Function in Health and Disease-Any role of SARS-CoV-2?** Microorganisms 2020; 8 Sharma L, Riva A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172188>
16. **Gastrointestinal and Renal Complications in SARS-CoV-2-Infected Patients: Role of Immune System.** Scand. J. Immunol. 2020:e12999 Maghool F, Valiani A, Safari T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190306>
17. **NAFLD and COVID-19: a Pooled Analysis.** SN Compr Clin Med 2020;1-4 Sachdeva S, Khandait H, Kopel J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173850>
18. **Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach.** SN Compr Clin Med 2020;1-12 Sonkar C, Kashyap D, Varshney N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169110>
19. **The influence of the COVID-19 epidemic on the gastrointestinal endoscopy practice in China: a national survey.** Surg. Endosc. 2020;1-8 Chai N, Tang X, Linghu E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179181>

Guidelines (8 articles)

1. **PRactice of VENTilation in Patients with Novel Coronavirus Disease (PRoVENT-COVID): rationale and protocol for a national multicenter observational study in The Netherlands.** Ann Transl Med 2020; 8:1251 Boers NS, Botta M, Tsonas AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178783>
2. **COVID-19 and maintenance hemodialysis: a systematic scoping review of practice guidelines.** BMC Nephrol. 2020; 21:470 Akbarialiabad H, Kavousi S,

- Ghahramani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172405>
3. **Guidelines for Pregnancy Management During the COVID-19 Pandemic: A Public Health Conundrum.** *Int J Environ Res Public Health* 2020; 17:Benski C, Di Filippo D, Taraschi G, Reich MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182412>
 4. **Weekly updates of national living evidence-based guidelines: Methods for the Australian Living Guidelines for Care of People with COVID-19.** *J. Clin. Epidemiol.* 2020; Tendal B, Vogel JP, McDonald S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188858>
 5. **Update from the Advisory Committee on Immunization Practices.** *J Pediatric Infect Dis Soc* 2020; O'Leary ST, Maldonado Y, Kimberlin DW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180938>
 6. **Psychological entitlement predicts noncompliance with the health guidelines of the COVID-19 pandemic.** *Pers. Individ. Dif.* 2020:110491Zitek EM, Schlund RJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162631>
 7. **EAES Recommendations for Recovery Plan in Minimally Invasive Surgery Amid COVID-19 Pandemic.** *Surg. Endosc.* 2020:1-17Arezzo A, Francis N, Mintz Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170335>
 8. **Update on Recommendations for SARS-CoV-2/COVID-19 during Pregnancy, Birth and Childbed.** *Z. Geburtshilfe Neonatol.* 2020; 224:217-222Zöllkau J, Hagenbeck C, Hecher K *et al.*

Imaging (23 articles)

1. **InstaCovNet-19: A deep learning classification model for the detection of COVID-19 patients using Chest X-ray.** *Appl Soft Comput* 2020:106859Gupta A, Anjum, Gupta S, Katarya R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162872>
2. **Clinical and radiographic characteristics, management and short-term outcomes of patients with COVID-19 in Wenzhou, China.** *BMC Infect. Dis.* 2020; 20:841Hong L, Ye E, Sun G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187475>
3. **Stability Analysis in COVID-19 Within-Host Model with Immune Response.** *Commun Nonlinear Sci Numer Simul* 2020:105584Almocera AES, Quiroz G, Hernandez-Vargas EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162723>
4. **Diagnostic Value of Initial Chest CT Findings for the Need of ICU Treatment/Intubation in Patients with COVID-19.** *Diagnostics (Basel)* 2020; 10:Büttner L, Aigner A, Fleckenstein FN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182695>
5. **Chest CT in COVID-19 pneumonia: what are the findings in mid-term follow-up?** *Emerg Radiol* 2020; Tabatabaei SMH, Rajebi H, Moghaddas F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165674>
6. **A case of postpartum thyroiditis following SARS-CoV-2 infection.** *Endocr. J.* 2020; Mizuno S, Inaba H, Kobayashi KI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177251>
7. **Submillisievert Chest-CT in patients with COVID-19- experiences of a German level I center.** *Eur J Radiol Open* 2020:100283Hamper CM, Fleckenstein FN, Büttner L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169104>
8. **Clinical Features and Temporal Changes of RT-PCR and Chest CT in COVID-19 Pediatric Patients.** *Front Pediatr* 2020; 8:579512Xia W, Guo Y, Tian Z *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163466>
9. **Transient (18)FDG-avid hilar lymph node on PET/CT imaging in asymptomatic COVID-19.** IDCases 2020; 22:e00981Karimi-Galougahi M, Yousefi-Koma A, Khalili N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173754>
 10. **Temporal changes of CT findings between non-severe and severe cases of COVID-19 pneumonia: a multi-center, retrospective, longitudinal Study.** Int. J. Med. Sci. 2020; 17:2653-2662Dai M, Liu X, Zhu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162793>
 11. **Clinical characteristics and longitudinal chest CT features of healthcare workers hospitalized with coronavirus disease 2019 (COVID-19).** Int. J. Med. Sci. 2020; 17:2644-2652Liu H, Luo S, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162792>
 12. **CT screening for COVID-19 in asymptomatic patients before hospital admission.** J Infect Chemother 2020; Uchida S, Uno S, Uwamino Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172767>
 13. **Morphological patterns and distributions in portable chest radiographs of COVID-19-positive cases admitted to a tertiary care hospital: An early experience from Scandinavia.** J. Med. Imaging Radiat. Oncol. 2020; Bharadwaz A, Langfeldt S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169487>
 14. **Evaluation of Scalability and Degree of Fine-Tuning of Deep Convolutional Neural Networks for COVID-19 Screening on Chest X-ray Images Using Explainable Deep-Learning Algorithm.** J Pers Med 2020; 10Lee KS, Kim JY, Jeon ET *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171723>
 15. **Using artificial intelligence to assist radiologists in distinguishing COVID-19 from other pulmonary infections.** J Xray Sci Technol 2020; Yang Y, Lure FYM, Miao H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164982>
 16. **A five-layer deep convolutional neural network with stochastic pooling for chest CT-based COVID-19 diagnosis.** Mach Vis Appl 2021; 32:14Zhang YD, Satapathy SC, Liu S, Li GR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169050>
 17. **Automatic COVID-19 Lung Infected Region Segmentation and Measurement Using CT-Scans Images.** Pattern Recognit 2020;107747Oulefki A, Agaian S, Trongtirakul T, Kassah Laouar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162612>
 18. **Role of 2-[(18)F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review.** Pharmaceuticals (Basel) 2020; 13Annunziata S, Delgado Bolton RC, Kamani CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182811>
 19. **Dosimetric and radiation cancer risk evaluation of high resolution thorax CT during COVID-19 outbreak.** Phys. Med. 2020; 80:119-124Ghetti C, Ortenzia O, Maddalo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171381>
 20. **Chest CT in the emergency department for suspected COVID-19 pneumonia.** Radiol Med 2020; Palmisano A, Scotti GM, Ippolito D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165767>
 21. **Role of diagnostic imaging technologists during the COVID-19 pandemic: the importance of organization and planning in the first line.** Radiologia (Roma) 2020; Ribas D, Del Riego J, Perendreu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176927>
 22. **Deep Learning and Medical Image Processing for Coronavirus (COVID-19) Pandemic: A Survey.** Sustain Cities Soc 2020;102589Bhattacharya S, Reddy

Maddikunta PK, Pham QV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169099>

23. **Utility of Point-of-Care Lung Ultrasound for Clinical Classification of COVID-19.** *Ultrasound Med. Biol.* 2020; Zhu ST, Tao FY, Xu JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168275>

Immune response (25 articles)

1. **Multisystem inflammatory syndrome in children rose and fell with the first wave of the COVID-19 pandemic in France.** *Acta Paediatr* 2020; Carbajal R, Lorrot M, Levy Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190340>
2. **A Descriptive and Quantitative Immunohistochemical Study Demonstrating a Spectrum of Platelet Recruitment Patterns Across Pulmonary Infections Including COVID-19.** *Am J Clin Pathol* 2020; McMullen PD, Cho JH, Miller JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174599>
3. **Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: a retrospective cohort study.** *Ann. Med.* 2020;1-24Ye F, Liu J, Chen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183091>
4. **Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications.** *Biochem. Soc. Trans.* 2020; Jiang JC, Zhang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170924>
5. **Kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19: a descriptive study.** *BMC Infect. Dis.* 2020; 20:818Wang QJ, Yao YZ, Song JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167900>
6. **Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.** *Cell* 2020; Chen Y, Zuiani A, Fischinger S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171099>
7. **Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.** *Euro Surveill* 2020; 25Mehew J, Johnson R, Roberts D, Harvala H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183404>
8. **Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?** *Front. Immunol.* 2020; 11:567710Beretta A, Cranage M, Zipeto D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178193>
9. **T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis.** *Front. Immunol.* 2020; 11:589380Kalfaoglu B, Almeida-Santos J, Tye CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178221>
10. **The Neat Dance of COVID-19: NEAT1, DANCER, and Co-Modulated Cholinergic RNAs Link to Inflammation.** *Front. Immunol.* 2020; 11:590870Meydan C, Madrer N, Soreq H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163005>
11. **Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.** *Front. Immunol.* 2020; 11:586984Reche PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178220>
12. **Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case Severity.** *Front. Microbiol.* 2020; 11:603509Liu T, Jia P, Fang B, Zhao Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178176>

13. **Revisiting the Immune Balance Theory: A Neurological Insight Into the Epidemic of COVID-19 and Its Alike.** Front. Neurol. 2020; 11:566680Wu J, Tang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178109>
14. **Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics.** Int Immunopharmacol 2020; 88:106980Kumar V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182073>
15. **Associations of medications used during hospitalization and immunological changes in patients with COVID-19 during 3-month follow-up.** Int Immunopharmacol 2020:107121Liu C, Dun Y, Liu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168413>
16. **Exposome and Immunity Training: How Pathogen Exposure Order Influences Innate Immune Cell Lineage Commitment and Function.** Int J Mol Sci 2020; 21Adams K, Weber KS, Johnson SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187101>
17. **Clinical significance of the serum IgM and IgG to SARS-CoV-2 in coronavirus disease-2019.** J. Clin. Lab. Anal. 2020:e23649Wu LX, Wang H, Gou D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184940>
18. **Lessons From the First Wave of the Pandemic: Skin Features of COVID-19 can be Divided Into Inflammatory and Vascular Patterns.** J. Cutan. Med. Surg. 2020:1203475420972343Naderi-Azad S, Vender R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179534>
19. **Multisystem Inflammatory Syndrome in Children.** J. Emerg. Med. 2020; Tabaac S, Kothari P, Cassidy-Smith T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162259>
20. **Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples.** J. Immunol. Methods 2020:112909Black MA, Shen G, Feng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166549>
21. **Immune responses and residual SARS-CoV-2 in two critically ill COVID-19 patients before and after lung transplantation.** J Infect 2020; Yan Y, Jiang X, Fu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188798>
22. **SARS-CoV-2 seroprevalence and antibody kinetics among health care workers in a Spanish hospital after three months of follow-up.** J Infect Dis 2020; Moncunill G, Mayor A, Santano R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175145>
23. **Multisystem Inflammatory Syndrome in Children Related to COVID-19: the First Case in Korea.** J Korean Med Sci 2020; 35:e391Kim H, Shim JY, Ko JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169560>
24. **Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.** mSphere 2020; 5Vetter P, Eberhardt CS, Meyer B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177214>
25. **High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households.** One Health 2021; 11:100192Fritz M, Rosolen B, Krafft E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169106>
26. **COVID-19 susceptibility in pregnancy: Immune/inflammatory considerations, the role of placental ACE-2 and research considerations.** Reprod. Biol. 2020; Malinowski AK, Noureldin A, Othman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183974>
27. **[Analysis of anti-SARS-CoV-2 IgG antibodies in hematologic patients with asymptomatic or mildly symptomatic COVID-19 infections].** Rinsho Ketsueki

- 2020; 61:1459-1463 Hagihara M, Ohara S, Ide S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162440>
28. **Coronavirus Disease 2019 (COVID-19): An Overview of the Immunopathology, Serological Diagnosis and Management.** *Scand. J. Immunol.* 2020:e12998 Anka AU, Tahir MI, Abubakar SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190302>
 29. **Gastrointestinal and Renal Complications in SARS-CoV-2-Infected Patients: Role of Immune System.** *Scand. J. Immunol.* 2020:e12999 Maghool F, Valiani A, Safari T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190306>
 30. **Using Anti-SARS-CoV-2 IgG and IgM Antibodies to Detect Outpatient Cases with Olfactory and Taste Disorders Suspected as Mild Form of COVID-19: a Retrospective Survey.** *SN Compr Clin Med* 2020:1-7 Taziki Balajelini MH, Vakili MA, Saeidi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169109>
 31. **COVID-19: Way Forward With Serosurveillance Without Overemphasizing Neutralizing Antibodies.** *Viral Immunol* 2020; Krsak M, Henao-Martínez AF, Franco-Paredes C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181055>

Management miscellaneous diseases (72 articles)

1. **Prone positioning in mechanically ventilated patients with severe acute respiratory distress syndrome and coronavirus disease 2019.** *Acta Anaesthesiol. Scand.* 2020; Gleissman H, Forsgren A, Andersson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165936>
2. **Re-organising primary health care to respond to the Coronavirus epidemic in Cape Town, South Africa.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e4 Mash R, Goliath C, Perez G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181873>
3. **The Cape Town International Convention Centre from the inside: The family physicians' view of the 'Hospital of Hope'.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e4 Reid S, Ras T, Von Pressentin K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181872>
4. **The influence of coronavirus disease 2019 on emergency department visits in Nanjing, China: A multicentre cross-sectional study.** *Am J Emerg Med* 2020; Sun H, Liu K, Li M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184025>
5. **A novel approach to spinal anaesthesia to avoid aerosol-generating procedures in a patient with COVID-19 presenting for laser prostate surgery.** *Anaesth Rep* 2020; 8:e12065 Oon Z, Ha C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173857>
6. **Response to 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis' by Shi et al.** *Ann. Rheum. Dis.* 2020; Akiyama S, Hamdeh S, Micic D, Sakuraba A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172858>
7. **COVID-19 pandemic: The new normal in breast cancer management - prioritization of care from a breast surgical unit's experience in Singapore.** *Asian J. Surg.* 2020; Tan SM, Melissa Seet YL, Mok CW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189525>
8. **Management of patients who opt for radical prostatectomy during the COVID-19 pandemic: An International Accelerated Consensus Statement.** *BJU Int* 2020; Tandogdu Z, Collins J, Shaw G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185026>

9. **The future of cancer screening after COVID-19 may be at home.** Cancer 2020; Gorin SNS, Jimbo M, Heizelman R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170520>
10. **Establishing a New Normal for Hospital Care: A Whole of Hospital Approach to COVID-19.** Clin Infect Dis 2020; Lum BX, Liu EH, Archuleta S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179039>
11. **The future of rehabilitation in the United Kingdom National Health Service: Using the COVID-19 crisis to promote change, increasing efficiency and effectiveness.** Clin. Rehabil. 2020:269215520971145Wade DT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167682>
12. **Incidence of COVID-19 in patients with rheumatic disease: is prior health education more important than shielding advice during the pandemic?** Clin Rheumatol 2020:1-5Kipps S, Paul A, Vasireddy S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174109>
13. **Perspectives on the Impact of the COVID-19 Pandemic on the Sports Medicine Surgeon: Implications for Current and Future Care.** Clin. Sports Med. 2021; 40:213-220Kunze KN, Fabricant PD, Marx RG, Nwachukwu BU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187611>
14. **Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic.** Curr. Oncol. 2020; 27:e501-e511Bennett S, Søreide K, Gholami S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173390>
15. **Canadian perspective on managing multiple myeloma during the COVID-19 pandemic: lessons learned and future considerations.** Curr. Oncol. 2020; 27:270-274Foley R, Kaedbey R, Song K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173379>
16. **Musculoskeletal oncology: patient triage and management during the COVID-19 pandemic.** Curr. Oncol. 2020; 27:e512-e515Olshinka N, Mottard S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173391>
17. **Does therapy with biological drugs influence COVID-19 infection? Observational, monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone.** Dermatol Ther 2020:e14516Brazzelli V, Isoletta E, Barak O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169500>
18. **The emergency department during the corona pandemic: Fewer non-COVID-19 emergencies.** Deutsches Arzteblatt International 2020; 117:A1201-A1205+A1205Gries A.
19. **Sepsis in times of corona: Stricter coding guidelines.** Deutsches Arzteblatt International 2020; 117:A1930Mainka P.
20. **A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies.** eNeurologicalSci 2020; 21:100287Kataria S, Tandon M, Melnic V, Sriwastava S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163634>
21. **COVID-19 containment and its unrestrained impact on epilepsy management in resource-limited areas of Pakistan.** Epilepsy Behav. 2020; 112:107476Saleem T, Sheikh N, Abbasi MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181895>
22. **Non-COVID-19 deaths after social distancing in Norway.** Eur. J. Epidemiol. 2020; Catalano R, Casey JA, Bruckner TA, Gemmill A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165759>

23. **Ethical Considerations for Treating Cancer Patients During the SARS-CoV-2 Virus Crisis: To Treat or Not to Treat? A Literature Review and Perspective From a Cancer Center in Low-Middle Income Country.** Front Med (Lausanne). 2020; 7:561168Al-Tabba A, Al-Hussaini M, Mansour R *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163499>
24. **From Standard to Escalated Anticoagulant Prophylaxis in Fractured Older Adults With SARS-CoV-2 Undergoing Accelerated Orthopedic Surgery.** Front Med (Lausanne). 2020; 7:566770Perazzo P, Giorgino R, Briguglio M *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178713>
25. **An Example of a Stroke Unit Reshaping in the Context of a Regional Hub and Spoke System in the COVID-19 Era.** Front. Neurol. 2020; 11:1029Candeloro E, Carimati F, Tabaei Damavandi P *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178094>
26. **An Italian Neurorehabilitation Hospital Facing the SARS-CoV-2 Pandemic: Data From 1207 Patients and Workers.** Front. Neurol. 2020; 11:584317Salvia A, Morone G, Iosa M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162930>
27. **Assessing the Attitudes, Awareness, and Behavioral Alterations of Patients Awaiting Total Hip Arthroplasty During the COVID-19 Crisis.** Geriatr Orthop Surg Rehabil 2020; 11:2151459320969377Fahy S, Moore J, Kelly M *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173605>
28. **COVID-19: Impacts on oral healthcare delivery in dependent older adults.** Gerodontology 2020; Lundberg A, Hillebrecht AL, McKenna G, Srinivasan M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169864>
29. **The COVID-19 Outbreak May Be Associated to a Reduced Level of Care for Breast Cancer. A Comparative Study with the Pre-COVID Era in an Italian Breast Unit.** Healthcare (Basel) 2020; 8Fancellu A, Sanna V, Rubino C *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33187343>
30. **APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19.** Hepatol Int 2020:1-10Shiina S, Gani RA, Yokosuka O *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174159>
31. **From the Front Lines of COVID-19 at HSS: An Oral History.** HSS J. 2020:1-9MacKenzie CR, Jacobson J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169073>
32. **Quantifying the Backlog of Total Hip and Knee Arthroplasty Cases: Predicting the Impact of COVID-19.** HSS J. 2020:1-7Wilson JM, Schwartz AM, Farley KX *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169071>
33. **Virtual Fracture Clinics in Orthopaedic Surgery - A Systematic Review of Current Evidence.** Injury 2020; Davey MS, Coveney E, Rowan F *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162011>
34. **How COVID-19 has affected emergent visits to a Latin-American trauma department: Experience at a Peruvian national trauma referral center.** Injury. 2020; Pintado JF, Gibaja W, Vallejos RA *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162012>
35. **Analysis of Emergency Department Visits and Hospital Activity during Influenza Season, COVID-19 Epidemic, and Lockdown Periods in View of Managing a Future Disaster Risk: A Multicenter Observational Study.** Int J Environ Res Public Health 2020; 17Casalino E, Choquet C, Bouzid D *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33182696>
36. **Physical Activity, Resilience, Sense of Coherence and Coping in People with Multiple Sclerosis in the Situation Derived from COVID-19.** Int J Environ Res

- [Public Health](http://www.ncbi.nlm.nih.gov/pubmed/?term=33172022) 2020; 17Reguera-García MM, Liébana-Presa C, Álvarez-Barrio L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172022>
37. **COVID-19 Pandemic Preparedness and Response of Chronic Disease Patients in Public Health Facilities.** *Int. J. Gen. Med.* 2020; 13:1011-1023Geleta TA, Deriba BS, Beyane RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177864>
 38. **Impact of the COVID-19 lockdown on the epidemiology of maxillofacial trauma activity: a French multicentre comparative study.** *Int J Oral Maxillofac Surg* 2020; de Boutray M, Kün-Darbois JD, Sigaux N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172710>
 39. **The risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case.** *Int. J. Radiat. Biol.* 2020;1-20Arruda GV, Weber R, Colello Bruno A, Pavoni JF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164596>
 40. **Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI.** *J Am Coll Cardiol* 2020; 76:2321-2330De Luca G, Verdoia M, Cercek M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183506>
 41. **First Wave of COVID-19 in French Patients with Cystic Fibrosis.** *J Clin Med* 2020; 9Corvol H, de Miranda S, Lemonnier L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182847>
 42. **Professional Assessment of the Impact of COVID-19 on Handling NET Patients.** *J Clin Med* 2020; 9Krug S, Garbe J, König S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187393>
 43. **Clinical Health Care during the COVID-19 Pandemic.** *J Clin Med* 2020; 9Luigetti M, Frisullo G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167325>
 44. **Awareness, Perception, Attitude Regarding CoViD -19 and Infection Control among Indian Pediatric Dentists: A Cross Sectional Study.** *J. Clin. Pediatr. Dent.* 2020; 44:211-220Maru V, Padawe D, Singh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167013>
 45. **The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.** *J Cyst Fibros* 2020; McClenaghan E, Cosgriff R, Brownlee K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183965>
 46. **Dental care during the Covid-19 pandemic - To treat or not to treat?** *J Infect Dev Ctries* 2020; 14:1111-1116Dacic SD, Miljkovic MN, Jovanovic MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175704>
 47. **A Retrospective Analysis of the Trends in Acute Appendicitis During the COVID-19 Pandemic.** *J. Laparoendosc. Adv. Surg. Tech. A* 2020; Finkelstein P, Picado O, Muddasani K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181062>
 48. **Feasibility of an online integrative oncology treatment program during COVID-19.** *J Pain Symptom Manage* 2020; Ben-Arye E, Gressel O, Samuels N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189855>
 49. **COVID-19 pandemic: Early effects on pediatric rehabilitation medicine training.** *J. Pediatr. Rehabil. Med.* 2020; Kivlehan E, Chaviano K, Fetsko L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164964>
 50. **Pediatric intrathecal baclofen management during the COVID-19 pandemic in the US and Canad.** *J. Pediatr. Rehabil. Med.* 2020; Thomas SP, Hardesty CK, Buxton KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164962>
 51. **Changes in Primary Care Visits in the 24 Weeks After COVID-19 Stay-at-Home Orders Relative to the Comparable Time Period in 2019 in Metropolitan Chicago and Northern Illinois.** *J. Prim. Care Community Health* 2020;

- 11:2150132720969557Macy ML, Huetteman P, Kan K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33174495>
52. **Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area.** *JHEP Rep* 2020;100199Amaddeo G, Brustia R, Allaire M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163949>
53. **Effects of the SARS-CoV-2 pandemic on the otorhinolaryngology university hospitals in the field of medical care.** *Laryngo- Rhino- Otologie* 2020; 99:694-706Stöver T, Dazert S, Hoffmann TK *et al.*
54. **COVID-19 in the Early Postoperative Period of Liver Transplantation: Is the Outcome Really So Positive?** *Liver Transpl.* 2020; Waisberg DR, Abdala E, Nacif LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166024>
55. **Social restrictions during COVID-19 and major trauma volume at a level 1 trauma centre.** *Med. J. Aust.* 2020; Way TL, Tarrant SM, Balogh ZJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33174251>
56. **Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic.** *Mult Scler Relat Disord* 2020; 47:102618Alschuler KN, Roberts MK, Herring TE, Ehde DM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33186805>
57. **COVID-19: The regional impact of COVID-19 on the certification of vision impairment in Northern Ireland.** *Ophthalmic Physiol. Opt.* 2020; Jackson J, Silvestri G, Stevenson M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165967>
58. **[Changes in epilepsy care during the first medical emergency period of COVID-19 pandemic in Hungary: A questionnaire survey].** *Orv. Hetil.* 2020; 161:1939-1943Fabó D, Horváth Z, Klivényi P, Kamondi A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33190124>
59. **Expenditure of time of a routinely performed vascular surgery of a patient with COVID 19- A case report.** *Phlebologie* 2020; 49:289-291Mühlberger D, Mumme A, Hummel T.
60. **Addressing the Needs of Rural Caregivers of Individuals With Alzheimer's Disease and Related Dementias During and Beyond Coronavirus Disease 2019 (COVID-19).** *Public Policy Aging Rep* 2020; 30:178-180Williamson HJ, McCarthy MJ, Garcia YE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185627>
61. **Impact of the COVID-19 pandemic on clinical radiography practice in low resource settings: The Ghanaian radiographers' perspective.** *Radiography (Lond)* 2020; Akudjedu TN, Botwe BO, Wuni AR, Mishio NA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33168371>
62. **The impact of COVID-19 on pharmacy transitions of care services.** *Res Social Adm Pharm* 2020; Herzik KA, Bethishou L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162381>
63. **Impact of COVID-19 on polio vaccination in Pakistan: a concise overview.** *Rev Med Virol* 2020; Din M, Ali H, Khan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176028>
64. **COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.** *Rheumatology (Oxford)* 2020; Murray K, Quinn S, Turk M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33164088>
65. **Coronavirus Disease (COVID-19) and Africa: acclaimed home remedies.** *Sci Afr* 2020:e00620Orisakwe OE, Orish CN, Nwanaforo EO.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163740>
66. **EAES Recommendations for Recovery Plan in Minimally Invasive Surgery Amid COVID-19 Pandemic.** Surg. Endosc. 2020;1-17Arezzo A, Francis N, Mintz Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170335>
 67. **COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatienT Outcomes in North London) cohort study.** Ther. Adv. Med. Oncol. 2020; 12:1758835920971147Crolley VE, Hanna D, Joharatnam-Hogan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178336>
 68. **Organ recovery from deceased donors with prior COVID-19: a case series.** Transpl Infect Dis 2020:e13503Neidlinger NA, Smith JA, D'Alessandro AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174324>
 69. **Surgical management of oncologic patient during and after the COVID-19 outbreak: practical recommendations from the Italian society of Surgical Oncology.** Updates Surg. 2020; Cavaliere D, Parini D, Marano L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184782>
 70. **Research initiatives of blood services worldwide in response to the covid-19 pandemic.** Vox Sang 2020; O'Brien SF, Lieshout-Krikke RW, Lewin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165917>
 71. **COVID-19 and neurosurgery consultation call volume at a single large tertiary center with a propensity-adjusted analysis.** World Neurosurg 2020; Koester SW, Catapano JS, Ma KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181382>
 72. **Coronavirus Pandemic - SARS-CoV-2 in Orthopedics and Trauma Surgery.** Z. Orthop. Unfall. 2020; Müller M, Stöckle U, Trampuz A *et al.*

Management (56 articles)

1. **Experience of percutaneous tracheostomy in critically ill COVID-19 patients.** Acute Crit Care 2020; Kim EJ, Yoo EH, Jung CY, Kim KC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176402>
2. **Adapted Diving Mask (ADM) device as respiratory support with oxygen output during COVID-19 pandemic.** Am J Emerg Med 2020; Bibiano-Guillen C, Arias-Arcos B, Collado-Escudero C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172745>
3. **Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium.** Anaesth Crit Care Pain Med 2020; Rello J, Belliato M, Dimopoulos MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172592>
4. **Triage during the COVID-19 pandemic.** Anaesthesiol Intensive Ther 2020; 52:312-315Kucewicz-Czech E, Damps M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165882>
5. **Short-term outcomes after Ivor Lewis oesophagectomy for cancer during the COVID-19 pandemic.** Ann. R. Coll. Surg. Engl. 2020; Chan D, MacCormick A, Rashid B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179514>
6. **PRactice of VENTilation in Patients with Novel Coronavirus Disease (PProVENT-COVID): rationale and protocol for a national multicenter observational study in The Netherlands.** Ann Transl Med 2020; 8:1251Boers NS, Botta M, Tsonas AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178783>
7. **Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza - a single-center registry**

- study.** Artif. Organs 2020; Jäckel M, Rilinger J, Lang CN *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33188714>
8. **Trace Element Zinc, a Nature's Gift to Fight Unprecedented Global Pandemic COVID-19.** Biol. Trace Elem. Res. 2020;1-9Sharma P, Reddy PK, Kumar B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33170448>
 9. **A stoic and altruistic orientation towards their work: a qualitative study of healthcare professionals' experiences of awaiting a COVID-19 test result.** BMC Health Serv. Res. 2020; 20:1031Missel M, Bernild C, Dagyan I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33176771>
 10. **First patient management of COVID-19 in Changsha, China: a case report.** BMC Infect. Dis. 2020; 20:824Zhou J, Cao Z, Wang W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33176693>
 11. **Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.** BMJ Open 2020; 10:e041520Tavernier E, McNicholas B, Pavlov I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33177145>
 12. **COVID-19, thromboembolic risk, and Virchow's triad: Lesson from the past.** Clin. Cardiol. 2020; Mehta JL, Calcaterra G, Bassareo PP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33176009>
 13. **Clinical experience with SARS CoV-2 related illness in children - hospital experience in Cape Town, South Africa.** Clin Infect Dis 2020; van der Zalm MM, Lishman J, Verhagen LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170927>
 14. **COVID-19-associated encephalitis successfully treated with combination therapy.** Clin Infect Pract 2020;100053Freire-Álvarez E, Guillén L, Lambert K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163956>
 15. **Prevalence and severity of malnutrition in hospitalized COVID-19 patients.** Clin Nutr ESPEN 2020; 40:214-219Bedock D, Bel Lassen P, Mathian A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33183539>
 16. **Copper as a potential adjunct therapy for critically ill COVID-19 patients.** Clin Nutr ESPEN 2020; 40:90-91Fooladi S, Matin S, Mahmoodpoor A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33183578>
 17. **Providing Culturally Competent Care for COVID-19 Intensive Care Unit Delirium: A Case Report and Review.** Cureus 2020; 12:e10867Lomiguen CM, Rosete I, Chin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178520>
 18. **The SARS-CoV-2 Pandemic in Latin America: the Need for Multidisciplinary Approaches.** Curr Trop Med Rep 2020;1-6Callejas D, Echevarría JM, Carrero Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169096>
 19. **Vitamin D requirement and COVID-19.** Deutsche Medizinische Wochenschrift 2020; 145:1526.
 20. **A COVID-19 Multipurpose Platform.** Digit Biomark 2020; 4:89-98Petrellis N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173844>
 21. **Impact of COVID-19: Nursing challenges to meeting the care needs of people with developmental disabilities.** Disabil Health J 2020;101015Desroches ML, Ailey S, Fisher K, Stych J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184022>
 22. **Is Timing of Tracheotomy a Factor Influencing the Clinical Course in COVID-19 Patients?** Ear Nose Throat J 2020;145561320974140Mesolella M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33172287>

23. **Tempering Macrophage Plasticity for Controlling SARS-CoV-2 Infection for Managing COVID-19 Disease.** Front. Pharmacol. 2020; 11:570698 Toor D, Jain A, Kalhan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178021>
24. **Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients.** Front. Pharmacol. 2020; 11:543718 Yang F, Yue R, Luo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178011>
25. **Use of Complementary and Alternative Medicine (CAM) and Home Remedies by COVID-19 Patients: A Telephonic Survey.** Indian J. Clin. Biochem. 2020; 1-4 Charan J, Bhardwaj P, Dutta S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162692>
26. **Associations of medications used during hospitalization and immunological changes in patients with COVID-19 during 3-month follow-up.** Int Immunopharmacol 2020; 107:121 Liu C, Dun Y, Liu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168413>
27. **Awareness, Attitudes, Prevention, and Perceptions of COVID-19 Outbreak among Nurses in Saudi Arabia.** Int J Environ Res Public Health 2020; 17:Al-Dossary R, Alamri M, Albaqawi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182352>
28. **Self-Medication-Related Behaviors and Poland's COVID-19 Lockdown.** Int J Environ Res Public Health 2020; 17: Makowska M, Boguszewski R, Nowakowski M, Podkowińska M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187315>
29. **Herbal plants coordinate COVID-19 in multiple dimensions - An insight analysis for clinically applied remedies.** Int. J. Med. Sci. 2020; 17:3125-3145 Zhang Y, Li Y, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173434>
30. **What surgeons should know about emergency operation for COVID-19 confirmed patients: A case report.** Int. J. Surg. Case Rep. 2020; Oh D, Kang YM, Choi JY, Lee WJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169098>
31. **Analgesia and sedation in patients with ARDS.** Intensive Care Med 2020; 1-15 Chanques G, Constantin JM, Devlin JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170331>
32. **Intensive care for COVID-19 in low- and middle-income countries: research opportunities and challenges.** Intensive Care Med 2020; Salluh JIF, Burghi G, Haniffa R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184695>
33. **Nurses' perceptions and demands regarding COVID-19 care delivery in critical care units and hospital emergency services.** Intensive Crit Care Nurs 2020; 102966 González-Gil MT, González-Blázquez C, Parro-Moreno AI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172732>
34. **Traditional Chinese Medicine as a complementary therapy in combat with COVID-19 - a review of evidence-based research and clinical practice.** J. Adv. Nurs. 2020; Wu XV, Dong Y, Chi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174654>
35. **"At home, with care": Lessons from New York City Home-based Primary Care practices managing COVID-19.** J Am Geriatr Soc 2020; Franzosa E, Gorbenko K, Brody AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179761>
36. **Safe Interorganizational Health Information Exchange During the COVID-19 Pandemic.** J. Am. Med. Dir. Assoc. 2020; Wong SP, Jacobson HN, Massengill J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162358>

37. **Risk Communication Should be Explicit About Values. A Perspective on Early Communication During COVID-19.** *J. Bioeth. Inq.* 2020;1-9 Hooker C, Leask J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169264>
38. **Imagining and Preparing for the Aftermath of the COVID-19 Pandemic: A Justification for Taking Caring Responsibilities into Consideration when Allocating Scarce Resources.** *J. Bioeth. Inq.* 2020;1-4 Jordens CFC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169246>
39. **Mental Capacity Assessments for COVID-19 Patients: Emergency Admissions and the CARD Approach.** *J. Bioeth. Inq.* 2020;1-6 Stewart C, Biegler P, Brunero S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169263>
40. **Evaluation of Job Strain of Family Physicians in COVID-19 Pandemic Period- An Example from Turkey.** *J. Community Health* 2020; Taş BG, Özceylan G, Öztürk GZ, Toprak D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188617>
41. **Food-derived antioxidants and COVID-19.** *J. Food Biochem.* 2020:e13557 Lammi C, Arnoldi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171544>
42. **Knowledge and attitude among healthcare workers towards COVID-19: a cross sectional study from Jeddah city, Saudi Arabia.** *J Infect Dev Ctries* 2020; 14:1090-1097 Qadah T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175701>
43. **Knowledge, attitude and precautionary practices towards COVID-19 among healthcare professionals in Karachi, Pakistan.** *J Infect Dev Ctries* 2020; 14:1117-1124 Shakeel S, Rehman H, Hassali MA, Hashmi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175705>
44. **Non-severe immunosuppression might be associated with a lower risk of moderate-severe acute respiratory distress syndrome in COVID-19: a pilot study.** *J Med Virol* 2020; Monreal E, de la Maza SS, Gullón P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165922>
45. **Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness.** *J Thromb Haemost* 2020; 18:3099-3105 Goldenberg NA, Sochet A, Albisetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174388>
46. **The Use of POCUS to Manage ICU Patients With COVID-19.** *J Ultrasound Med* 2020; Schrift D, Barron K, Arya R, Choe C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174650>
47. **Coronavirus in human diseases: Mechanisms and advances in clinical treatment.** *MedComm (Beijing)* 2020; Lin P, Wang M, Wei Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173860>
48. **Sacrificed: Ontario Healthcare Workers in the Time of COVID-19.** *New Solut.* 2020;1048291120974358 Brophy JT, Keith MM, Hurley M, McArthur JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174768>
49. **A comparative analysis of the COVID-19 pandemic response: The case of Turkey.** *North Clin Istanbul* 2020; 7:443-451 Simsek EE, Guner AE, Kul S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163879>
50. **[Air ambulance intensive care transport in prone position for COVID-19 ARDS].** *Notf Rett Med* 2020;1-5 Schellhaaß A, Pösel S, Schwietering J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173408>
51. **COVID-19 IN Turkey: A tertiary center experience.** *Pediatr. Int.* 2020; Önal P, Kılınç AA, Aygün F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190342>
52. **Travelling to High Altitude Destinations after Recovery from COVID-19-infection: New Aspects of Medical Advice in Altitude Medicine.** *Pneumologie*

- (Stuttgart, Germany)_2020; Grannemann JJ, Röper A.
53. **Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID-19.** Respirol Case Rep 2020; 8:e00679Ishiwari M, Togashi Y, Takoi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163186>
 54. **[Covid-19: clinical aspects and management].** Rev Francoph Lab 2020; 2020:40-47Desvaux É, Faucher JF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163103>
 55. **The use of the independent sector in providing NHS services during the Covid-19 outbreak; two hospitals experience.** Surgeon 2020; Barker T, Barker P, Sokalsky L, McNamara I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172728>
 56. **Specific Management of Patients with Acute Abdomen during the COVID-19 Pandemic: A Surgical Perspective from Germany.** Visc Med 2020; 36:417-420Kühn F, Klein M, Laven H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173797>

Mental – public health (90 articles)

1. **Exploring the illness experiences amongst families living with 2019 coronavirus disease in Ghana: Three case reports.** Afr J Prim Health Care Fam Med 2020; 12:e1-e3Ayisi-Boateng NK, Egblewogbe D, Owusu-Antwi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181874>
2. **Stress and behavioral changes with remote E-exams during the Covid-19 pandemic: A cross-sectional study among undergraduates of medical sciences.** Ann Med Surg (Lond) 2020; 60:271-279Elsalem L, Al-Azzam N, Jum'ah AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163179>
3. **Containing COVID: the establishment and management of a COVID-19 ward in an adult psychiatric hospital.** BJPsych Open 2020; 6:e140Knowles M, Aref-Adib G, Moslehi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176900>
4. **COVID-19 and violence: a research call to action.** BMC Womens Health 2020; 20:249Evans DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172466>
5. **Mental health impact of admission to the intensive care unit for COVID-19.** Br. J. Community Nurs. 2020; 25:526-530McDonald G, Clark LL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33161746>
6. **The effect of nationwide quarantine on anxiety levels during the COVID-19 outbreak in China.** Brain Behav 2020:e01938Zhu J, Su L, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174360>
7. **Strengthening collaborations at the public health system-academic interface: a call to action.** Can. J. Public Health. 2020:1-5Di Ruggiero E, Papadopoulos A, Steinberg M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175335>
8. **Changes in health behaviours during early COVID-19 and socio-demographic disparities: a cross-sectional analysis.** Can. J. Public Health. 2020:1-10Zajacova A, Jehn A, Stackhouse M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170494>
9. **Reporting of child maltreatment during the SARS-CoV-2 pandemic in New York City from March to May 2020.** Child Abuse Negl. 2020:104719Rapoport E, Reisert H, Schoeman E, Adesman A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162107>
10. **Changes in pediatric emergency department visits for mental health during the COVID-19 pandemic: A cross-sectional study.** Clin. Child Psychol. Psychiatry. 2020:1359104520972453Leff RA, Setzer E, Cicero MX, Auerbach M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183097>

11. **Anxiety and depression levels in Covid-19 disease and their relation to hypertension.** Clin. Exp. Hypertens. 2020;1-5Sensoy B, Gunes A, Ari S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33176496>
12. **Predicting psychological service providers' empowerment in the light of the COVID-19 pandemic outbreak: A structural equation modelling analysis.** Couns Psychother Res 2020; 20:406-418Arnout BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162833>
13. **Personality Disorders in Time of Pandemic.** Curr Psychiatry Rep 2020; 22:80Preti E, Di Pierro R, Fanti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170391>
14. **The differential mental health impact of COVID-19 in Arab countries.** Curr. Psychol. 2020;1-15Shuwiekh HAM, Kira IA, Sous MSF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162726>
15. **Alcohol and smoking: The COVID-19 pandemic as an ideal breeding ground for addictions.** Deutsches Arzteblatt International 2020; 117:A1251-A1254Georgiadou E, Hillemacher T, Müller A *et al.*
16. **Impact of COVID-19: Nursing challenges to meeting the care needs of people with developmental disabilities.** Disabil Health J 2020;101015Desroches ML, Ailey S, Fisher K, Stych J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184022>
17. **Rehabilitation services lockdown during the COVID-19 emergency: the mental health response of caregivers of children with neurodevelopmental disabilities.** Disabil. Rehabil. 2020;1-6Grumi S, Provenzi L, Gardani A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167738>
18. **Attitudes about COVID-19 Lockdown among General Population, France, March 2020.** Emerg Infect Dis 2020; 27Peretti-Watel P, Seror V, Cortaredona S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183493>
19. **Exposome-based public health interventions for infectious diseases in urban settings.** Environ Int 2020; 146:106246Andrianou XD, Pronk A, Galea KS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181410>
20. **Mental health problems and correlates among 746 217 college students during the coronavirus disease 2019 outbreak in China.** Epidemiol Psychiatr Sci 2020; 29:e181Ma Z, Zhao J, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185174>
21. **Neurobiology of suicide in times of social isolation and loneliness.** Eur. Neuropsychopharmacol. 2020; 40:1-3Zalsman G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33161991>
22. **Neuropsychology in the Times of COVID-19. The Role of the Psychologist in Taking Charge of Patients With Alterations of Cognitive Functions.** Front. Neurol. 2020; 11:573207Sozzi M, Algeri L, Corsano M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178114>
23. **Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey.** Front. Oncol. 2020; 10:584612Catania C, Spitaleri G, Del Signore E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163413>
24. **The Effects of COVID-19 and Quarantine Measures on the Lifestyles and Mental Health of People Over 60 at Increased Risk of Dementia.** Front Psychiatry 2020; 11:578628Di Santo SG, Franchini F, Filiputti B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173523>

25. **Telepsychiatry During the COVID-19 Pandemic: Development of a Protocol for Telemental Health Care.** Front Psychiatry 2020; 11:552450 Ramalho R, Adiukwu F, Gashi Bytyçi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173507>
26. **Meaning in Life and Self-Control Buffer Stress in Times of COVID-19: Moderating and Mediating Effects With Regard to Mental Distress.** Front Psychiatry 2020; 11:582352 Schnell T, Krampe H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173525>
27. **Acompaniment in Grief. Times of Coronavirus.** Front. Psychol. 2020; 11:583233 Bermejo JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178084>
28. **Impact of the Family Environment on the Emotional State of Medical Staff During the COVID-19 Outbreak: The Mediating Effect of Self-Efficacy.** Front. Psychol. 2020; 11:576515 Hu N, Li Y, He SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162916>
29. **2020s Heroes Are Not Fearless: The Impact of the COVID-19 Pandemic on Wellbeing and Emotions of Italian Health Care Workers During Italy Phase 1.** Front. Psychol. 2020; 11:588762 Marton G, Vergani L, Mazzocco K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178088>
30. **Being My Own Companion in Times of Social Isolation - A 14-Day Mobile Self-Compassion Intervention Improves Stress Levels and Eating Behavior.** Front. Psychol. 2020; 11:595806 Schnepfer R, Reichenberger J, Blechert J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162922>
31. **Panic During COVID-19 Pandemic! A Qualitative Investigation Into the Psychosocial Experiences of a Sample of Indian People.** Front. Psychol. 2020; 11:575491 Sharma GD, Ghura AS, Mahendru M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178077>
32. **Framework for a Community Health Observing System for the Gulf of Mexico Region: Preparing for Future Disasters.** Front Public Health 2020; 8:578463 Sandifer P, Knapp L, Lichtveld M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178663>
33. **Genomics in the era of COVID-19: ethical implications for clinical practice and public health.** Genome Med. 2020; 12:95 Geller G, Duggal P, Thio CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168072>
34. **COVID-19 pandemic: Psychological impact on anaesthesiologists.** Indian J. Anaesth. 2020; 64:774-783 Jain A, Singariya G, Kamal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162572>
35. **Sexuality, sexual well being, and intimacy during COVID-19 pandemic: An advocacy perspective.** Indian J. Psychiatry 2020; 62:418-426 Banerjee D, Rao TSS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165372>
36. **State of mental health services in various training centers in India during the lockdown and COVID-19 pandemic.** Indian J. Psychiatry 2020; 62:363-369 Grover S, Mehra A, Sahoo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165355>
37. **Psychological impact of COVID-19 lockdown: An online survey from India.** Indian J. Psychiatry 2020; 62:354-362 Grover S, Sahoo S, Mehra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165368>
38. **Changes in sleep pattern and sleep quality during COVID-19 lockdown.** Indian J. Psychiatry 2020; 62:370-378 Gupta R, Grover S, Basu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165382>
39. **Evaluation of lifestyle, attitude and stressful impact amid COVID-19 among adults in Shanghai, China.** Int. J. Environ. Health Res. 2020:1-10 Cao Y, Ma ZF,

- Zhang Y, Zhang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164565>
40. **Guidelines for Pregnancy Management During the COVID-19 Pandemic: A Public Health Conundrum.** *Int J Environ Res Public Health* 2020; 17Benski C, Di Filippo D, Taraschi G, Reich MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182412>
 41. **Stress, Resilience, and Well-Being in Italian Children and Their Parents during the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17Cusinato M, Iannattone S, Spoto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182661>
 42. **Psychotherapy via the Internet: What Programs Do Psychotherapists Use, How Well-Informed Do They Feel, and What Are Their Wishes for Continuous Education?** *Int J Environ Res Public Health* 2020; 17Humer E, Stippl P, Pieh C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167478>
 43. **A 2-Month Follow-Up Study of Psychological Distress among Italian People during the COVID-19 Lockdown.** *Int J Environ Res Public Health* 2020; 17Roma P, Monaro M, Colasanti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167479>
 44. **Health Anxiety Predicts Postponing or Cancelling Routine Medical Health Care Appointments among Women in Perinatal Stage during the Covid-19 Lockdown.** *Int J Environ Res Public Health* 2020; 17Shayganfar M, Mahdavi F, Haghighi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182388>
 45. **COVID-19 Pandemic Preparedness and Response of Chronic Disease Patients in Public Health Facilities.** *Int. J. Gen. Med.* 2020; 13:1011-1023Geleta TA, Deriba BS, Beyane RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177864>
 46. **The impact of COVID-19 pandemic on people with mild cognitive impairment/dementia and on their caregivers.** *Int. J. Geriatr. Psychiatry* 2020; Tsapanou A, Papatriantafyllou JD, Yiannopoulou K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166418>
 47. **The impact of COVID-19 pandemic on people with Mild Cognitive Impairment / Dementia and on their caregivers.** *Int. J. Geriatr. Psychiatry* 2020; Tsapanou A, Papatriantafyllou JD, Yiannopoulou KG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166418>
 48. **Fear of COVID-19 Scale for Hospital Staff in Regional Hospitals in Mexico: a Brief Report.** *Int J Ment Health Addict* 2020;1-12García-Reyna B, Castillo-García GD, Barbosa-Camacho FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169075>
 49. **Psychological Impact of COVID-19 Duties During Lockdown on Police Personnel and Their Perception About the Behavior of the People: an Exploratory Study from India.** *Int J Ment Health Addict* 2020;1-12Grover S, Sahoo S, Dua D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173448>
 50. **Monitoring the psychological, social, and economic impact of the COVID-19 pandemic in the population: Context, design and conduct of the longitudinal COVID-19 psychological research consortium (C19PRC) study.** *Int. J. Methods Psychiatr. Res.* 2020:e1861McBride O, Murphy J, Shevlin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166018>
 51. **Psychological response of children to home confinement during COVID-19: A qualitative arts-based research.** *Int J Soc Psychiatry* 2020;20764020972439Abdulah DM, Abdulla BMO, Liamputtong P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183155>
 52. **Job Insecurity and Symptoms of Anxiety and Depression Among U.S. Young Adults During COVID-19.** *J. Adolesc. Health* 2020; Ganson KT, Tsai AC, Weiser

- SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183926>
53. **Self-reported changes in anxiety, depression and suicidality during the COVID-19 lockdown in Greece.** *J. Affect. Disord.* 2020; 279:624-629 Fountoulakis KN, Apostolidou MK, Atsiova MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190113>
 54. **Adaptation or Revolution: Telemental Health and Advanced Practice Psychiatric Nursing During COVID-19.** *J. Am. Psychiatr. Nurses Assoc.* 2020:1078390320970638 Schroeder RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164642>
 55. **Obsessive-compulsive disorder during COVID-19: Turning a problem into an opportunity?** *J. Anxiety Disord.* 2020; 77:102329 Jelinek L, Moritz S, Miegel F, Voderholzer U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190017>
 56. **Social Justice for Public Health: The COVID-19 Response in Portugal.** *J. Bioeth. Inq.* 2020:1-6 Cordeiro-Rodrigues L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169259>
 57. **Telling the Truth to Child Cancer Patients in COVID-19 Times.** *J. Bioeth. Inq.* 2020:1-5 Gillam L, Spriggs M, Delany C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169257>
 58. **Changes in Depression and Physical Activity Among College Students on a Diverse Campus After a COVID-19 Stay-at-Home Order.** *J. Community Health* 2020; Coughenour C, Gakh M, Pharr JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165765>
 59. **Evaluation of Job Strain of Family Physicians in COVID-19 Pandemic Period- An Example from Turkey.** *J. Community Health* 2020; Taş BG, Özceylan G, Öztürk GZ, Toprak D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188617>
 60. **Study of resilience and loneliness in youth (18-25 years old) during the COVID-19 pandemic lockdown measures.** *J. Community Psychol.* 2020; Marchini S, Zaurino E, Bouziotis J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169377>
 61. **Loneliness and the COVID-19 Pandemic: Implications for Intimate Partner Violence Survivors.** *J Fam Violence* 2020:1-8 Goodman LA, Epstein D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169047>
 62. **The Impact of COVID-19 on the Delivery of an Evidence-Based Child Maltreatment Prevention Program: Understanding the Perspectives of SafeCare® Providers.** *J Fam Violence* 2020:1-11 Self-Brown S, Reuben K, Perry EW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173254>
 63. **The COVID-19 stress may influence on the sex ratio at birth.** *J Matern Fetal Neonatal Med* 2020:1-6 Abdoli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179546>
 64. **Pandemic-related mental health risk among front line personnel.** *J. Psychiatr. Res.* 2020; Wright HM, Griffin BJ, Shoji K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189356>
 65. **The COVID-19 Psychological Wellbeing Study: Understanding the Longitudinal Psychosocial Impact of the COVID-19 Pandemic in the UK; a Methodological Overview Paper.** *J Psychopathol Behav Assess* 2020:1-17 Armour C, McGlinchey E, Butter S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169046>
 66. **Expressive writing to combat distress associated with the COVID-19 pandemic in people with inflammatory bowel disease (WriteForIBD): A trial protocol.** *J. Psychosom. Res.* 2020; 139:110286 Mikocka-Walus A, Olive L, Skvarc D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171431>

67. **Trust and compliance to public health policies in times of COVID-19.** J Public Econ 2020; 192:104316Bargain O, Aminjonov U.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162621>
68. **Sleep and circadian problems during the coronavirus disease 2019 (COVID-19) pandemic: the International COVID-19 Sleep Study (ICOSS).** J. Sleep Res. 2020:e13206Partinen M, Bjorvatn B, Holzinger B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33179820>
69. **The next wave? Mental health comorbidities and patients with substance use disorders in under-resourced and rural areas.** J. Subst. Abuse Treat. 2020:108189Warfield SC, Pack RP, Degenhardt L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162261>
70. **Psychological impact of the COVID-19 pandemic on health care workers.** J Taibah Univ Med Sci 2020; Qasem Surrati AM, Asad Mansuri FM, Ayadh Alihabi AA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173451>
71. **Standalone Smartphone Cognitive Behavioral Therapy-Based Ecological Momentary Interventions to Increase Mental Health: Narrative Review.** JMIR Mhealth Uhealth 2020; 8:e19836Marciniak MA, Shanahan L, Rohde J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33180027>
72. **Emotional impact of the Covid-19 pandemic on healthcare workers in one of the most important infection outbreaks in Europe.** Med Clin (Engl Ed) 2020; Erquicia J, Valls L, Barja A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163628>
73. **Optimizing clinical research procedures in public health emergencies.** Med. Res. Rev. 2020; Madariaga A, Kasherman L, Karakasis K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33174617>
74. **Prevalence of posttraumatic stress symptoms in health care workers after exposure to patients with COVID-19.** Neurobiol Stress 2020; 13:100261Chen H, Wang B, Cheng Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163588>
75. **Cognitive testing in the COVID-19 era: can existing screeners be adapted for telephone use?** Neurodegener. Dis. Manag. 2020; Larner AJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33172353>
76. **Mental health research in the lower-middle-income countries of Africa and Asia during the COVID-19 pandemic: A scoping review.** Neurol Psychiatry Brain Res 2020; 38:54-64Kar SK, Oyetunji TP, Prakash AJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162686>
77. **Physical and Psychological Effects Related to Food Habits and Lifestyle Changes Derived from Covid-19 Home Confinement in the Spanish Population.** Nutrients 2020; 12López-Moreno M, López MTI, Miguel M, Garcés-Rimón M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182816>
78. **What doubts, concerns and fears about COVID-19 emerged during the first wave of the pandemic?** Patient Educ. Couns. 2020; Leão T, Amorim M, Fraga S, Barros H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172735>
79. **The role of online social comparison as a protective factor for psychological wellbeing: A longitudinal study during the COVID-19 quarantine.** Pers. Individ. Dif. 2020:110486Ruggieri S, Ingoglia S, Bonfanti RC, Lo Coco G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169042>
80. **Psychological entitlement predicts noncompliance with the health guidelines of the COVID-19 pandemic.** Pers. Individ. Dif. 2020:110491Zitek EM, Schlund RJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162631>

81. **"I'm a hero, but...": An evaluation of depression, anxiety, and stress levels of frontline healthcare professionals during COVID-19 pandemic in Turkey.** Perspect. Psychiatr. Care 2020; Alan H, Eskin Bacaksiz F, Tiryaki Sen H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169851>
82. **A case report: Challenges in COVID-19 modeling at a public health department.** Proc Assoc Inf Sci Technol 2020; 57:e426Rogers M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173831>
83. **COVID-19 Pandemic and Mental Health of the General Public: Is there a Tsunami of Mental Disorders?** Psychiatr. Prax. 2020; 47:452-456Riedel-Heller S, Richter D.
84. **Psychological impact of the COVID-19 outbreak on students in a French region severely affected by the disease: results of the PIMS-CoV 19 study.** Psychiatry Res 2020:113559Bourion-Bédès S, Tarquinio C, Batt M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189368>
85. **COVID-19 preventive behaviours among people with anxiety and depressive symptoms: findings from Japan.** Public Health 2020; 189:91-93Stickley A, Matsubayashi T, Sueki H, Ueda M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189941>
86. **The Relationship Among Organizational Identity, Psychological Resilience and Work Engagement of the First-Line Nurses in the Prevention and Control of COVID-19 Based on Structural Equation Model.** Risk Manag. Healthc. Policy 2020; 13:2379-2386Lyu H, Yao M, Zhang D, Liu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173362>
87. **Increased Levels of Anxiety Among Medical and Non-Medical University Students During the COVID-19 Pandemic in the United Arab Emirates.** Risk Manag. Healthc. Policy 2020; 13:2395-2406Saddik B, Hussein A, Sharif-Askari FS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177898>
88. **Is fighting against COVID-19 enough?** Scand J Public Health 2020:1403494820969539Kofler W, Glazachev OS, Lyshol H, Tellnes G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176585>
89. **Motivating social distancing during the COVID-19 pandemic: An online experiment.** Soc. Sci. Med. 2020:113478Lunn PD, Timmons S, Belton CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162198>
90. **The psychosocial impact of the COVID-19 pandemic on changes in smoking behavior: Evidence from a nationwide survey in the UK.** Tob Prev Cessat 2020; 6:59Tzu-Hsuan Chen D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163705>

Meta-analyses - systematic reviews (13 articles)

1. **Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis.** Ann Gastroenterol 2020; 33:615-630Aziz M, Haghbin H, Lee-Smith W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162738>
2. **Response to 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis' by Shi et al.** Ann. Rheum. Dis. 2020; Akiyama S, Hamdeh S, Micic D, Sakuraba A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172858>
3. **Newly Reported Studies on the Increase in Gastrointestinal Symptom Prevalence with COVID-19 Infection: A Comprehensive Systematic Review and**

- Meta-Analysis.** Diseases 2020; 8Akin H, Kurt R, Tufan F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33182651>
4. **Factors affecting the mortality of patients with COVID-19 undergoing surgery and the safety of medical staff: A systematic review and meta-analysis.** EClinicalMedicine 2020;100612Wang K, Wu C, Xu J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169112>
 5. **Predictors of COVID-19 severity: a systematic review and meta-analysis.** F1000Res 2020; 9:1107Mudatsir M, Fajar JK, Wulandari L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163160>
 6. **Psychological Impact of COVID-19 Duties During Lockdown on Police Personnel and Their Perception About the Behavior of the People: an Exploratory Study from India.** Int J Ment Health Addict 2020;1-12Grover S, Sahoo S, Dua D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173448>
 7. **Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.** J. Cardiol. 2020; Ren L, Yu S, Xu W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33168337>
 8. **Association Between Ethnicity and Severe COVID-19 Disease: a Systematic Review and Meta-analysis.** J Racial Ethn Health Disparities 2020; Raharja A, Tamara A, Kok LT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180278>
 9. **The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.** Mayo Clin Proc Innov Qual Outcomes 2020; Tleyjeh IM, Kashour Z, AlDosary O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163895>
 10. **Psychological entitlement predicts noncompliance with the health guidelines of the COVID-19 pandemic.** Pers. Individ. Dif. 2020;110491Zitek EM, Schlund RJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162631>
 11. **Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.** Pharmacy_(Basel) 2020; 8Hong TS, Gonzalez J, Nahass RG, Brunetti L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167571>
 12. **Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients.** Public Health 2020; 189:66-72Prado-Galbarro FJ, Sanchez-Piedra C, Gamiño-Arroyo AE, Cruz-Cruz C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166857>
 13. **An Analysis of Newspaper Depictions of Schooling: a Participatory Study for the Development of a Teacher Education Curriculum.** Syst Pract Action Res 2020;1-20Mabunda P, McKay V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162730>

Mortality (32 articles)

1. **Risk factors for intensive care unit admission and mortality in hospitalized COVID-19 patients.** Acute Crit Care 2020; Ayaz A, Arshad A, Malik H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33172229>
2. **COVID-19 mortality and neighborhood characteristics in Chicago.** Ann. Epidemiol. 2020; Bryan MS, Sun J, Jagai J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181262>
3. **Factors associated with increased mortality in hospitalized COVID-19 patients.** Ann Med Surg_(Lond) 2020; 60:308-313Shah C, Grando DJ, Rainess RA *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169090>
4. **Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK Biobank.** *BMC Med* 2020; 18:355 Petermann-Rocha F, Hanlon P, Gray SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167965>
 5. **Factors associated with COVID-19 infections and mortality in Africa: a cross-sectional study using publicly available data.** *BMJ Open* 2020; 10:e042750 Okeahalam C, Williams V, Ot wombe K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177146>
 6. **Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19: a retrospective multicentre cohort study.** *BMJ Open* 2020; 10:e041989 Park JG, Kang MK, Lee YR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184086>
 7. **Smoking Doubles the Mortality Risk in COVID-19: A Meta-Analysis of Recent Reports and Potential Mechanisms.** *Cureus* 2020; 12:e10837 Salah HM, Sharma T, Mehta J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173643>
 8. **Decreased Mortality in Patients With Severe Bronchospasm Associated With SARS-CoV-2: An Alternative to Invasive Mechanical Ventilation.** *Cureus* 2020; 12:e10822 Salazar R, Sr., Hallo A, Vasquez S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173630>
 9. **Factors affecting the mortality of patients with COVID-19 undergoing surgery and the safety of medical staff: A systematic review and meta-analysis.** *EClinicalMedicine* 2020;100612 Wang K, Wu C, Xu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169112>
 10. **Air pollutants and risk of death due to COVID-19 in Italy.** *Environ. Res.* 2020;110459 Dettori M, Deiana G, Balletto G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188767>
 11. **Non-COVID-19 deaths after social distancing in Norway.** *Eur. J. Epidemiol.* 2020; Catalano R, Casey JA, Bruckner TA, Gemmill A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165759>
 12. **Impact of lockdown on COVID-19 prevalence and mortality during 2020 pandemic: observational analysis of 27 countries.** *Eur. J. Med. Res.* 2020; 25:56 Meo SA, Abukhalaf AA, Alomar AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168104>
 13. **Potential Role of Autonomic Dysfunction in Covid-19 Morbidity and Mortality.** *Front. Physiol.* 2020; 11:561749 Del Rio R, Marcus NJ, Inestrosa NC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178034>
 14. **Older People Living in Long-Term Care Facilities and Mortality Rates During the COVID-19 Pandemic in Italy: Preliminary Epidemiological Data and Lessons to Learn.** *Front Psychiatry* 2020; 11:586524 de Girolamo G, Bellelli G, Bianchetti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173526>
 15. **A Fatal Course of Multiple Inflammatory Syndrome in Children Coinfection with Dengue. A Case Report from Indonesia.** *IDCases* 2020:e01002 Somasetia DH, Malahayati TT, Andriyani FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163360>
 16. **COVID-19 and sudden cardiac death: A new potential risk.** *Indian Heart J.* 2020; 72:333-336 Yadav R, Bansal R, Budakoty S, Barwad P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189190>

17. **The Role of the Social Vulnerability Index in Personal Protective Equipment Shortages, Number of Cases, and Associated Mortality During the COVID-19 Pandemic in Michigan Skilled Nursing Facilities.** Infect Control Hosp Epidemiol 2020;1-10LeRose J, Merlo C, Duong P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183395>
18. **Lower levels of vitamin D are associated with SARS-CoV-2 infection and mortality in the Indian population: An observational study.** Int Immunopharmacol 2020; 88:107001Padhi S, Suvankar S, Panda VK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182040>
19. **Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D.** Int Immunopharmacol 2020; 88:106995Silberstein M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182059>
20. **Coronavirus Disease 2019 (COVID-19): A Modeling Study of Factors Driving Variation in Case Fatality Rate by Country.** Int J Environ Res Public Health 2020; 17Pan J, St Pierre JM, Pickering TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167564>
21. **Performance of the Quick COVID-19 Severity Index and the Brescia-COVID Respiratory Severity Scale in hospitalized patients with COVID-19 in a community hospital setting.** Int J Infect Dis 2020; Rodriguez-Nava G, Yanez-Bello MA, Trelles-Garcia DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181332>
22. **Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry.** Intern Emerg Med 2020; Núñez-Gil IJ, Fernández-Pérez C, Estrada V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165755>
23. **Delay, Death, and Heterogeneity of Primary PCI During the COVID-19 Pandemic: An International Perspective.** J Am Coll Cardiol 2020; 76:2331-2333Park DW, Yang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183507>
24. **Admission cardiac diagnostic testing with electrocardiography and troponin measurement prognosticates increased 30-day mortality in COVID-19.** J Am Heart Assoc 2020:e018476Poterucha TJ, Elias P, Jain SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169643>
25. **Post-Mortem Diagnostics in COVID-19 AKI, More Often but Timely.** J Am Soc Nephrol 2020; Zijlstra JG, van Meurs M, Moser J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170136>
26. **COVID-19, Moral Conflict, Distress, and Dying Alone.** J. Bioeth. Inq. 2020:1-6Anderson-Shaw LK, Zar FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169271>
27. **Early, low-dose, short-term methylprednisolone decreased the mortality in critical COVID-19 patients: a multicenter retrospective cohort study.** J Infect 2020; Ji J, Wu M, Zhong L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176176>
28. **Demystifying the varying case fatality rates (CFR) of COVID-19 in India: Lessons learned and future directions.** J Infect Dev Ctries 2020; 14:1128-1135Asirvatham ES, Lakshmanan J, Sarman CJ, Joy M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175707>
29. **Factors Associated with COVID-Related Mortality: the Case of Texas.** J Racial Ethn Health Disparities 2020:1-6Ojinnaka CO, Adepoju OE, Burgess AV, Woodard L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169310>
30. **Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study.** Mayo

- Clin Proc Innov Qual Outcomes 2020; Rodriguez-Nava G, Yanez-Bello MA, Trelles-Garcia DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173851>
31. **Prevalence of SARS-CoV-2 in human post-mortem ocular tissues.** Ocul Surf 2020; Sawant OB, Singh S, Wright RE, 3rd *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176215>
 32. **Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19.** Oral Oncol 2020; 112:105087Hanna GJ, Rettig EM, Park JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190021>

Online – IT – Apps (63 articles)

1. **Exploring the Residents' Perspective on Smart learning Modalities and Contents for Virtual Urology Education: Lesson Learned During the COVID-19 Pandemic.** Actas Urol. Esp. 2020; Campi R, Amparore D, Checcucci E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168176>
2. **Life in lockdown: A telephone survey to investigate the impact of COVID-19 lockdown measures on the lives of older people (≥ 75 years).** Age Ageing 2020; Brown L, Mossabir R, Harrison N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173949>
3. **Integrating Medical Students in Tele-Palliative Care.** Am. J. Hosp. Palliat. Care 2020;1049909120973199Chow B, Rallis KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167668>
4. **The impact of new modes of electronic communication in the treatment of severe acute respiratory syndrome coronavirus 2 infection.** Ann Transl Med 2020; 8:1239Fang Z, Gu Z, Zhang T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178771>
5. **Impact of an e-learning module on personal protective equipment knowledge in student paramedics: a randomized controlled trial.** Antimicrob Resist Infect Control 2020; 9:185Suppan L, Stuby L, Gartner B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168097>
6. **Effects of misinformation diffusion during a pandemic.** Appl Netw Sci 2020; 5:82Prandi L, Primiero G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163618>
7. **Telemonitoring type 1 diabetes patients during the COVID-19 pandemic in Brazil: was it useful?** Arch Endocrinol Metab 2020; de Mattos Matheus AS, Cabizuca CA, Tannus LRM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166438>
8. **Attitudes and concerns of undergraduate university health sciences students in Croatia regarding complete switch to e-learning during COVID-19 pandemic: a survey.** BMC Med. Educ. 2020; 20:416Puljak L, Čivljak M, Haramina A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167960>
9. **Readability of online COVID-19 health information: a comparison between four English speaking countries.** BMC Public Health 2020; 20:1635Worrall AP, Connolly MJ, O'Neill A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183297>
10. **The future of cancer screening after COVID-19 may be at home.** Cancer 2020; Gorin SNS, Jimbo M, Heizelman R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170520>
11. **Youtube as an Information Source During the Coronavirus Disease (COVID-19) Pandemic: Evaluation of the Turkish and English Content.** Cureus 2020;

- 12:e10795Ataç Ö, Özalp YC, Kurnaz R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163299>
12. **Corona skeptics: Understandable theory.** Deutsches Arzteblatt International 2020; 117:A1929Streit S.
13. **A COVID-19 Multipurpose Platform.** Digit Biomark 2020; 4:89-98Petrellis N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173844>
14. **Telepsychiatry During the COVID-19 Pandemic: Development of a Protocol for Telemental Health Care.** Front Psychiatry 2020; 11:552450Ramalho R, Adiukwu F, Gashi Bytyçi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173507>
15. **Using Social Media to Communicate Sustainable Preventive Measures and Curtail Misinformation.** Front. Psychol. 2020; 11:568324Hauer MK, Sood S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178073>
16. **Telemedicine Across the Globe-Position Paper From the COVID-19 Pandemic Health System Resilience PROGRAM (REPROGRAM) International Consortium (Part 1).** Front Public Health 2020; 8:556720Bhaskar S, Bradley S, Chattu VK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178656>
17. **Roles for mHealth to support Community Health Workers addressing COVID-19.** Glob Health Promot 2020;1757975920967924O'Donovan J, Hamala R, Nalubwama M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176572>
18. **Healthcare information technology convergence to effectively cope with the COVID- 19 crisis.** Health Policy Technol 2020; Hau YS, Chang MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163353>
19. **Telepharmacy: An opportunity for community pharmacists during the COVID-19 pandemic in Sub Saharan Africa.** Health Policy Technol 2020; Hedima EW, Okoro RN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169100>
20. **COVID-19 misinformation: Accuracy of articles about coronavirus prevention mostly shared on social media.** Health Policy Technol 2020; Obiała J, Obiała K, Mańczak M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163352>
21. **Applying software-defined networking to support telemedicine health consultation during and post Covid-19 era.** Health Technol (Berl) 2020;1-9Jnr BA, Nweke LO, Al-Sharafi MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163323>
22. **The Efficacy of Telehealth for the Treatment of Spinal Disorders: Patient-Reported Experiences During the COVID-19 Pandemic.** HSS J. 2020;1-7Shafi K, Lovecchio F, Forston K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169072>
23. **A review and content analysis of national apps for COVID-19 management using Mobile Application Rating Scale (MARS).** Inform Health Soc Care 2020;1-14Salehinejad S, Niakan Kalhori SR, Hajesmaeel Gohari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164594>
24. **Virtual Fracture Clinics in Orthopaedic Surgery - A Systematic Review of Current Evidence.** Injury 2020; Davey MS, Coveney E, Rowan F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162011>
25. **A Social Network Analysis of Tweets Related to Masks during the COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17Ahmed W, Vidal-Alaball J, Lopez Segui F, Moreno-Sánchez PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171843>
26. **Information in Spanish on the Internet about the Prevention of COVID-19.** Int J Environ Res Public Health 2020; 17Hernández-García I, Giménez-Júlvez T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171724>

27. **Psychotherapy via the Internet: What Programs Do Psychotherapists Use, How Well-Informed Do They Feel, and What Are Their Wishes for Continuous Education?** Int J Environ Res Public Health 2020; 17:Humer E, Stippl P, Pieh C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167478>
28. **The experience of contact tracing in Singapore in the control of COVID-19: highlighting the use of digital technology.** Int. Orthop. 2020; Lai SHS, Tang CQY, Kurup A, Thevendran G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188602>
29. **Unveiling the silent threat among us: leveraging health information technology in the search for asymptomatic COVID 19 healthcare workers.** J Am Med Inform Assoc 2020; McKeeby JW, Siwy CM, Revoir J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165614>
30. **Heralding the Digitalization of Life in Post-Pandemic East Asian Societies.** J. Bioeth. Inq. 2020;1-5Ho CW, Caals K, Zhang H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169256>
31. **Caregiver Satisfaction and Effectiveness of Teleconsultation in Children and Adolescents With Migraine During the Ongoing COVID-19 Pandemic.** J. Child Neurol. 2020;883073820968653Sharawat IK, Panda PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170754>
32. **Impact of COVID-19 Lockdown Measures on Spanish People with Chronic Pain: An Online Study Survey.** J Clin Med 2020; 9Nieto R, Pardo R, Sora B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167322>
33. **Partisan public health: how does political ideology influence support for COVID-19 related misinformation?** J Comput Soc Sci 2020;1-24Havey NF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163686>
34. **Influencing overseas Chinese by tweets: text-images as the key tactic of Chinese propaganda.** J Comput Soc Sci 2020;1-18Wang AH, Lee MC, Wu MH, Shen P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169108>
35. **Adoption of telemedicine applications among Saudi citizens during COVID-19 pandemic: An alternative health delivery system.** J Infect Public Health 2020; Yamin MAY, Alyoubi BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172819>
36. **Changes in the office for civil rights enforcement policy on telehealth remote communications in response to COVID-19.** J. Pediatr. Rehabil. Med. 2020; Mortell TJ, Strobel AT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164963>
37. **AI-driven quantification, staging and outcome prediction of COVID-19 pneumonia.** Med. Image Anal. 2020; 67:101860Chassagnon G, Vakalopoulou M, Battistella E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171345>
38. **Digging the Rabbit Hole, COVID-19 Edition: Anti-Vaccine Themes and the Discourse Around COVID-19.** Microbes Infect 2020; Smith TC, Reiss DR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171267>
39. **Telemedicine Aids in Initial Deep Brain Stimulation Programming for Dystonia.** Mov Disord Clin Pract 2020; 7:1002-1003Prakash N, Zadikoff C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163578>
40. **Cognitive testing in the COVID-19 era: can existing screeners be adapted for telephone use?** Neurodegener. Dis. Manag. 2020; Lerner AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172353>
41. **The Need for Digital Health Solutions in Deep Brain Stimulation for Parkinson's Disease in the Time of COVID-19 and Beyond.** Neuromodulation 2020; Rammo R, Gostkowski M, Rasmussen PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174292>

42. **COVID-19 and abortion right.** Obstet Gynecol Sci 2020; Rashidpouraie R, Sharifi MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167115>
43. **Medical Student Participation in Otolaryngology Telemedicine Clinic During COVID-19: A Hidden Opportunity.** Otolaryngol Head Neck Surg 2020;194599820970964Pellegrini WR, Danis DO, 3rd, Levi JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167750>
44. **The role of online social comparison as a protective factor for psychological wellbeing: A longitudinal study during the COVID-19 quarantine.** Pers. Individ. Dif. 2020;110486Ruggieri S, Ingoglia S, Bonfanti RC, Lo Coco G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169042>
45. **Telemedizin in der Rhythmologie-gewappnet für Pandemiezeiten Telemedicine in Rhythmology-Prepared for Pandemics.** Praxis 2020; 109:1135-1140Roten L.
46. **What we can learn from information flows about COVID-19: Implications for research and practice.** Proc Assoc Inf Sci Technol 2020; 57:e245Afzal W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173811>
47. **Social media and COVID-19: Can social distancing be quantified without measuring human movements?** Proc Assoc Inf Sci Technol 2020; 57:e378Anderson M, Karami A, Bozorgi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173828>
48. **Network typology, information sources, and messages of the infodemic twitter network under COVID-19.** Proc Assoc Inf Sci Technol 2020; 57:e363Chong M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173826>
49. **COVID-19 pandemic and information diffusion analysis on Twitter.** Proc Assoc Inf Sci Technol 2020; 57:e252Dinh L, Parulian N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173813>
50. **Stigmatization in social media: Documenting and analyzing hate speech for COVID-19 on Twitter.** Proc Assoc Inf Sci Technol 2020; 57:e313Fan L, Yu H, Yin Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173820>
51. **Social media and COVID-19: Characterizing anti-quarantine comments on Twitter.** Proc Assoc Inf Sci Technol 2020; 57:e349Karami A, Anderson M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173823>
52. **A preliminary investigation of COVID-19 transmission in the United States by incorporating social media sentiments.** Proc Assoc Inf Sci Technol 2020; 57:e370Tan T, Huang T, Wang X, Zuo Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173827>
53. **The state of practice of COVID-19 tracking systems: An inventory study.** Proc Assoc Inf Sci Technol 2020; 57:e397Tang R, Erdelez S, May E, Zhang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173829>
54. **The use of ICT during COVID-19.** Proc Assoc Inf Sci Technol 2020; 57:e297Yang S, Fichman P, Zhu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173819>
55. **Investigating COVID-19-Related query logs of Chinese search engine users.** Proc Assoc Inf Sci Technol 2020; 57:e424Ye Z, Mao J, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173830>
56. **Uncovering temporal differences in COVID-19 tweets.** Proc Assoc Inf Sci Technol 2020; 57:e233Zheng H, Goh DH, Lee CS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173810>
57. **Elasticity as a measure for online determination of remission points in ongoing epidemics.** Stat. Med. 2020; Veres-Ferrer EJ, Pavia JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174250>

58. **A city cluster risk-based approach for Sars-CoV-2 and isolation barriers based on anonymized mobile phone users' location data.** Sustain Cities Soc 2020:102574Silva JCS, de Lima Silva DF, Delgado Neto AS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178556>
59. **An Analysis of Newspaper Depictions of Schooling: a Participatory Study for the Development of a Teacher Education Curriculum.** Syst Pract Action Res 2020:1-20Mabunda P, McKay V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162730>
60. **An intelligent framework using disruptive technologies for COVID-19 analysis.** Technol Forecast Soc Change 2020:120431Abdel-Basset M, Chang V, Nabeeh NA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162617>
61. **Role of Media Coverage in Mitigating COVID-19 Transmission: Evidence from China.** Technol Forecast Soc Change 2020:120435Liu N, Chen Z, Bao G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162619>
62. **CAFE: An Instructional Design Model to Assist K-12 Teachers to Teach Remotely during and beyond the Covid-19 Pandemic.** TechTrends 2020:1-9Wang CX. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169121>
63. **Perception of Neurosurgery Residents and Attendings on Online Webinars During COVID-19 Pandemic and Implications on Future Education.** World Neurosurg 2020; Al-Ahmari AN, Ajlan AM, Bajunaid K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181378>

Other – Miscellaneous (84 articles)

1. **How the Covid-19 pandemic is impacting sexual and reproductive health and rights and response: results from a global survey of providers, researchers, and policy makers.** Acta Obstet Gynecol Scand 2020; Endler M, Al-Haidari T, Benedetto C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179265>
2. **Disparity in ozone trends under COVID-19 lockdown in a closely located coastal and hillocky metropolis of India.** Air Qual Atmos Health 2020:1-10Korhale N, Anand V, Beig G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163121>
3. **Physician wellness in Allergy and Immunology: Personal resiliency.** Ann. Allergy. Asthma. Immunol. 2020; Nanda A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181326>
4. **Emergency Food Provision for Children and Families during the COVID-19 Pandemic: Examples from Five U.S. Cities.** Appl Econ Perspect Policy 2020:e13096Jablonski BBR, Casnovsky J, Clark JK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173572>
5. **Labor Issues in the Food Supply Chain Amid the COVID-19 Pandemic.** Appl Econ Perspect Policy 2020; Luckstead J, Nayga RM, Jr., Snell HA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173571>
6. **Fail to Prepare and you Prepare to Fail: the Human Rights Consequences of the UK Government's Inaction during the COVID-19 Pandemic.** Asian Bioeth Rev 2020:1-22Frowde R, Dove ES, Laurie GT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163110>
7. **Effect of Covid-19 on food security: A cross-sectional survey.** Clin Nutr ESPEN 2020; 40:171-178Elsahoryi N, Al-Sayyed H, Odeh M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33183533>

8. **In-silico analysis of angiotensin converting enzyme 2 (ACE2) of livestock, pet and poultry animals to determine its susceptibility to SARS-CoV- 2 infection.** Comb. Chem. High Throughput Screen. 2020; Kumar A, Panwar A, Batra K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172369>
9. **A Computational Model to Predict Consumer Behaviour During COVID-19 Pandemic.** Comput Econ 2020:1-14Safara F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169049>
10. **A survey dataset to evaluate the changes in mobility and transportation due to COVID-19 travel restrictions in Australia, Brazil, China, Ghana, India, Iran, Italy, Norway, South Africa, United States.** Data Brief 2020; 33:106459Barbieri DM, Lou B, Passavanti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163599>
11. **Radical Approaches During Unusual Circumstances: Intellectual Property Regulation and the COVID-19 Dilemma.** Development (Rome) 2020:1-10El Said M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173258>
12. **Purchasing, consumption, demographic and socioeconomic variables associated with shifts in alcohol consumption during the COVID-19 pandemic.** Drug Alcohol Rev 2020; Callinan S, Mojica-Perez Y, Wright CJC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170976>
13. **The outbreak of methanol intoxication during COVID-19 pandemic: prevalence of brain lesions and its predisposing factors.** Drug Chem. Toxicol. 2020:1-4Simani L, Ramezani M, Roozbeh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172326>
14. **Two-step seismic noise reduction caused by COVID-19 induced reduction in social activity in metropolitan Tokyo, Japan.** Earth Planets Space 2020; 72:167Yabe S, Imanishi K, Nishida K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169064>
15. **Air pollutants and risk of death due to COVID-19 in Italy.** Environ. Res. 2020:110459Dettori M, Deiana G, Balletto G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188767>
16. **Impact of Covid-19 lockdown on air quality in the Poland, Eastern Europe.** Environ. Res. 2020:110454Filonchik M, Hurynovich V, Yan H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188759>
17. **Online trade in wildlife and the lack of response to COVID-19.** Environ. Res. 2020:110439Morcatty TQ, Feddema K, Nekaris KAI, Nijman V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171119>
18. **Unprecedented environmental and energy impacts and challenges of COVID-19 pandemic.** Environ. Res. 2020:110443Siddique A, Shahzad A, Lawler J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171120>
19. **Impact of hydrological factors on the dynamic of COVID-19 epidemic: A multi-region study in China.** Environ. Res. 2020:110474Wang J, Li W, Yang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189742>
20. **It is time to control the worst: testing COVID-19 outbreak, energy consumption and CO(2) emission.** Environ. Sci. Pollut. Res. Int. 2020; Iqbal S, Bilal AR, Nurunnabi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184786>
21. **Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?** Euro Surveill 2020; 25Monnet DL, Harbarth S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183403>
22. **Disease, downturns, and wellbeing: Economic history and the long-run impacts of COVID-19.** Explor Econ Hist 2020:101381Arthi V, Parman J.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162564>
23. **International Law, COVID-19 and Feminist Engagement with the United Nations Security Council: The End of the Affair?** *Fem Leg Stud* 2020;1-8O'Rourke C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162691>
 24. **Food waste in Italian households during the Covid-19 pandemic: a self-reporting approach.** *Food Secur* 2020;1-13Amicarelli V, Bux C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173548>
 25. **Detraining Effects Prevention: A New Rising Challenge for Athletes.** *Front. Physiol.* 2020; 11:588784Girardi M, Casolo A, Nuccio S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178050>
 26. **From Shattered Goals to Meaning in Life: Life Crafting in Times of the COVID-19 Pandemic.** *Front. Psychol.* 2020; 11:577708de Jong EM, Ziegler N, Schippers MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178081>
 27. **Genomics in the era of COVID-19: ethical implications for clinical practice and public health.** *Genome Med.* 2020; 12:95Geller G, Duggal P, Thio CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168072>
 28. **A warm summer is unlikely to stop transmission of COVID-19 naturally.** *Geohealth* 2020:e2020GH000292Su M, Peng S, Chen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173840>
 29. **Air Quality Response in China Linked to the 2019 Novel Coronavirus (COVID-19) Lockdown.** *Geophys. Res. Lett.* 2020; 47:e2020GL089252Miyazaki K, Bowman K, Sekiya T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173248>
 30. **Minimal Climate Impacts From Short-Lived Climate Forcers Following Emission Reductions Related to the COVID-19 Pandemic.** *Geophys. Res. Lett.* 2020; 47:e2020GL090326Weber J, Shin YM, Staunton Sykes J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173249>
 31. **Physical activity during COVID-19 Pandemic in the Iranian population: A brief report.** *Heliyon* 2020:e05411Amini H, Isanejad A, Chamani N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163638>
 32. **The social-economic impact of COVID-19 pandemic: implications for potential forest degradation.** *Heliyon* 2020; 6:e05354Golar G, Malik A, Muis H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163655>
 33. **National survey of home injuries during the time of COVID-19: who is at risk?** *Inj Epidemiol* 2020; 7:63Gielen AC, Bachman G, Badaki-Makun O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176881>
 34. **Understanding the reactions of government and gaming concessionaires on COVID-19 through the neo-institutional theory - The case of Macao.** *Int J Hosp Manag* 2020;102755Loi KI, Lei WS, Lourenço F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162641>
 35. **Older Adults Post-Incarceration: Restructuring Long-term Services and Supports in the Time of COVID-19.** *J. Am. Med. Dir. Assoc.* 2020; Boucher NA, Van Houtven CH, Dawson WD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189565>
 36. **Athletic Trainers' Job Tasks and Status During the Coronavirus Disease 2019 Pandemic: A Preliminary Analysis.** *J Athl Train* 2020; Winkelmann ZK, Games KE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176352>
 37. **COVID-19, Moral Conflict, Distress, and Dying Alone.** *J. Bioeth. Inq.* 2020;1-6Anderson-Shaw LK, Zar FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169271>

38. **Venenum, Virus, Fear, and Politics.** *J. Bioeth. Inq.* 2020:1-4Bekerman Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169250>
39. **Justice, Well-Being, and Civic Duty in the Age of a Pandemic: Why we all Need to Do our bit.** *J. Bioeth. Inq.* 2020:1-6Bester JC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169261>
40. **We Need to Talk About Rationing: The Need to Normalize Discussion About Healthcare Rationing in a Post COVID-19 Era.** *J. Bioeth. Inq.* 2020:1-5Bhatia N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169254>
41. **Ethical Challenges in Clinical Research During the COVID-19 Pandemic.** *J. Bioeth. Inq.* 2020:1-6Bierer BE, White SA, Barnes JM, Gelinas L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169251>
42. **Interview: Mourning Is a Political Act Amid the Pandemic and Its Disparities (Republication).** *J. Bioeth. Inq.* 2020:1-5Butler J, Yancy G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169248>
43. **It Didn't Have to be This Way: Reflections on the Ethical Justification of the Running Ban in Northern Italy in Response to the 2020 COVID-19 Outbreak.** *J. Bioeth. Inq.* 2020:1-6Camporesi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169266>
44. **Ought Conscientious Refusals to Implement Reverse Triage Decisions be Accommodated?** *J. Bioeth. Inq.* 2020:1-5Emmerich N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169245>
45. **Telling the Truth to Child Cancer Patients in COVID-19 Times.** *J. Bioeth. Inq.* 2020:1-5Gillam L, Spriggs M, Delany C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169257>
46. **Beyond Duty: Medical "Heroes" and the COVID-19 Pandemic.** *J. Bioeth. Inq.* 2020:1-8Lipworth W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169270>
47. **What Triage Issues Reveal: Ethics in the COVID-19 Pandemic in Italy and France.** *J. Bioeth. Inq.* 2020:1-5Orfali K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169260>
48. **What Matters? Palliative Care, Ethics, and the COVID-19 Pandemic.** *J. Bioeth. Inq.* 2020:1-4Sheahan L, Brennan F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169252>
49. **Ethical Considerations for Restrictive and Physical Distancing Measures in Brazil During COVID-19: Facilitators and Barriers.** *J. Bioeth. Inq.* 2020:1-5Thomé BC, Matta GC, Rego STA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169249>
50. **The Way We Live Now.** *J. Bioeth. Inq.* 2020:1-3Wiltshire J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169268>
51. **The Circadian Clock and Viral Infections.** *J. Biol. Rhythms* 2020:748730420967768Borrmann H, McKeating JA, Zhuang X.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33161818>
52. **Impact of the COVID-19 Pandemic on environmental awareness, sustainable consumption and social responsibility: evidence from generations in Brazil and Portugal.** *J Clean Prod* 2020:124947Severo EA, de Guimarães JCF, Dellarmelin ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173257>
53. **Significant concurrent decrease in PM(2.5) and NO(2) concentrations in China during COVID-19 epidemic.** *J. Environ. Sci. (China)* 2021; 99:346-353Chu B, Zhang S, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183713>
54. **A Commentary on the Review Entitled, "A Scoping Review of the Human Milk Microbiome" by Groer et al.** *J Hum Lact* 2020; 36:644-646Wagner CL.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181051>
55. **COVID-19, indications for professional football teams and referees training resumption.** *J Infect Dev Ctries* 2020; 14:1084-1089 Donadu MG, Pizzi AR, Zeppilli P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175700>
 56. **Long-term survival of SARS-CoV-2 on salmon as a source for international transmission.** *J Infect Dis* 2020; Dai M, Li H, Yan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179031>
 57. **Insights into Disparities Observed with COVID-19.** *J Intern Med* 2020; Carethers JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164230>
 58. **Aspiration of periodontopathic bacteria due to poor oral hygiene potentially contributes to the aggravation of COVID-19.** *J. Oral Sci.* 2020; Takahashi Y, Watanabe N, Kamio N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177276>
 59. **Relationship between parenting practices and children's screen time during the COVID-19 Pandemic in Turkey.** *J. Pediatr. Nurs.* 2020; 56:24-29 Ozturk Eyimaya A, Yalçın Irmak A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181369>
 60. **Pricing the global health risks of the COVID-19 pandemic.** *J Risk Uncertain* 2020:1-28 Viscusi WK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162671>
 61. **Navigating the Risks of Flying During COVID-19: A Review for Safe Air Travel.** *J Travel Med* 2020; Khatib AN, Carvalho AM, Primavesi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184655>
 62. **[Decisions on the state of health of employees and applicants for work with the use of ICT media].** *Med. Pr.* 2020; Zajdel-Całkowska J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162558>
 63. **COVID-19 Pandemic in the Midst of Civil War: Planetary Health and Plant Omics Field Notes from Aden, Yemen.** *OMICS* 2020; Abdullah AT, Hassen J, Abdullah AA, Ağırbaşı M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180003>
 64. **High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households.** *One Health* 2020; 11:100192 Fritz M, Rosolen B, Krafft E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169106>
 65. **High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households.** *One Health* 2021; 11:100192 Fritz M, Rosolen B, Krafft E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169106>
 66. **Network interventions for managing the COVID-19 pandemic and sustaining economy.** *Proc Natl Acad Sci U S A* 2020; Nishi A, Dewey G, Endo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177237>
 67. **Addressing the Urgent Housing Needs of Vulnerable Women in the Era of COVID-19: The Los Angeles County Experience.** *Psychiatr. Serv.* 2020:appips202000318 Goodsmith N, Ijadi-Maghsoodi R, Melendez RM, Dossett EC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167810>
 68. **A moment for reflection. Ethical aspects in the pandemic SARS-CoV-2/COVID-19 in our clinical practice.** *Rev. Esp. Anesthesiol. Reanim.* 2020; Yepes-Temiño MJ, Callejas González R, Álvarez Avello JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162118>
 69. **[Remain alert for Covid-19 in Mayotte].** *Rev Francoph Lab* 2020; 2020:70-75 Bourée P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163107>
 70. **Confidence vanished or impaired until distrust in the doctor-patient relationship because of COVID-19: Confidence vanished or impaired until distrust: "COVID" in relationship.** *Rev. Med. Interne* 2020; Roubille C, Ribstein J, Hurpin G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168352>

71. **Risk assessment of SARS-CoV-2 in Antarctic wildlife.** Sci Total Environ 2020:143352Barbosa A, Varsani A, Morandini V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162142>
72. **Detection of SARS-CoV-2 RNA in hospital wastewater from a low COVID-19 disease prevalence area.** Sci Total Environ 2020:143226Gonçalves J, Koritnik T, Mioč V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176933>
73. **Review on the contamination of wastewater by COVID-19 virus: Impact and treatment.** Sci Total Environ 2021; 751:142325Lahrich S, Laghrib F, Farahi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33182015>
74. **Ozone over Mexico City during the COVID-19 pandemic.** Sci Total Environ 2020:143183Peralta O, Ortínez-Alvarez A, Torres-Jardón R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33168247>
75. **Letter to the editor regarding Rodrigues et al. 2020: Is COVID-19 halting wildfires in the Mediterranean? Insights for wildfire science under a pandemic context.** Sci Total Environ 2020:143347Resco de Dios V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162124>
76. **Impact of emission reductions and meteorology changes on atmospheric mercury concentrations during the COVID-19 lockdown.** Sci Total Environ 2021; 750:142323Wu Q, Tang Y, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182196>
77. **COVID-19: The Role of the Ophthalmologist in ICU.** Semin. Ophthalmol. 2020:1-3Bhalla M, Jolly R, Jain S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164658>
78. **Population-weighted exposure to air pollution and COVID-19 incidence in Germany.** Spat Stat 2021; 41:100480Huang G, Brown PE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163351>
79. **A deep learning-based social distance monitoring framework for COVID-19.** Sustain Cities Soc 2020:102571Ahmed I, Ahmad M, Rodrigues J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163330>
80. **Living environment matters: Unravelling the spatial clustering of COVID-19 hotspots in Kolkata megacity, India.** Sustain Cities Soc 2020:102577Das A, Ghosh S, Das K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163331>
81. **Towards the sustainable development of smart cities through mass video surveillance: A response to the COVID-19 pandemic.** Sustain Cities Soc 2021; 64:102582Shorfuzzaman M, Hossain MS, Alhamid MF.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178557>
82. **Tobacco and e-cigarette shops awarded 'essential business' labels in France during COVID-19.** Tob Induc Dis 2020; 18:90Brailon A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33177969>
83. **Differences in levels of stress, social support, health behaviours, and stress-reduction strategies for women pregnant before and during the COVID-19 pandemic, and based on phases of pandemic restrictions, in Ireland.** Women Birth 2020; Matvienko-Sikar K, Pope J, Cremin A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162362>
84. **Human factors and ergonomics in the context of COVID-19: Planning for concepts insertion in a productive systems discipline.** Work 2020; Anholon R, Rampasso IS, Cooper Ordóñez RE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164968>

1. **Why does COVID-19 pathology have several clinical forms?** Bioessays 2020:e2000198Aliabadi F, Ajami M, Pazoki-Toroudi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174637>
2. **Brain donation in the era of COVID 19: challenges to the harvest in the face of a pandemic.** Cell Tissue Bank 2020:1-7Iglesias-Hernandez D, Radler KH, Hernandez N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175287>
3. **Post-Mortem Diagnostics in COVID-19 AKI, More Often but Timely.** J Am Soc Nephrol 2020; Zijlstra JG, van Meurs M, Moser J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170136>
4. **Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: autopsy results from 'Spanish flu' 1918/1919 in Switzerland to Coronavirus disease 2019.** J Pathol Clin Res 2020; Burkhard-Koren NM, Haberecker M, Maccio U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185036>
5. **Prevalence of SARS-CoV-2 in human post-mortem ocular tissues.** Ocul Surf 2020; Sawant OB, Singh S, Wright RE, 3rd *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176215>
6. **Evidences of SARS-CoV-2 virus air transmission indoors using several untouched surfaces: A pilot study.** Sci Total Environ 2021; 751:142317Orenes-Piñero E, Baño F, Navas-Carrillo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182011>
7. **Organ recovery from deceased donors with prior COVID-19: a case series.** Transpl Infect Dis 2020:e13503Neidlinger NA, Smith JA, D'Alessandro AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174324>
8. **Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN- γ as a Novel Antiviral Approach Against COVID-19.** Viral Immunol 2020; Anjum FR, Anam S, Abbas G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181057>

Protection (26 articles)

1. **Adapted Diving Mask (ADM) device as respiratory support with oxygen output during COVID-19 pandemic.** Am J Emerg Med 2020; Bibiano-Guillen C, Arias-Arcos B, Collado-Escudero C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172745>
2. **Barrier enclosure use during aerosol-generating medical procedures: A scoping review.** Am J Emerg Med 2020; Price C, Ben-Yakov M, Choi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189515>
3. **Filtration Efficiency of Surgical Sterilization Fabric for Respiratory Protection during COVID-19 Pandemic.** Am. J. Infect. Control 2020; Sousan S, Garcia N, White A, Balanay JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166599>
4. **Aerosol and droplet generation from mandible and midface fixation: Surgical risk in the pandemic era.** Am. J. Otolaryngol. 2020; 42:102829Ye MJ, Sharma D, Campiti VJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33186853>
5. **Respiratory personal protective equipment for healthcare workers: impact of sex differences on respirator fit test results.** Br J Anaesth 2020; Ascott A, Crowest P, de Sausmarez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183736>

6. **Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series.** Cureus 2020; 12:e11315Go CC, Pandav K, Sanchez-Gonzalez MA, Ferrer G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173650>
7. **Modifying regulatory practices to create a safe and effective working environment within a Shared Resource Laboratory (SRL) during a global pandemic.** Cytometry A 2020; Filby A, Haviland DL, Jones DD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190383>
8. **Contact dermatitis due to masks and respirators during COVID-19 pandemic: what we should know and what we should do.** Dermatol Ther 2020; Di Altobrando A, La Placa M, Neri I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174266>
9. **So far, how effective were distancing measures during the COVID-19 pandemic?** Deutsche Medizinische Wochenschrift 2020; 145:1530-1531 Klein F.
10. **Corona pandemic: Defective masks.** Deutsches Arzteblatt International 2020; 117:A1660-A1664ärzteblatt D.
11. **Factors affecting the mortality of patients with COVID-19 undergoing surgery and the safety of medical staff: A systematic review and meta-analysis.** EClinicalMedicine 2020:100612Wang K, Wu C, Xu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169112>
12. **Access and Use Experience of Personal Protective Equipment Among Frontline Healthcare Workers in Pakistan During the COVID-19 Emergency: A Cross-Sectional Study.** Health Secur 2020; Hakim M, Khattak FA, Muhammad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175583>
13. **Infection control in dentistry during COVID - 19 pandemic: what has changed?** Heliyon 2020; 6:e05402Patel M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163669>
14. **The Role of the Social Vulnerability Index in Personal Protective Equipment Shortages, Number of Cases, and Associated Mortality During the COVID-19 Pandemic in Michigan Skilled Nursing Facilities.** Infect Control Hosp Epidemiol 2020:1-10LeRose J, Merlo C, Duong P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183395>
15. **A Social Network Analysis of Tweets Related to Masks during the COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17Ahmed W, Vidal-Alaball J, Lopez Segui F, Moreno-Sánchez PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171843>
16. **Knowledge, attitude and precautionary practices towards COVID-19 among healthcare professionals in Karachi, Pakistan.** J Infect Dev Ctries 2020; 14:1117-1124Shakeel S, Rehman H, Hassali MA, Hashmi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175705>
17. **Modeling aerosol transmission of SARS-CoV-2 in multi-room facility.** J Loss Prev Process Ind 2020:104336Kennedy M, Lee SJ, Epstein M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173256>
18. **Navigating the Risks of Flying During COVID-19: A Review for Safe Air Travel.** J Travel Med 2020; Khatib AN, Carvalho AM, Primavesi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184655>
19. **Evaluating the Quality of Rigid Optic Videolaryngoscopy Image Taken Through Dental Protection Cap and Its Feasibility as Additional Barrier Method Against COVID-19.** J. Voice 2020; Nagata Cavalheiro M, Fonseca VR, Zeigelboim BS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168360>

20. **Which protective mask protects against COVID-19? What is evidence-based?** Laryngo- Rhino- Otologie 2020; 99:779-787 Schulze-Röbbecke R, Reska M, Lemmen S.
21. **A hospital-wide response to multiple outbreaks of COVID-19 in health care workers: lessons learned from the field.** Med. J. Aust. 2020; Buising KL, Williamson D, Cowie BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190286>
22. **Intestinal Barrier Function in Health and Disease-Any role of SARS-CoV-2?** Microorganisms 2020; 8 Sharma L, Riva A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172188>
23. **Hand Sanitizers Marketed in the Streets of Addis Ababa, Ethiopia, in the Era of COVID-19: A Quality Concern.** Risk Manag. Healthc. Policy 2020; 13:2483-2487 Selam MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177903>
24. **Scenarios to Manage the Demand for N95 Respirators for Healthcare Workers During the COVID-19 Pandemic.** Risk Manag. Healthc. Policy 2020; 13:2489-2496 Sun Y, Otomaru H, Quaye SED *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177904>
25. **Evidences of SARS-CoV-2 virus air transmission indoors using several untouched surfaces: A pilot study.** Sci Total Environ 2021; 751:142317 Orenes-Piñero E, Baño F, Navas-Carrillo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182011>
26. **Simulation and Measurement of Aerosolisation in Different Chest Drainage Systems.** Semin. Thorac. Cardiovasc. Surg. 2020; Mustaev M, Bille A, Hasan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171236>

Pulmonary disease (13 articles)

1. **Pneumomediastinum and subcutaneous emphysema after noninvasive ventilation in a COVID-19 patient.** Adv Respir Med 2020; 88:466-467 Vazzana N, Ognibene S, Dipaola F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169823>
2. **Pulmonary Endothelial Dysfunction and Thrombotic Complications in COVID-19 Patients.** Am. J. Respir. Cell Mol. Biol. 2020; Rodríguez C, Luque N, Blanco I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180562>
3. **COVID-19 pneumonia and pulmonary microembolism in a patient with B-thalassemia major.** Clin Case Rep 2020; Marziali M, Ribersani M, Losardo AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173583>
4. **Asthma and COVID-19: What do we know now.** Clin. Med. Insights Circ. Respir. Pulm. Med. 2020; 14:1179548420966242 Hughes-Visentin A, Paul ABM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173369>
5. **Decreased Mortality in Patients With Severe Bronchospasm Associated With SARS-CoV-2: An Alternative to Invasive Mechanical Ventilation.** Cureus 2020; 12:e10822 Salazar R, Sr., Hallo A, Vasquez S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173630>
6. **Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?** Expert Rev. Respir. Med. 2020; Rogliani P, Lauro D, di Daniele N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183113>
7. **Postoperative COVID-19 pneumonia in an asymptomatic patient: a case report.** Infect Disord Drug Targets 2020; Asadollahi-Amin A, Shahmohamadi E, Hasibi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183212>

8. **Clinical characteristics of COVID-19 patients with asthma in Wuhan, China: a retrospective cohort study.** J. Asthma 2020;1-14 Jin M, Chen C, Huang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183117>
9. **Habit Mimics the Illness: EVALI During the Era of the COVID-19 Pandemic.** J Investig Med High Impact Case Rep 2020; 8:2324709620972243 Kichloo A, Khan A, Siddiqui N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174465>
10. **Residual Lung Injury in Patients Recovering From COVID-19 Critical Illness: A Prospective Longitudinal Point-of-Care Lung Ultrasound Study.** J Ultrasound Med 2020; Alharthy A, Abuhamdah M, Balhamar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185316>
11. **Treating exuberant, non-resolving inflammation in the lung; implications for acute respiratory distress syndrome and COVID-19.** Pharmacol. Ther. 2020;107745 Gilroy DW, De Maeyer RPH, Tepper M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188794>
12. **Tuberculosis and COVID-19.** Pneumologie 2020; 74:639 Manych M.
13. **Perception of the COVID-19 Pandemic among Pneumology Professionals in Germany.** Pneumologie (Stuttgart, Germany) 2020; Peine A, Paffenholz P, Hellmich M *et al.*

Renal disease (18 articles)

1. **COVID-19 patients in intensive care develop predominantly oliguric acute kidney injury.** Acta Anaesthesiol. Scand. 2020; Luther T, Bülow-Anderberg S, Larsson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190222>
2. **Continuous renal replacement therapy with the addition of CytoSorb® cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series.** Artif. Organs 2020; Alharthy A, Faqih F, Memish ZA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190288>
3. **COVID-19 and maintenance hemodialysis: a systematic scoping review of practice guidelines.** BMC Nephrol. 2020; 21:470 Akbarialiabad H, Kavousi S, Ghahramani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172405>
4. **Renal ultrasound findings secondary to COVID-19 related collapsing focal segmental glomerulosclerosis - A case report.** Clin Imaging 2020; 71:34-38 Tancredi T, DeWaters A, McGillen KL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171364>
5. **Renal transplantation during the SARS-CoV-2 pandemic in the UK: experience from a large volume centre.** Clin. Transplant. 2020:e14150 Georgiades F, Summers DM, Butler AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170982>
6. **What can a home hemodialysis program offer to patients in a nursing home setting? A case series and feasibility analysis.** Hemodial Int 2020; Scarpioni R, Ricardi M, Manini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184982>
7. **Lesson for the clinical nephrologist: Kidney transplant, COVID-19 and pregnancy.** J Nephrol 2020; Gleeson S, Noori M, Lightstone L, Webster P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180315>
8. **Home hemodialysis during the COVID-19 epidemic: comment on the French experience from the viewpoint of a French home hemodialysis care network.** J Nephrol 2020;1-3 Michel PA, Piccoli GB, Couchoud C, Fessi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175342>

9. **Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19.** Kidney Blood Press. Res. 2020;1-15Chaudhri I, Moffitt R, Taub E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171466>
10. **Atypical HUS relapse triggered by Covid-19.** Kidney Int 2020; Ville S, Bot SL, Chapelet-Debout A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188793>
11. **Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring.** Kidney Int 2020; Waldman M, Soler MJ, García-Carro C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181156>
12. **Informing the risk of kidney transplantation versus remaining on the wait list in the COVID-19 era.** Kidney Int Rep 2020; Clarke C, Lucisano G, Predecki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173838>
13. **COVID-19 and kidney transplantation: A systematic review.** Kidney Int Rep 2020; Mahalingasivam V, Craik A, Tomlinson LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163708>
14. **Acute kidney failure in patients admitted due to COVID-19.** Nefrologia 2020; Tarragón B, Valdenebro M, Serrano ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162225>
15. **Peritoneal dialysis for acute kidney injury: Equations for dosing in pandemics, disasters, and beyond.** Perit. Dial. Int. 2020;896860820970066Chionh CY, Finkelstein FO, Ronco C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174468>
16. **Gastrointestinal and Renal Complications in SARS-CoV-2-Infected Patients: Role of Immune System.** Scand. J. Immunol. 2020:e12999Maghool F, Valiani A, Safari T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190306>
17. **Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection.** Transpl Infect Dis 2020:e13500Chowdary P, Shetty S, Booth J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174284>
18. **Clinical course of COVID-19 disease in immunosuppressed renal transplant patients.** Turk J Med Sci 2020; Dheir H, Sipahi S, Yaylaci S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185367>

Reviews (34 articles)

1. **The coronavirus disease 2019: the prevalence, prognosis, and recovery from olfactory dysfunction (OD).** Acta Otolaryngol. 2020;1-10Samimi Ardestani SH, Mohammadi Ardehali M, Rabbani Anari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176530>
2. **COVID-19 in pregnancy and the puerperium: A review for emergency physicians.** Am J Emerg Med 2020; Boushra MN, Koyfman A, Long B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162266>
3. **Barrier enclosure use during aerosol-generating medical procedures: A scoping review.** Am J Emerg Med 2020; Price C, Ben-Yakov M, Choi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189515>
4. **Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.** Ann Transl Med 2020; 8:1247Sabarimurugan S, Dharmarajan A, Warriar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178779>

5. **SARS-CoV-2: Remarks on the COVID-19 Pandemic.** Arch. Immunol. Ther. Exp. (Warsz.) 2020; 68:35Piasecki E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33185755>
6. **A review of COVID-19 vaccines and major considerations for diabetic patients.** Biotechnol. Appl. Biochem. 2020; Soltani S, Zandi M, Aghbash PS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179788>
7. **COVID-19 and maintenance hemodialysis: a systematic scoping review of practice guidelines.** BMC Nephrol. 2020; 21:470Akbarialiabad H, Kavousi S, Ghahramani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172405>
8. **Differences in terms of presentation and outcomes between patients with lung cancer as opposed to other solid organ cancer after infection with SARS-CoV-2: protocol for a systematic review.** BMJ Open 2020; 10:e041790Chen H, Shi J, Shi W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172947>
9. **COVID-19 and stroke, a case series and review of literature.** Brain Behav Immun Health 2020; 9:100172Elkhider H, Ibrahim F, Sharma R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173859>
10. **Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.** Brain Sci 2020; 10Dragoi AM, Radulescu I, Năsu BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187329>
11. **Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.** Cureus 2020; 12:e10869Kotak S, Khatri M, Malik M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178522>
12. **COVID-19 and Comorbidities: is Inflammation the Underlying Condition in Children? A narrative Review.** Curr. Pediatr. Rev. 2020; Pinna G, Sanfilippo L, Bassareo PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183207>
13. **A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies.** eNeurologicalSci 2020; 21:100287Kataria S, Tandon M, Melnic V, Sriwastava S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163634>
14. **A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.** Front. Immunol. 2020; 11:585354Sharma O, Sultan AA, Ding H, Triggie CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163000>
15. **Ethical Considerations for Treating Cancer Patients During the SARS-CoV-2 Virus Crisis: To Treat or Not to Treat? A Literature Review and Perspective From a Cancer Center in Low-Middle Income Country.** Front Med (Lausanne) 2020; 7:561168Al-Tabba A, Al-Hussaini M, Mansour R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163499>
16. **Systematic Review of the Literature About the Effects of the COVID-19 Pandemic on the Lives of School Children.** Front. Psychol. 2020; 11:569348Cachón-Zagalaz J, Sánchez-Zafra M, Sanabrias-Moreno D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162910>
17. **Containing the impact of COVID-19: Review of Ghana's response approach.** Health Policy Technol 2020; Sibiri H, Prah D, Zankawah SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169101>
18. **An overview on COVID-19 pandemic: from discovery to treatment.** Infect Disord Drug Targets 2020; Panati K, Tatireddygar VRA, Narala VR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167846>
19. **May 2020: Is It Always COVID-19 No Matter What?** Int Med Case Rep J 2020; 13:563-567Livrieri F, Ghidoni G, Piro R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167846>

term=33173352

20. **Traditional Chinese Medicine as a complementary therapy in combat with COVID-19 - a review of evidence-based research and clinical practice.** J. Adv. Nurs. 2020; Wu XV, Dong Y, Chi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174654>
21. **Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines.** J Clin Med 2020; 9Omersel J, Karas Kuželički N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167413>
22. **The novel zoonotic Coronavirus disease 2019 (COVID-19) pandemic: Health perspective on the outbreak.** J Healthc Qual Res 2020; Mazinani M, Rude BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162382>
23. **A Commentary on the Review Entitled, "A Scoping Review of the Human Milk Microbiome" by Groer et al.** J Hum Lact 2020; 36:644-646Wagner CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181051>
24. **Cerebral Venous Sinus Thrombosis in COVID-19 Infection: A Case Series and Review of The Literature.** J. Stroke Cerebrovasc. Dis. 2020; 30:105434Dakay K, Cooper J, Bloomfield J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190109>
25. **Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.** JACC Case Rep 2020; Gubitosa JC, Kakar P, Gerula C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163977>
26. **COVID-19 and kidney transplantation: A systematic review.** Kidney Int Rep 2020; Mahalingasivam V, Craik A, Tomlinson LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163708>
27. **Coronavirus in human diseases: Mechanisms and advances in clinical treatment.** MedComm (Beijing) 2020; Lin P, Wang M, Wei Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173860>
28. **Mental health research in the lower-middle-income countries of Africa and Asia during the COVID-19 pandemic: A scoping review.** Neurol Psychiatry Brain Res 2020; 38:54-64Kar SK, Oyetunji TP, Prakash AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162686>
29. **SARS-CoV-2 associated COVID-19 in Geriatric Population: A Brief Narrative Review.** Saudi J. Biol. Sci. 2020; Mohamad Al-Zahrani J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169063>
30. **Coronavirus Disease 2019 (COVID-19): An Overview of the Immunopathology, Serological Diagnosis and Management.** Scand. J. Immunol. 2020:e12998Anka AU, Tahir MI, Abubakar SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190302>
31. **Gastrointestinal and Renal Complications in SARS-CoV-2-Infected Patients: Role of Immune System.** Scand. J. Immunol. 2020:e12999Maghool F, Valiani A, Safari T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190306>
32. **COVID-19 in HIV: a Review of Published Case Reports.** SN Compr Clin Med 2020:1-11Morani Z, Patel S, Ghosh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163861>
33. **CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study.** Viruses 2020; 12Calvet J, Gratacós J, Amengual MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182268>
34. **Insufficient etiological workup of COVID-19-associated acute pancreatitis: A systematic review.** World J. Gastroenterol. 2020; 26:6270-6278Juhász MF, Ocskay

Risk factors (60 articles)

1. **Risk factors for intensive care unit admission and mortality in hospitalized COVID-19 patients.** *Acute Crit Care* 2020; Ayaz A, Arshad A, Malik H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172229>
2. **A predictive model for the severity of COVID-19 in elderly patients.** *Aging (Albany NY)* 2020; 12Zeng F, Deng G, Cui Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170150>
3. **Linking lactate dehydrogenase to the severity of COVID-19 cannot ignore the employed methodology.** *Am J Emerg Med* 2020; Aloisio E, Pasqualetti S, Panteghini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168383>
4. **Identifying patients with symptoms suspicious for COVID-19 at elevated risk of adverse events: The COVAS score.** *Am J Emerg Med* 2020; Sharp AL, Huang BZ, Broder B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189516>
5. **SARS-CoV-2: Influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP)-metabolism and on severity of COVID-19.** *Am J Physiol Endocrinol Metab* 2020; van Kempen TA, Deixler E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174766>
6. **Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections.** *Am J Physiol Lung Cell Mol Physiol* 2020; Eapen MS, Lu W, Hackett TL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174446>
7. **Association between red blood cell distribution width and mortality of COVID-19 patients.** *Anaesth Crit Care Pain Med* 2020; Lorente L, Martín MM, Argueso M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171297>
8. **Factors associated with increased mortality in hospitalized COVID-19 patients.** *Ann Med Surg (Lond)* 2020; 60:308-313 Shah C, Grando DJ, Rainess RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169090>
9. **Red cell distribution width (RDW): a prognostic indicator of severe COVID-19.** *Ann Transl Med* 2020; 8:1230 Wang C, Zhang H, Cao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178762>
10. **Lymphocyte percentage and hemoglobin as a joint parameter for the prediction of severe and nonsevere COVID-19: a preliminary study.** *Ann Transl Med* 2020; 8:1231 Zhang W, Zhang Z, Ye Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178763>
11. **Clinical and radiographic characteristics, management and short-term outcomes of patients with COVID-19 in Wenzhou, China.** *BMC Infect. Dis.* 2020; 20:841 Hong L, Ye E, Sun G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187475>
12. **Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK Biobank.** *BMC Med* 2020; 18:355 Petermann-Rocha F, Hanlon P, Gray SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167965>
13. **What items should be included in an early warning score for remote assessment of suspected COVID-19? qualitative and Delphi study.** *BMJ Open* 2020; 10:e042626 Greenhalgh T, Thompson P, Weiringa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184088>

14. **Factors associated with COVID-19 infections and mortality in Africa: a cross-sectional study using publicly available data.** BMJ Open 2020; 10:e042750 Okeahalam C, Williams V, Otworld K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177146>
15. **Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19: a retrospective multicentre cohort study.** BMJ Open 2020; 10:e041989 Park JG, Kang MK, Lee YR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184086>
16. **Bioinformatic analysis of SMN1-ACE/ACE2 interactions hinted at a potential protective effect of spinal muscular atrophy against COVID-19-induced lung injury.** Brief. Bioinform. 2020; Li Z, Li X, Shen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190150>
17. **Cardiovascular view of intermediate and high-risk COVID-19 patients: single-centre experience with low mortality and intensive care hospitalisation rates.** Cardiovasc. J. Afr. 2020; 31:1-9 Medetalibeyoglu A, Emet S, Senkal N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165497>
18. **The endothelium as Achilles' heel in COVID-19 patients.** Cardiovasc Res 2020; Gladka MM, Maack C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167001>
19. **Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.** Cell 2020; Su Y, Chen D, Yuan D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171100>
20. **Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients.** Cell Rep Med 2020:100144 Mueller AA, Tamura T, Crowley CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163981>
21. **Prevalence of obesity and hypovitaminosis D in elderly with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** Clin Nutr ESPEN 2020; 40:110-114 Gonçalves TJM, Gonçalves S, Guarnieri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183522>
22. **High neutrophil to lymphocyte ratio as a prognostic marker in COVID-19 patients.** Clin Nutr ESPEN 2020; 40:101-102 Pimentel GD, Dela Vega MCM, Laviano A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183520>
23. **Smoking Doubles the Mortality Risk in COVID-19: A Meta-Analysis of Recent Reports and Potential Mechanisms.** Cureus 2020; 12:e10837 Salah HM, Sharma T, Mehta J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173643>
24. **Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19.** EMBO Mol Med 2020:e13424 Marfia G, Navone S, Guarnaccia L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190411>
25. **Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.** Eur J Heart Fail 2020; Tomasoni D, Inciardi RM, Lombardi CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179839>
26. **Age-related mitochondrial dysfunction as a key factor in COVID-19 disease.** Exp. Gerontol. 2020; 142:111147 Moreno Fernández-Ayala DJ, Navas P, López-Lluch G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171276>
27. **Age-related mitochondrial dysfunction as a key factor in COVID-19 disease.** Exp. Gerontol. 2020; 142:111147 Moreno-Fernández Ayala DJ, Navas P, López-Lluch G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171276>
28. **Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?** Expert Rev. Respir. Med. 2020; Rogliani P,

- Lauro D, di Daniele N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183113>
29. **Frequencies of CD33+CD11b+HLA-DR-CD14-CD66b+ and CD33+CD11b+HLA-DR-CD14+CD66b- Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19.** *Front Med (Lausanne)* 2020; 7:580677 Alberca RW, Andrade MMS, Branco A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178720>
 30. **Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case Severity.** *Front. Microbiol.* 2020; 11:603509 Liu T, Jia P, Fang B, Zhao Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178176>
 31. **Potential Role of Autonomic Dysfunction in Covid-19 Morbidity and Mortality.** *Front. Physiol.* 2020; 11:561749 Del Rio R, Marcus NJ, Inestrosa NC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178034>
 32. **Composition of the immunoglobulin G glycome associates with the severity of COVID-19.** *Glycobiology* 2020; Petrović T, Alves I, Bugada D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174592>
 33. **Association of HLA-B22 serotype with SARS-CoV-2 susceptibility in Hong Kong Chinese patients.** *Hla* 2020; Yung YL, Cheng CK, Chan HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179437>
 34. **Lower levels of vitamin D are associated with SARS-CoV-2 infection and mortality in the Indian population: An observational study.** *Int Immunopharmacol* 2020; 88:107001 Padhi S, Suvankar S, Panda VK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182040>
 35. **Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D.** *Int Immunopharmacol* 2020; 88:106995 Silberstein M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182059>
 36. **Coronavirus Disease 2019 (COVID-19): A Modeling Study of Factors Driving Variation in Case Fatality Rate by Country.** *Int J Environ Res Public Health* 2020; 17Pan J, St Pierre JM, Pickering TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167564>
 37. **Performance of the Quick COVID-19 Severity Index and the Brescia-COVID Respiratory Severity Scale in hospitalized patients with COVID-19 in a community hospital setting.** *Int J Infect Dis* 2020; Rodriguez-Nava G, Yanez-Bello MA, Trelles-Garcia DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181332>
 38. **Temporal changes of CT findings between non-severe and severe cases of COVID-19 pneumonia: a multi-center, retrospective, longitudinal Study.** *Int. J. Med. Sci.* 2020; 17:2653-2662 Dai M, Liu X, Zhu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162793>
 39. **Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry.** *Intern Emerg Med* 2020; Núñez-Gil IJ, Fernández-Pérez C, Estrada V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165755>
 40. **COVID-19 and Heart Failure: Harsh Reality of Pre-Existing Conditions.** *J Am Coll Cardiol* 2020; 76:2349-2351 Panjrath GS, Krepp J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183508>
 41. **Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.** *J. Cardiol.* 2020; Ren L, Yu S, Xu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168337>
 42. **Habit Mimics the Illness: EVALI During the Era of the COVID-19 Pandemic.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620972243 Kichloo A, Khan A, Siddiqui N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33174465>

43. **Desaturation and heme elevation during COVID-19 infection: A potential prognostic factor of heme oxygenase-1.** J Microbiol Immunol Infect 2020; Su WL, Lin CP, Hang HC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176981>
44. **Factors Associated with COVID-Related Mortality: the Case of Texas.** J Racial Ethn Health Disparities 2020;1-6Ojinnaka CO, Adepoju OE, Burgess AV, Woodard L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169310>
45. **Association Between Ethnicity and Severe COVID-19 Disease: a Systematic Review and Meta-analysis.** J Racial Ethn Health Disparities 2020; Raharja A, Tamara A, Kok LT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180278>
46. **Evaluating Clinical Course and Risk Factors of Infection and Demographic Characteristics of Pregnant Women with COVID-19 in Hamadan Province, West of Iran.** J Res Health Sci 2020; 20:e00488Sattari M, Bashirian S, Masoumi SZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169720>
47. **Determining the relationship between SARS-CoV-2 infection, dopamine, and COVID-19 complications.** J Taibah Univ Med Sci 2020; Khalefah MM, Khalifah AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173452>
48. **Comparative analysis of nanomechanical features of coronavirus spike proteins and correlation with lethality and infection rate.** Matter 2020; Hu Y, Buehler MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163958>
49. **Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study.** Mayo Clin Proc Innov Qual Outcomes 2020; Rodriguez-Nava G, Yanez-Bello MA, Trelles-Garcia DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173851>
50. **Effect of pre-existing diseases on COVID-19 infection and role of new sensors and biomaterials for its detection and treatment.** Med Devices Sens 2020:e10140Singh A, Kumar M, Dubey AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173852>
51. **AI-driven quantification, staging and outcome prediction of COVID-19 pneumonia.** Med. Image Anal. 2020; 67:101860Chassagnon G, Vakalopoulou M, Battistella E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171345>
52. **Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus.** medRxiv 2020; Gupta S, Nakabo S, Chu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184616>
53. **Age separation dramatically reduces COVID-19 mortality rate in a computational model of a large population.** Open Biol 2020; 10:200213Mizrahi L, Shekhidem HA, Stern S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171068>
54. **Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19.** Oral Oncol 2020; 112:105087Hanna GJ, Rettig EM, Park JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190021>
55. **Analysis of genomic distributions of SARS-CoV-2 reveals a dominant strain type with strong allelic associations.** Proc Natl Acad Sci U S A 2020; Yang HC, Chen CH, Wang JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184173>
56. **Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients.** Public Health 2020; 189:66-72Prado-Galbarro FJ, Sanchez-Piedra C, Gamiño-Arroyo AE, Cruz-Cruz C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166857>
57. **High-density lipoprotein cholesterol as a factor affecting virus clearance in covid-19 patients.** Respir. Med. 2020; 175:106218Ding X, Zhang J, Liu L *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181413>

58. **Pit latrines may be a potential risk in rural China and low-income countries when dealing with COVID-19.** *Sci Total Environ* 2020;143283Liu L, Hu J, Hou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162149>
59. **Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN- γ as a Novel Antiviral Approach Against COVID-19.** *Viral Immunol* 2020; Anjum FR, Anam S, Abbas G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181057>
60. **A Prognostic Model to Predict Recovery of COVID-19 Patients Based on Longitudinal Laboratory Findings.** *Virologica Sinica* 2020;1-9Tian S, Zhu X, Sun X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33170450>

Safety (7 articles)

1. **Dexmedetomidine in COVID-19: probing promises with prudence!** *Am J Emerg Med* 2020; Magoon R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168381>
2. **Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.** *Brain Sci* 2020; 10Dragoi AM, Radulescu I, Năsu BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33187329>
3. **Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines.** *J Clin Med* 2020; 9Omersel J, Karas Kuželicki N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167413>
4. **The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.** *J. Electrocardiol.* 2020; 63:115-119Çap M, Bilge Ö, Işık F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181454>
5. **Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.** *JACC Case Rep* 2020; Gubitosa JC, Kakar P, Gerula C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163977>
6. **The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.** *Mayo Clin Proc Innov Qual Outcomes* 2020; Tleyjeh IM, Kashour Z, AlDosary O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163895>
7. **Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.** *Pharmacy (Basel)* 2020; 8Hong TS, Gonzalez J, Nahass RG, Brunetti L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167571>

Treatment options (84 articles)

1. **Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.** *Adv Respir Med* 2020; 88:468-469Mohebbi N, Abedini A, Lashgari R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169824>
2. **Bioinspired DNase-I-Coated Melanin-Like Nanospheres for Modulation of Infection-Associated NETosis Dysregulation.** *Adv Sci (Weinh)* 2020;2001940Park HH, Park W, Lee YY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173718>
3. **Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-**

- 2, **a Deadly Nanovector.** *Adv Ther (Weinh)*. 2020:2000172Dube T, Ghosh A, Mishra J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173808>
4. **Dexmedetomidine in COVID-19: probing promises with prudence!** *Am J Emerg Med* 2020; Magoon R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168381>
5. **Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: a retrospective cohort study.** *Ann. Med.* 2020:1-24Ye F, Liu J, Chen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183091>
6. **Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.** *Ann Med Surg (Lond)*. 2020; Mady A, Aletreby W, Abdulrahman B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169088>
7. **Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.** *Ann Med Surg (Lond)*. 2020; 60:417-424Mady A, Aletreby W, Abdulrahman B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169088>
8. **Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.** *Ann Transl Med* 2020; 8:1247Sabarimurugan S, Dharmarajan A, Warriar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178779>
9. **Can immunological manipulation defeat SARS-CoV-2? Why G-CSF induced neutrophil expansion is worth a clinical trial: G-CSF treatment against COVID-19.** *Bioessays* 2020:e2000232Katayama H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166093>
10. **Fragment Library of Natural Products and Compound Databases for Drug Discovery.** *Biomolecules* 2020; 10Chávez-Hernández AL, Sánchez-Cruz N, Medina-Franco JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33172012>
11. **Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill Patients with SARS-CoV2 Pneumonia.** *Blood Purif.* 2020:1-6Rampino T, Gregorini M, Perotti L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181508>
12. **Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial.** *BMJ Open* 2020; 10:e040110Smit M, Marinosci A, Nicoletti GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184083>
13. **Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets.** *Brief. Bioinform.* 2020; Li R, Li Y, Liang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169132>
14. **In silico analysis of selected alkaloids against main protease (M(pro)) of COVID-19.** *Chem. Biol. Interact.* 2020:109309Garg S, Roy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181114>
15. **In silico analysis of selected alkaloids against main protease (M(pro)) of SARS-CoV-2.** *Chem. Biol. Interact.* 2020:109309Garg S, Roy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181114>
16. **Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for Patients Infected with COVID-19: Real Opportunities and Range of Promises.** *Chem. Phys. Lipids* 2020:105009Rezakhani L, Kelishadrokh AF, Soleimanizadeh A, Rahmati S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189639>
17. **Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.**

- Clin Immunol 2020;108631Corominas H, Castellví I, Pomar V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33189888>
18. **Culinary spice bioactives as potential therapeutics against SARS-CoV-2: Computational investigation.** Comput. Biol. Med. 2020; 128:104102Natesh J, Mondal P, Penta D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33190011>
 19. **Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.** Cureus 2020; 12:e10869Kotak S, Khatri M, Malik M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33178522>
 20. **Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach Against COVID-19.** Curr. Pharm. Biotechnol. 2020; Balkrishna A, Mittal R, Arya V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33176643>
 21. **Potential implications of black seed and its principal constituent Thymoquinone in the treatment of COVID-19 patients.** Curr. Pharm. Biotechnol. 2020; Khan MA, Younus H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176642>
 22. **CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.** Drug Dev Res 2020; Nagoor Meeran MF, Sharma C, Goyal SN *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33190277>
 23. **Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection.** EMBO Mol Med 2020:e13426Monteil V, Dyczynski M, Lauschke VM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33179852>
 24. **Exploring the potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019 (COVID-19) through a combination of data mining and network pharmacology analysis.** Eur J Integr Med 2020; 40:101242Sun X, Jiang J, Wang Y, Liu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163124>
 25. **Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.** Eur J Intern Med 2020; Di Nisio M, Potere N, Candeloro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162299>
 26. **Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.** Euro Surveill 2020; 25Mehew J, Johnson R, Roberts D, Harvala H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183404>
 27. **A Comprehensive Review on Sarilumab in COVID-19.** Expert Opin Biol Ther 2020; Khiali S, Rezagholizadeh A, Entezari-Maleki T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33161757>
 28. **Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints.** Expert Rev. Anti Infect. Ther. 2020;1-10Rai M, Bonde S, Yadav A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164589>
 29. **Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis and COVID 19 infection: optimising the therapeutic potential.** Expert Rev. Respir. Med. 2020; Gorman E, Millar J, McAuley D, O'Kane C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33172313>
 30. **Commentary: A Human Pluripotent Stem Cell-Based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids.** Front. Endocrinol. (Lausanne) 2020; 11:585922Ardestani A, Maedler K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162939>

31. **Prokaryote-Eukaryote Symbiosis to Produce RNA-Based Therapeutics.** Front Genet 2020; 11:583464Tahayori B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178254>
32. **Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity-Opportunity for Repurposed Chemotherapy of COVID-19 Infection.** Front. Pharmacol. 2020; 11:585408Al-Motawa MS, Abbas H, Wijten P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162891>
33. **Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins.** Heliyon 2020; 6:e05421Weissshoff H, Krylova O, Nikolenko H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163683>
34. **Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope.** Int Immunopharmacol 2020:107156Kumar A, Dey AD, Behl T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189613>
35. **Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics.** Int Immunopharmacol 2020; 88:106980Kumar V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182073>
36. **Application value of artificial liver support system in the treatment of cytokine storm in patients with COVID-19.** Int Immunopharmacol 2020:107120Xia Q, Xu K, Yu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162345>
37. **LPD-12, a Promising Lipopeptide to Control COVID-19.** Int J Antimicrob Agents 2020:106218Chowdhury T, Baindara P, Mandal SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166692>
38. **Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality? The PEP-CQ Study.** Int J Antimicrob Agents 2020:106224Dhibar DDP, Arora DN, Kakkar DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166694>
39. **Network pharmacology-based study of the molecular mechanisms of Qixuekang in treating COVID-19 during the recovery period.** Int. J. Clin. Exp. Pathol. 2020; 13:2677-2690Tian J, Sun D, Xie Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165417>
40. **Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.** Int J Infect Dis 2020; Khamis F, Al Naabi H, Al Lawati A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181328>
41. **Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection.** Int J Mol Sci 2020; 21Festa M, Sansone C, Brunet C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171852>
42. **Optimization and Evaluation of Propolis liposomes as a promising therapeutic approach for COVID-19.** Int. J. Pharm. 2020:120028Refaat H, Mady FM, Sarhan HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166584>
43. **Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19.** J. Aerosol Med. Pulm. Drug Deliv. 2020; Albariqi AH, Chang RYK, Tai W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179983>
44. **Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study.** J Biomol Struct Dyn 2020:1-15Kumar P, Bhardwaj T, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179586>
45. **Identification of natural inhibitors against prime targets of SARS-CoV-2 using molecular docking, molecular dynamics simulation and MM-PBSA**

- approaches.** *J Biomol Struct Dyn* 2020;1-16 Sharma A, Vora J, Patel D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183178>
46. **In-silico drug repurposing for targeting SARS-CoV-2 main protease (M(pro)).** *J Biomol Struct Dyn* 2020;1-8 Sharma S, Deep S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179568>
 47. **A preparative chiral separation of hydroxychloroquine using supercritical fluid chromatography.** *J. Chromatogr. A* 2020; 1634:461661 Wilson LJ, Mi C, Kraml CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166894>
 48. **Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.** *J. Clin. Immunol.* 2020; Roumier M, Paule R, Vallée A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33188624>
 49. **Treatment with Tocilizumab for Patients with Covid-19 Infections: A Case-series Study.** *J. Clin. Pharmacol.* 2020; Mo Y, Adarkwah O, Zeibeq J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180360>
 50. **The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.** *J. Electrocardiol.* 2020; 63:115-119 Çap M, Bilge Ö, Işık F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181454>
 51. **Early, low-dose, short-term methylprednisolone decreased the mortality in critical COVID-19 patients: a multicenter retrospective cohort study.** *J Infect* 2020; Ji J, Wu M, Zhong L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176176>
 52. **Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient.** *J Infect Dev Ctries* 2020; 14:1138-1145 Tao J, Nie Y, Wu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175709>
 53. **Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.** *J Infect Public Health* 2020; Indu P, Rameshkumar MR, Arunagirinathan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168456>
 54. **Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.** *J. Mol. Model.* 2020; 26:338 Alazmi M, Motwalli O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175236>
 55. **Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?** *J Pers Med* 2020; 10 Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182350>
 56. **A comprehensive overview of proteomics approach for COVID 19: new perspectives in target therapy strategies.** *J Proteins Proteom* 2020;1-10 Rana R, Rath V, Ganguly NK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162722>
 57. **Why will it never be known if convalescent plasma is effective for COVID-19.** *J Transl Autoimmun* 2020; 3:100069 Rojas M, Anaya JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169114>
 58. **Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of IL-23.** *JAAD Case Rep* 2020; Ward M, Gooderham M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173806>
 59. **Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.** *JACC Case Rep* 2020; Gubitosa JC, Kakar P, Gerula C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163977>

60. **Quantum mechanical, spectroscopic and docking studies of (2E)-1-(4-aminophenyl)-3-(4-benzyloxyphenyl)-prop-2-en-1-one Chalcone derivative by density functional theory - A prospective respiratory drug.** Mater Today Proc 2020; Hannah Clara T, Muthu S, Christian Prasana J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33173755>
61. **The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.** Mayo Clin Proc Innov Qual Outcomes 2020; Tleyjeh IM, Kashour Z, AlDosary O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163895>
62. **Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases.** Microorganisms 2020; 8Thijssen M, Devos T, Ejtahed HS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167389>
63. **Drug Re-purposing Approach and Potential Therapeutic Strategies to Treat COVID-19.** Mini Rev. Med. Chem. 2020; Reddy EK, Battula S, Anwar S, Sajith AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33185159>
64. **Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M(pro) Protease.** Molecules 2020; 25Tejera E, Munteanu CR, López-Cortés A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33172092>
65. **Insights from nanotechnology in COVID-19 treatment.** Nano Today 2021; 36:101019Tang Z, Zhang X, Shu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178330>
66. **Antibody-Based Immunotherapeutic Strategies for COVID-19.** Pathogens 2020; 9Hussen J, Kandeel M, Hemida MG, Al-Mubarak AIA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167401>
67. **Necrostatin-1 and necroptosis inhibition: pathophysiology and therapeutic implications.** Pharmacol. Res. 2020:105297Cao L, Mu W.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33181319>
68. **Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study.** Pharmacol. Res. 2020:105290Shi N, Liu B, Liang N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181320>
69. **Treating exuberant, non-resolving inflammation in the lung; implications for acute respiratory distress syndrome and COVID-19.** Pharmacol. Ther. 2020:107745Gilroy DW, De Maeyer RPH, Tepper M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33188794>
70. **Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.** Pharmacy (Basel) 2020; 8Hong TS, Gonzalez J, Nahass RG, Brunetti L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167571>
71. **Treatment with Dexamethasone in Patients with COVID-19: A Position Paper of the German Respiratory Society (DGP).** Pneumologie 2020; 74:493-495Kolditz M, Dellweg D, Geerdes-Fenge H *et al.*
72. **Recent Patents and Advances on Nanotechnologies against Coronavirus.** Recent Pat Nanotechnol 2020; Abedini-Nassab R, Mahdaviyan N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33172382>
73. **Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.** Respir. Med. 2020;

- 175:106188Gluck WL, Callahan SP, Brevetta RA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33190086>
74. **[Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review].** Sheng Wu Gong Cheng Xue Bao 2020; 36:1979-1991Shi X, Yu L, Ding C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169564>
 75. **[Mesenchymal stem cells in the treatment of COVID-19-progress and challenges].** Sheng Wu Gong Cheng Xue Bao 2020; 36:1970-1978Wang J, Zou W, Liu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169563>
 76. **Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.** SN Compr Clin Med 2020;1-10Ahmed MH, Hassan A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33163859>
 77. **The use of nebulized pharmacotherapies during the COVID-19 pandemic.** Ther. Adv. Respir. Dis. 2020; 14:1753466620954366Sethi S, Barjaktarevic IZ, Tashkin DP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167796>
 78. **N-Acetylcysteine to Combat COVID-19: An Evidence Review.** Ther. Clin. Risk Manag. 2020; 16:1047-1055Shi Z, Puyo CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177829>
 79. **Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy.** Transfus. Apher. Sci. 2020:102993Balaghali S, Dabbaghi R, Eshghi P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33162341>
 80. **A patient affected by critical COVID-19 pneumonia, successfully treated with convalescent plasma.** Transfus. Apher. Sci. 2020:102995Einollahi B, Cegolon L, Abolghasemi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183986>
 81. **Synergy of melanin and vitamin-D may play a fundamental role in preventing SARS-CoV-2 infections and halt COVID-19 by inactivating furin protease.** Transl Med Commun 2020; 5:21Paria K, Paul D, Chowdhury T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33169107>
 82. **The effect of surfactant on clinical outcome of patients with COVID-19 under mechanical ventilation: A structured summary of a study protocol for a randomised controlled trial.** Trials 2020; 21:919Dabbagh A, Rajaei S, Ghahremani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176850>
 83. **The Effect of Therapeutic Plasma Exchange on COVID-19 Therapy.** Turk J Pharm Sci 2020; 17:463-464GÖncÜoĞlu C, Balli FN, Bayraktar EkİncİoĞlu A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33177924>
 84. **Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome.** World J. Stem Cells 2020; 12:1067-1079Lin F, Ichim TE, Pingle S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178392>

Trials (6 articles)

1. **Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial.** BMJ Open 2020; 10:e040110Smit M, Marinosci A, Nicoletti GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184083>
2. **Causal inference methods for small non-randomized studies: Methods and an application in COVID-19.** Contemp Clin Trials 2020:106213Friedrich S, Friede T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33188930>

3. **Randomized Controlled Trials for COVID-19: Evaluation of Optimal Randomization Methodologies - Need for the Data Validation of the Completed Trials, and to Improve the Ongoing and Future Randomized Trial Designs.** Int J Antimicrob Agents 2020;106222Emani VR, Goswami S, Nandanor D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189891>
4. **Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.** Int J Infect Dis 2020; Khamis F, Al Naabi H, Al Lawati A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181328>
5. **Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry.** Intern Emerg Med 2020; Núñez-Gil IJ, Fernández-Pérez C, Estrada V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33165755>
6. **Sleep and circadian problems during the coronavirus disease 2019 (COVID-19) pandemic: the International COVID-19 Sleep Study (ICOSS).** J. Sleep Res. 2020:e13206Partinen M, Bjorvatn B, Holzinger B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179820>
7. **[Corona in Children: the Co-Ki Study].** Monatsschr Kinderheilkd 2020;1-6Schwarz S, Jenetzky E, Krafft H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162611>
8. **The effect of surfactant on clinical outcome of patients with COVID-19 under mechanical ventilation: A structured summary of a study protocol for a randomised controlled trial.** Trials 2020; 21:919Dabbagh A, Rajaei S, Ghahremani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176850>
9. **Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:920Lins PRG, de Albuquerque CCC, Assis CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176886>

Vaccines (20 articles)

1. **Vaccines and vitriol: an anthropological commentary on vaccine hesitancy, decision-making and interventionism among religious minorities.** Anthropol. Med. 2020;1-9Kasstan B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183060>
2. **Can BCG vaccine protect against COVID-19 via trained immunity and tolerogenesis?** Bioessays 2020:e2000200Basak P, Sachdeva N, Dayal D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169410>
3. **A review of COVID-19 vaccines and major considerations for diabetic patients.** Biotechnol. Appl. Biochem. 2020; Soltani S, Zandi M, Aghbash PS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179788>
4. **Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries.** Clin Epidemiol Glob Health 2020; Joy M, Malavika B, Asirvatham ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163696>
5. **Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.** Front. Immunol. 2020; 11:586984Reche PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33178220>
6. **A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.** Front. Immunol. 2020; 11:585354Sharma O, Sultan AA, Ding H, Triggle CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33163000>

7. **A Drive-through Simulation Tool for Mass Vaccination during COVID-19 Pandemic.** Healthcare (Basel) 2020; 8Asgary A, Najafabadi MM, Karsseboom R, Wu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182336>
8. **Impact of COVID-19 on women and children and the need for a gendered approach in vaccine development.** Hum Vaccin Immunother 2020;1-6Vora KS, Sundararajan A, Saiyed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33175602>
9. **Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines.** J Clin Med 2020; 9Omersel J, Karas Kuželički N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167413>
10. **Update from the Advisory Committee on Immunization Practices.** J Pediatric Infect Dis Soc 2020; O'Leary ST, Maldonado Y, Kimberlin DW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180938>
11. **Digging the Rabbit Hole, COVID-19 Edition: Anti-Vaccine Themes and the Discourse Around COVID-19.** Microbes Infect 2020; Smith TC, Reiss DR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33171267>
12. **SARS-CoV-2 Vaccines: Inactivation by Gamma Irradiation for T and B Cell Immunity.** Pathogens 2020; 9Mullbacher A, Pardo J, Furuya Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182546>
13. **Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy.** Respir. Med. 2020; 175:106204Torre A, Aliberti S, Castellotti PF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33186846>
14. **Impact of COVID-19 on polio vaccination in Pakistan: a concise overview.** Rev Med Virol 2020; Din M, Ali H, Khan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33176028>
15. **Access considerations for a COVID-19 vaccine for South Africa.** S Afr Fam Pract (2004) 2020; 62:e1-e4Bangalee V, Suleman F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179954>
16. **The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG).** Vaccine 2020; Chen RT, Kochhar S, Condit R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168344>
17. **Influenza vaccination among infection control teams: A EUCIC survey prior to COVID-19 pandemic.** Vaccine 2020; Keske Ş, Mutters NT, Tsioutis C, Ergönül Ö. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183855>
18. **Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein.** Vaccine 2020; 38:7697-7701Muraoka D, Situo D, Sawada SI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33164796>
19. **Missed Opportunities of Flu Vaccination in Italian Target Categories: Insights from the Online EPICOVID 19 Survey.** Vaccines (Basel) 2020; 8Giacomelli A, Galli M, Maggi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182426>
20. **Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses.** Vaccines (Basel) 2020; 8Makhoul M, Ayoub HH, Chemaitelly H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182403>

Women – pregnancy (18 articles)

1. **COVID-19 in pregnancy and the puerperium: A review for emergency physicians.** Am J Emerg Med 2020; Boushra MN, Koyfman A, Long B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33162266>
2. **COVID-19 pandemic effect on early pregnancy: are miscarriage rates altered, in asymptomatic women?** Arch. Gynecol. Obstet. 2020;1-7Rotshenker-Olshinka K, Volodarsky-Perel A, Steiner N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33169234>
3. **Attitudes and precaution practices towards COVID-19 among pregnant women in Singapore: a cross-sectional survey.** BMC Pregnancy Childbirth 2020; 20:675Lee RWK, Loy SL, Yang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167918>
4. **A case of postpartum thyroiditis following SARS-CoV-2 infection.** Endocr. J. 2020; Mizuno S, Inaba H, Kobayashi KI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33177251>
5. **The German version of the pandemic-related pregnancy stress scale: A validation study.** Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; 256:40-45Schaal NK, Marca-Ghaemmaghami P, Preis H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33166796>
6. **Perinatal COVID-19: review of current evidence and practical approach towards prevention and management.** Eur. J. Pediatr. 2020; Vardhelli V, Pandita A, Pillai A, Badatya SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184730>
7. **Management of Pregnancy during the COVID-19 Pandemic.** Glob Chall 2020:2000052Wu D, Fang D, Wang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33173591>
8. **Guidelines for Pregnancy Management During the COVID-19 Pandemic: A Public Health Conundrum.** Int J Environ Res Public Health 2020; 17Benski C, Di Filippo D, Taraschi G, Reich MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182412>
9. **Health Anxiety Predicts Postponing or Cancelling Routine Medical Health Care Appointments among Women in Perinatal Stage during the Covid-19 Lockdown.** Int J Environ Res Public Health 2020; 17Shayganfar M, Mahdavi F, Haghighi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33182388>
10. **Will prenatal exposure to SARS-CoV-2 define a birth cohort with accelerated aging in the century ahead?** J. Dev. Orig. Health Dis. 2020:1-5Easterlin MC, Crimmins EM, Finch CE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33168125>
11. **A Commentary on the Review Entitled, "A Scoping Review of the Human Milk Microbiome" by Groer et al.** J Hum Lact 2020; 36:644-646Wagner CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33181051>
12. **The COVID-19 stress may influence on the sex ratio at birth.** J Matern Fetal Neonatal Med 2020:1-6Abdoli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33179546>
13. **Breastfeeding during the novel coronavirus (COVID-19) pandemic: guidelines and challenges.** J Matern Fetal Neonatal Med 2020:1-7Dimopoulou D, Triantafyllidou P, Daskalaki A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33161802>
14. **Lesson for the clinical nephrologist: Kidney transplant, COVID-19 and pregnancy.** J Nephrol 2020; Gleeson S, Noori M, Lightstone L, Webster P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33180315>

15. **COVID-19 and abortion right.** Obstet Gynecol Sci 2020; Rashidpouraie R, Sharifi MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33167115>
16. **Principles of approach to suspected or infected patients related Covid-19 in newborn intensive care unit and pediatric intensive care unit.** Perspect. Psychiatr. Care 2020; Sarman A, Tuncay S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33184910>
17. **COVID-19 susceptibility in pregnancy: Immune/inflammatory considerations, the role of placental ACE-2 and research considerations.** Reprod. Biol. 2020; Malinowski AK, Nouredin A, Othman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33183974>
18. **Update on Recommendations for SARS-CoV-2/COVID-19 during Pregnancy, Birth and Childbed.** Z. Geburtshilfe Neonatol. 2020; 224:217-222 Zöllkau J, Hagenbeck C, Hecher K *et al.*

to subscribe click [here](#)

mailing address is:
lansberg@gmail.com

[unsubscribe from this list](#) [update subscription preferences](#)
© P.J. Lansberg

This email was sent to lansberg@gmail.com
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
Peter Lansberg · Van Lennepweg 50 · Den Haag, Zuid Holland 2597LK · Netherlands

